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Abstract 
Background 
The early identification of disease can benefit patients clinically and provide a 
powerful research tool. This thesis aims to identify subclinical cardiac change using 
cardiovascular magnetic resonance (CMR) in both disease and health and evaluate 
its diagnostic and prognostic uses.  
Methods  
We have prospectively recruited and conducted multi-parametric CMR in 50 
patients with hypertrophic cardiomyopathy (HCM), 40 endurance athletes and 100 
asymptomatic patients with type 2 diabetes mellitus.  
Results  
Study 1 and 2 evaluated CMR in the early diagnosis of HCM. Study 1 demonstrated 
the diagnostic accuracy of extracellular volume (ECV) mapping is superior to 
volumetric methods of differentiating HCM from athletic left ventricular (LV) 
hypertrophy. Study 2 demonstrated that ECV expansion could be detected prior to 
overt hypertrophy or impairment of contractile function in patients with HCM. 
Study 3 demonstrated that LV torsion is lower in endurance athletes than controls 
and is predominantly influenced by lactate threshold and intensity of training. 
Study 4 and 5 investigated the role of CMR in identifying patients with type 2 
diabetes at risk of heart failure and silent myocardial infarction. Study 4 found that 
the increased risk of heart failure in patients with type 2 diabetes was mediated by 
ECV expansion and diffuse fibrosis. There was a high rate of silent myocardial 
infarction (17 %) which was unrelated to heart failure risk. In study 5 we developed 
a simple screening tool, using measures that can be carried out in a cardiology 
clinic, for the detection of silent myocardial infarction in type 2 diabetes.  
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Conclusions 
CMR is able to detect subclinical change in both tissue characteristics and function 
of the heart. This can aid the early and appropriate diagnosis of disease and 
identify those at the highest risk of adverse outcomes.   
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1.  Introduction 
Cardiovascular disease is the now the largest cause of death worldwide (Mortality 
and Causes of Death, 2015). Advancements in blood pressure control and smoking 
cessation are leading to improving primary prevention globally. However even if all 
international targets are met it is estimated that 5.7 million preventable 
cardiovascular deaths will occur each year (Roth et al., 2015).   
Advances in primary prevention are imperative to reduce the burden of 
cardiovascular disease and will continue to be a fundamental method for reducing 
mortality. Screening for subclinical disease offers an additional method to identify 
those at the highest risk of mortality and offer targeted interventions (Berger et al., 
2010).  In order to justify focussing resources on screening for those at the highest 
risk the disease has to be important, have a latent period and have a suitable 
diagnostic test (Wilson and Jungner, 1968). Furthermore the disease has to be 
treatable in the early phases so disease progression or the risk of mortality can be 
reduced, Figure 1.1.  
 
 
Figure 1.1 Schematic depicting the progression of cardiovascular disease from 
predisposition to death. For detection of subclinical disease in the asymptomatic 
prodrome to be beneficial it has to be possible to alter the risk of disease 
progression or mortality.  
 
Cardiovascular magnetic resonance (CMR) has potential to be an important tool for 
the identification of subclinical cardiac disease. It is able to make accurate and 
reproducible assessment of ventricular morphology, tissue composition and 
function on both a global and regional level. There are many disease processes that 
Predisposition
•Genetic factors
•Lifestyle factors
Asymptomatic 
phenotypic 
expression
•Screening for 
subclinical disease
Symptomatic 
phenotypic 
expression
•Medical intervention
Death
Risk of sudden death 
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lead to alteration in the morphology, tissue characteristics and function of the 
heart. Identifying these changes early can ensure prompt diagnosis and timely 
intervention. The focus of this thesis is three important areas of cardiovascular 
medicine in which there are known to be morphological cardiac changes but 
identification of the diagnosis, particularly in the subclinical stage can be 
challenging.   These are hypertrophic cardiomyopathy (HCM) and in particular how 
CMR can be used to diagnose it appropriately early in the disease progression; 
athletic remodelling of the heart which can be difficult to differentiate from HCM 
or dilated cardiomyopathy (DCM); and subclinical asymptomatic cardiac disease 
secondary to type 2 diabetes mellitus.  The basic principles of CMR assessment of 
cardiac structure, function and tissue characterisation are discussed in detail 
before an appraisal of how each of these techniques can be applied to the areas 
investigated in this thesis.  
 
1.1 CMR techniques used in the detection of subclinical change 
A typical CMR study takes between 30 and 60 minutes and typically includes T1 
weighted black blood images for assessment of anatomy, cine images in multiple 
planes for assessment of left ventricular (LV) and right ventricular (RV) volumes as 
well as late gadolinium enhancement (LGE) for delineation of scar and fibrosis 
(Figure 1.2). This basic protocol can be complemented with stress perfusion for 
ischaemia detection, T2-weighted imaging to detect myocardial oedema or T2* 
imaging for assessment of cardiac iron loading. Tissue tagging can be used for an 
assessment of regional or global strain and T1 mapping techniques can be used for 
assessment of the extracellular volume (ECV) fraction.     
- 22 - 
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Figure 1.2 Typical flow chart of CMR protocol for the investigation of 
cardiomyopathy 
1.1.1 Volumetric Analysis 
Assessment of LV chamber volumes and ejection fraction (EF) forms the 
cornerstone of assessment of cardiac structure by CMR. Echocardiography is the 
most widely available and utilised non-invasive imaging modality for the 
assessment ventricular volumes. When suboptimal imaging quality does not allow 
for assessment of EF or more accurate assessment of EF is required, both American 
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(Yancy et al., 2013) and European (McMurray et al., 2012) guidelines recommend 
the use of CMR.  
EF is usually measured by CMR with the acquisition of a two dimensional 
continuous stack of short axis gradient-echo cine images covering the length of the 
left ventricle (LV). The number of slices, and consequently the number of breath-
holds, depends on the length of the ventricle and the chosen imaging parameters, 
in particular slice thickness and slice gap. In patients with poor breath-hold 
capacity, the acquisition can be shortened close to “real-time” with acceleration 
techniques (such as sensitivity encoding [SENSE], simultaneous acquisition of 
spatial harmonics [SMASH] and generalized autocalibrating partially parallel 
acquisitions [GRAPPA]), usually at the expense of signal-to-noise ratio, spatial or 
temporal resolution (Larkman and Nunes, 2007). The EF is typically calculated from 
these images by the “summation of discs” method (Utz et al., 1987). On each cine 
image within the stack, endocardial contours are drawn at end-systole and end-
diastole. As the slice thickness is known, the volume of each disc can be calculated 
and by adding the volumes of each slice end-diastolic volume (EDV), end-systolic 
volume (ESV) and consequently EF can be calculated. This technique has been 
shown to be highly reproducible with interstudy reproducibility that is significantly 
better than two-dimensional echocardiography (Grothues et al., 2002). It has been 
estimated that to detect a 3% change in EF by echocardiography 87 patients are 
needed whereas only 11 patients are needed by CMR.  
Measurement of EF by CMR can be used both to guide diagnosis and prognosis. It 
is well known that the degree of LV impairment is associated with adverse 
outcomes and increased mortality (Gradman et al., 1989; Unverferth et al., 1984). 
In the Candesartan in Heart Failure: Assessment of Reduction in Mortality and 
Morbidity (CHARM) study, each 10% decrease in EF below 45% was associated with 
a 39% increase in all-cause mortality (Solomon et al., 2005). For a more 
comprehensive assessment of prognosis, EF can also be incorporated as one of 
several factors in a risk score (Aaronson et al., 1997; Ketchum and Levy, 2011).  
RV volumes and RV EF can also be calculated by CMR using the summation of discs 
method described above. Impaired RV function is associated with adverse 
outcomes in conditions that primarily affect the RV such as pulmonary arterial 
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hypertension and arrhythmogenic right ventricular cardiomyopathy (ARVC) 
(Valsangiacomo Buechel and Mertens, 2012) but also adds prognostic information 
in patients with heart failure. When assessed by CMR in patients with previous 
myocardial infarction (MI), RV EF <40% was associated with adverse outcomes 
independently of other factors including LV EF (Larose et al., 2007). 
Atrial dimensions can be reproducibly measured by CMR using the summation of 
discs technique or from long axis cines (Maceira et al., 2010). Increased left atrial 
volume assessed by CMR has been shown to be a strong predictor of mortality in 
patients with heart failure (Gulati et al., 2013). 
From the same continuous short axis LV stack used to measured EF LV mass can 
also be measured. Contours are drawn on the endocardial and epicardial borders 
at one point in the cardiac cycle, usually end diastole and the LV mass calculated 
using the summation of discs principle. It is possible in include or exclude papillary 
muscles with both techniques providing similar interobserver reproducibility (Han 
et al., 2009). Assessment of LV mass by this method has excellent interstudy 
reproducibility. It is estimated to detect a 10g change in LV mass using 
echocardiography 132 subjects would be needed compared with only 13 by CMR 
(Grothues et al., 2002).  
Several cardiac diseases cause concentric remodelling of the LV which can be 
assessed by dividing LV mass by LV EDV. Concentric remodelling has been reported 
in diabetes and is associated with adverse outcomes (Heckbert et al., 2006; de 
Simone et al., 2008). This ratio has also been proposed as a method to differentiate 
athletic remodelling of the LV from HCM (Luijkx et al., 2013).  
1.1.2 Tissue characterisation 
The currently used gadolinium based CMR contrast agents are exclusively 
extracellular and can only passively enter damaged cells with a leaky cell 
membrane. These contrast agents therefore accumulate in areas with damaged 
cells and avascular extracellular regions. This phenomenon is exploited in LGE CMR 
imaging. LGE imaging involves administration of typically 0.1-0.2mmol/kg of a 
gadolinium based contrast agent. After a delay of 5-20 minutes the contrast agent 
is retained to a greater extent in areas of scar or fibrosis than in normal 
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myocardium. An inversion recovery sequence with an inversion time specified to 
null “normal” myocardium then displays scarred myocardium as bright when 
compared to the reference. The pattern of enhancement on LGE can aid in the 
diagnosis of the aetiology of asymptomatic disease with characteristic appearances 
of LGE in many conditions (Mahrholdt et al., 2005). For example, subendocardial or 
transmural LGE is seen in ischemic cardiomyopathy, mid wall LGE in dilated and 
hypertrophic cardiomyopathies, epicardial LGE in myocarditis and global 
subendocardial LGE in amyloidosis (see examples in Figure 1.3). The presence of 
enhancement on LGE imaging is shown to correspond well with discrete fibrosis on 
histology and confers an adverse prognosis in many cardiomyopathies (Ismail et al., 
2012).  
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Figure 1.3 Typical distribution of LGE in various aetiologies of cardiomyopathy. 
Ischaemic cardiomyopathy (top left) near transmural infarction of the septum and 
apex and subendocardial infarction of the lateral wall (arrow), note the artefact 
secondary to sternomy wires. Dilated cardiomyopathy (top right) dilated ventricular 
chambers with midwall fibrosis (arrow). Myocarditis (bottom left) with 
subepicardial LGE of the lateral wall (arrow). Hypertrophic cardiomyopathy (bottom 
right) asymmetric septal hypertrophy with patchy midwall LGE within the 
hypertrophied septum (arrow).  
 
Extracellular fibrosis is a common pathological finding in many aetiologies of heart 
failure. As described in the preceding section, CMR to assess LGE is a well-
established method by which to assess and quantify the size and transmurality of 
discrete areas of fibrosis. However this process relies on nulling the healthy 
myocardium and on comparing the enhancement of healthy and diseased 
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myocardium qualitatively. When the myocardium is diffusely diseased, techniques 
that characterize the myocardium quantitatively provide additional insights into 
myocardial disease. 
There has been renewed recent interest in methods that quantify the intrinsic T1 
(Messroghli et al., 2004) and T2 (Verhaert et al., 2011) signal of the myocardium 
and create a map of their values. Native tissue maps alone can be used for tissue 
characterization or can be combined with post contrast acquisitions. Gadolinium-
based contrast agents shorten in particular the T1 relaxation time and tissues with 
an expanded extracellular space due to fibrosis, infiltration or scar have a larger 
distribution volume for the extracellular contrast agent. In these tissues, the 
reduction in T1 relaxation time is therefore more pronounced than in normal tissue 
and is correlated with the extent of the extracellular space. Post-contrast 
myocardial T1 has been shown to significantly correlate with histological areas of 
fibrosis (Iles et al., 2008).  
Post contrast T1 mapping makes assumptions about the kinetics of gadolinium 
contrast agents and the results can be influenced by renal function, haematocrit 
and body composition. These assumptions can be overcome by combining pre and 
post contrast T1 mapping of both myocardium and blood and correcting for the 
blood volume of distribution (1-haematocrit). From these data, maps of the ECV 
fraction can be calculated which show significant correlation with histological 
degree of fibrosis and volume of collagen in the myocardium (Flett et al., 2010). 
ECV is calculated using the formula: 
 
𝐸𝐶𝑉 = (1 − 𝐻𝑐𝑡)
𝑅1(𝑚𝑦𝑜 𝑝𝑟𝑒)−𝑅1(𝑚𝑦𝑜 𝑝𝑜𝑠𝑡)
𝑅1(𝑏𝑙𝑜𝑜𝑑 𝑝𝑟𝑒)−𝑅1(𝑏𝑙𝑜𝑜𝑑 𝑝𝑜𝑠𝑡)
      where R1=1/T1 
 
Lengthened pre-contrast T1 times, shortened post-contrast T1 times and increased 
ECV have been reported in several cardiomyopathies including amyloidosis, DCM 
and HCM (Dass et al., 2012; Puntmann et al., 2013; Sado et al., 2012).  
In the largest CMR study of ECV to date, T1 mapping was carried out in 793 
patients at the time of CMR being done for clinical purposes (36% were for known 
or suspected cardiomyopathy, 35% for known or suspected IHD and 26% to 
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identify a substrate for arrhythmia) (Wong et al., 2012). Patients with HCM or 
amyloidosis were excluded. Over median follow up 0.8 years ECV related to all-
cause mortality (hazard ratio 1.55 for every 3% increase in ECV). In multivariable 
regression analysis of this heterogeneous population only ECV, EF, age and extent 
of LGE (if there was previous infarction) were able to significantly predict mortality.  
By using a combination of LGE and T1 mapping it is possible to map out the entire 
left ventricle delineating both areas of extracellular matrix expansion and areas of 
scarring, infarction and replacement fibrosis. Both of these techniques can detect 
pathological changes in asymptomatic subjects and have the potential to be used 
as screening tools for the detection of subclinical disease.  
1.1.3 Strain analysis 
Ejection fraction is the most widely used and best validated measure of left 
ventricular function. It is also possible to measure contraction of myocardium by 
measurement of either regional or global strain. In cardiac terms strain is defined 
as the amount of myocardial fibre shortening in a given time divided by the 
precontraction length. The measurements of length are usually made at end-
systole and end-diastole. By convention this number is negative if the fibre has 
shortened and positive if it has lengthened.   
It is possible to measure strain by CMR using tissue tagging techniques where a 
selective radiofrequency saturation pulse prior to the acquisition is used to 
generate a tag line or grid in the myocardium that can be tracked throughout the 
cardiac cycle (Ibrahim el, 2011). Using either long or short axis tagged cines it is 
possible to measure myocardial strain in radial, circumferential or longitudinal 
directions. Tagged cines can also be used to measure twist and torsion of the left 
ventricle. The heart has a complex twisting motion where the base rotates 
clockwise in early systole and the apex rotates anticlockwise in later systole. These 
opposing directions of rotation at the apex and base generate maximal torsional 
force at end systole (Burns et al., 2008). LV twist is defined as apical minus basal 
rotation. Torsion takes into account the length and diameter of the ventricle 
allowing comparison of torsional forces between ventricles of different sizes 
(Young and Cowan, 2012). Both strain and torsion measured by CMR tagging 
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techniques have good interstudy reproducibility allowing measurement of serial 
global and regional function (Swoboda et al., 2013). 
Feature tracking is a new post processing technique which allows for tracking of 
myocardial features from cine imaging throughout the cardiac cycle. This technique 
is analogous and provides similar results to speckle tracking, which is a well 
validated echocardiography measure of strain (Onishi et al., 2015). Feature tracking 
allows for quantification of strain without the need for the acquisition of tagged 
cine imaging. Results from reproducibility studies of feature tracking have proved 
very promising and it is reported to have similar reproducibility to strain measured 
by CMR tissue tagging (Moody et al., 2015).    
Strain and torsion measured by CMR both provide important diagnostic and 
prognostic information and have been used to detect subclinical impairment of 
both regional and global cardiac function in a wide variety of conditions including 
HCM (Kramer et al., 1994), type 2 diabetes (Giannetta et al., 2012; Larghat et al., 
2014), ischaemic, valvular and congenital heart disease (Ibrahim el, 2011). 
 
1.2 CMR assessment of hypertrophic cardiomyopathy  
HCM is commonly defined as a disease of hypertrophy of the left ventricle in the 
absence of another cardiac or systemic cause (Gersh et al., 2011).  It is typically 
caused by autosomal dominant mutations of genes encoding sarcomeric proteins 
and myofilament elements (Bos et al., 2009). These mutations lead to micro- and 
macroscopic changes within the heart including cellular disarray, hypertrophy and 
interstitial fibrosis. When myocyte disarray is widespread it is a sensitive and 
specific marker for HCM (Hughes, 2004). These changes lead to hypertrophy that 
can affect the heart in a variety of patterns, and may affect any segment  of the left 
ventricle (Klues et al., 1995). Although hypertrophy can be widespread, phenotypic 
expression within the same heart can be variable and less than half of the ventricle 
may be hypertrophied in as many as 50% of patients (Maron et al., 2009b).  
At present the diagnosis of HCM is primarily made by the identification of one or 
more hypertrophied segments by a cardiac imaging modality (Gersh et al., 2011; 
Elliott et al., 2014).  In the majority of cases this involves identification of a 
- 30 - 
 
 
 
segment ≥15mm by echocardiography. Increasingly CMR is used to confirm or 
make diagnosis of HCM when echocardiography is restricted by limited acoustic 
windows or the inability to assess all segments of the left ventricle. In addition to 
accurate measurement of segment thickness CMR is also able to make an 
assessment of the cellular composition and function of segments that are 
borderline in terms of being diagnostic for HCM. Furthermore CMR imaging is able 
to evaluate and exclude the possibility of alternative causes of hypertrophy such as 
aortic stenosis, amyloidosis, Fabry’s disease or systemic hypertension. 
 
1.2.1 Morphologic assessment  
CMR cine imaging is able to make an accurate and reproducible assessment of the 
extent and location of hypertrophy when considering a diagnosis of HCM. It is 
reported that CMR detects hypertrophy in around 12% of patients with HCM that 
was not detected by echocardiography (Maron et al., 2009b). The areas where 
hypertrophy is most commonly detected by CMR but not echocardiography include 
the anterolateral wall, the inferior septum and the apex. Imaging the apex of the 
left ventricle can be notoriously difficult by echocardiography and it is quite 
possible for severe hypertrophy to be missed by this technique but detected by 
CMR (Moon et al., 2004b).  
It is possible for echocardiography to overestimate the wall thickness in HCM 
because of difficulty planning the acquisitions exactly perpendicular to the long 
axis of the left ventricle, resulting in an oblique cut. The improved spatial 
resolution of CMR also allows for accurate delineation of endocardial borders and 
exclusion of structures such as the moderator band or false tendons from 
measurements. It is reported that these differences can lead to measurements of 
segment thickness being approximately 20% less when measured by CMR 
compared to echocardiography (Valente et al., 2013).  
In addition to accurate and reproducible measurements of wall thickness CMR can 
also assess LV mass (usually by the summation of discs techniques outlined in 
1.1.1). However LV mass has been shown to only correlate weakly to maximum 
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segment thickness which is a more powerful prognostic predictor (Olivotto et al., 
2008).  
CMR imaging can also detect diagnostic features of HCM that may be missed on 
echocardiography including apical aneurysm formation (Maron et al., 2008), 
thrombus formation, papillary muscle abnormalities and myocardial crypts 
(Germans et al., 2006). Myocardial Crypts are typically identified in the basal or mid 
inferior or inferoseptal walls of the LV and are thought to represent an early 
phenotypic manifestation of HCM. They are reported to be present in 70% of 
patients who have a HCM causing mutation without over hypertrophy but only 
12% of genotype negative controls (Brouwer et al., 2012). Myocardial crypts can be 
difficult to detect using conventional echocardiography and offer a good example 
of how CMR is able to detect subclinical disease in otherwise asymptomatic 
carriers of a significant genetic mutation (Germans et al., 2006).  
The left atrium is often dilated in HCM due to a combination of elevated filling 
pressures and mitral regurgitation due to systolic anterior motion of the anterior 
mitral valve leaflet. It is possible to measure left atrial volumes accurately and 
reproducibly by CMR (Maceira et al., 2010). However the mechanisms leading to LA 
dilatation occur late in the disease progression of HCM and left atrial dilatation 
although a powerful prognostic marker is a feature of advanced disease and less 
useful for the detection of subclinical disease (Nistri et al., 2006).  
1.2.2 CMR tissue characterisation 
Using CMR tissue characterisation techniques it is possible to detect and quantify 
myocyte disarray and replacement fibrosis, the histological hallmarks of HCM. 
Histological studies of patients who have died and undergone post mortem have 
revealed that myocyte disarray is an early feature of HCM and likely a direct 
consequence of dysfunction mutations of sarcomeric proteins. Replacement 
fibrosis and small vessel disease appear to occur later in the disease process and 
are attributed to factors unrelated to disarray including wall thickness, gender and 
even local autocrine factors (Varnava et al., 2000).   
The presence of LGE is suggestive of replacement fibrosis and on necropsy there is 
a strong linear correlation between the extent of LGE within a particular segment 
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and the amount of collagen measured histologically (Moon et al., 2004c). Small 
intramural coronary arteriole dysplasia has been suggested to cause replacement 
fibrosis by local ischaemia (Maron et al., 1986). The degree of small intramural 
coronary arteriole dysplasia on histological specimens after surgical myomectomy 
has been demonstrated to correlate with the extent of LGE on pre-operative CMR 
(Kwon et al., 2009).  
CMR studies have also shown a correlation between the extent of LGE and the 
degree of hypertrophy, with some studies suggesting that hypertrophy occurs prior 
to the development of fibrosis (Choudhury et al., 2002; Moon et al., 2005). Studies 
using serial CMR have shown that replacement fibrosis is an ongoing dynamic 
characteristic of the disease process in HCM. Once replacement fibrosis detected 
by the presence of LGE it is associated with both progressive development of 
further replacement fibrosis and LV dilatation and adverse remodelling (Todiere et 
al., 2012; Moon et al., 2003).  
Mechanistically it seems very plausible that replacement fibrosis detected by CMR 
could act as a substrate for malignant tachyarrhythmia. However studies that have 
investigated the prognostic potential of LGE in predicted sudden cardiac death or 
appropriate implantable cardioverter-defibrillator (ICD) therapy have given mixed 
results. This has largely been because of the low event rates and high prevalence of 
LGE. However all studies have shown that the presence of LGE is a marker with 
more advanced disease and is therefore associated with increased mortality and 
heart failure (Green et al., 2012). In the largest study to date, 1293 patients with 
HCM were followed up for 3.3 years. The presence of LGE was associated with 
malignant arrhythmia (Chan et al., 2014). However the event rate of malignant 
arrhythmia was low (around 1% per year) and the presence of LGE was more 
strongly associated with heart failure outcomes than arrhythmic outcomes.  
With T1 and ECV mapping it is now possible to detect phenotypic expression of 
HCM prior to the onset of overt hypertrophy or replacement fibrosis. Cellular 
disarray and extracellular matrix expansion occur early in the disease process and 
can be detected by using quantitative T1 and ECV mapping techniques. Results 
demonstrate good correlation with histological fibrosis quantification from 
specimens taken at the time of surgical myomectomy (Flett et al., 2010). One study 
- 33 - 
 
 
 
has attempted to validate post contrast T1 mapping in HCM hearts explanted at 
the time of transplant and did report a correlation between the degree of fibrosis 
histologically and post contrast T1 time (Iles et al., 2015). Unfortunately in this 
study ECV (which is better validated than post-contrast T1 time) was not 
calculated, the sample size was small (4 HCM necropsy specimens) and there was a 
long interval between the CMR and surgical explant (median 546 days).  
Myocyte disarray and collagen deposition are early features of HCM and can be 
detected histologically or biochemically in genotype positive subjects prior to the 
onset of hypertrophy (Varnava et al., 2001; Ho et al., 2010). It has been reported 
that ECV expansion can also be detected in the same cohort, adding further 
support to the hypothesis that ECV mapping is able to detect early phenotypic 
expression of HCM (Ho et al., 2013). 
1.2.3 CMR assessment of regional function 
Studies, predominantly using echocardiography speckle tracking to measure 
regional and global strain have demonstrated that impaired contractility is related 
to the extent of hypertrophy and the presence of replacement fibrosis detected by 
LGE (Urbano-Moral et al., 2014; Popovic et al., 2008). Current guidelines therefore 
recommend that strain imaging could be used to investigate unexplained left 
ventricular hypertrophy that is not diagnostic of HCM (Gersh et al., 2011; Elliott et 
al., 2014).  
CMR tissue tagging is an alternative method to echocardiography for the 
assessment of regional strain and is highly reproducible in this setting (Shehata et 
al., 2009; Swoboda et al., 2013). Using CMR tissue tagging it is reported that 
significant heterogeneity in contractile function can be detected in different 
regions of the heart depending upon the extent of phenotypic expression in that 
region (Kramer et al., 1994). It was subsequently confirmed that the presence of 
LGE strongly correlated with impaired strain detected by tissue tagging (Kim et al., 
2008).  
One recent study has used CMR feature tracking to investigate regional strain in 
subjects under the age of 20 with HCM. They report that regional strain is most 
impaired in areas of hypertrophy or replacement fibrosis detected as LGE (Smith et 
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al., 2014). These findings are in keeping with previous echocardiography and CMR 
tagging studies.   
1.2.4 Diastolic dysfunction and LV outflow tract obstruction 
In addition to the CMR techniques that have been discussed other diagnostic 
features of HCM can be detected during a routine CMR examination. HCM is 
associated with impaired relaxation of the left ventricle which can be detected as 
diastolic dysfunction on Doppler echocardiography. Whilst it is possible to make an 
assessment of LV filling pattern and longitudinal function by CMR using cine 
imaging, phase velocity flow mapping, tissue tagging and feature tracking none of 
these techniques have been validated to the same extent as echocardiographic 
assessment of diastolic dysfunction. In addition the temporal resolution is higher 
when assessed by echocardiography, which is an important consideration when 
measuring diastolic function.  
LV outflow tract (LVOT) obstruction is another diagnostic feature of HCM that is 
present in approximately one third of patients. Conventionally this assessment has 
been carried out by Doppler echocardiography. It is possible to make an 
assessment of flow obstruction using phase velocity flow mapping during a routine 
CMR examination. However alignment of the imaging plane can be difficult, 
intravoxel dephasing and signal loss due to phase offset errors can lead to errors in 
quantification and it can only be measured at rest. A significant proportion of 
patients with HCM only have LVOT obstruction during exercise, termed dynamic 
outflow tract obstruction. Technically it is much easier to make an assessment of 
dynamic outflow tract obstruction during echocardiography than CMR.   
It is possible to make an assessment of both LV diastolic function and LV outflow 
tract obstruction during a routine CMR examination. However results from 
echocardiography appear to be more reproducible, easier to acquire and are better 
validated. Furthermore they both tend to be a consequence of significant 
hypertrophy or replacement fibrosis and therefore occur later in the disease 
process. For these reasons these techniques are not routinely used for the 
assessment of subclinical disease in HCM.  
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From one CMR examination it is now possible to make an accurate assessment of 
the expression of HCM phenotype by measuring myocardial hypertrophy, myocyte 
disarray and collagen deposition (with ECV mapping) and replacement fibrosis 
(LGE). During the same examination the functional consequences of these changes 
in tissues characteristic can be assessed (using either tissue tagging or feature 
tracking). Additional techniques to assess diastolic function or LVOT obstruction 
can also be added if required. Using these techniques it is possible to detect 
subclinical features of HCM in an otherwise asymptomatic subject.  
1.3 Subclinical cardiac changes in endurance athletes 
1.3.1 Change in cardiac morphology in trained athletes 
It is well recognised that athletic training leads to ventricular remodelling, 
specifically increases in LV EDV and RV EDV and LV mass (Maron and Pelliccia, 
2006). These structural changes are most frequently seen in athletes who undergo 
prolonged periods of endurance training (Utomi et al., 2013) and are typically 
subclinical with no associated symptoms. The increase in LV mass occurs as early as 
6 months after commencement of endurance training (Arbab-Zadeh et al., 2014) 
and may be accompanied by an increase in LV EDV resulting in a typical phenotype 
of eccentric remodelling referred to as “athlete’s heart” (Maron, 2003; Utomi et 
al., 2013).  
CMR volumetric assessment of LV EDV and mass is established to be accurate and 
reproducible (Grothues et al., 2002) and is therefore an ideal tool for the 
quantification of the cardiac structural changes that can be detected in athletes.  
Although athlete’s heart has a fairly well established phenotype in certain cases the 
extent of LV hypertrophy can overlap into the pathological range. In these cases it 
is important to exclude a diagnosis of HCM. Although rare (Basavarajaiah et al., 
2008), HCM is the leading cause of sudden cardiac death in young athletes (Maron 
et al., 2009a). Current guidelines advise that patients with HCM should avoid 
competitive sport and it is therefore imperative that HCM and physiological 
remodelling are correctly distinguished in an athlete with LV hypertrophy (Gersh et 
al., 2011; Elliott et al., 2014). 
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Several imaging parameters have been previously proposed to distinguish between 
physiological LVH and HCM including: EDV/LV mass (Luijkx et al., 2013), left atrial 
remodelling (Pelliccia et al., 2005), changes in strain pattern (Vinereanu et al., 
2001), maximal oxygen consumption during cardiopulmonary exercise testing 
(Sharma et al., 2000) or composite assessments of multiple imaging findings 
(Caselli et al., 2014).  
In subjects with very localised and asymmetric hypertrophy, the differentiation 
between the two entities can be straight-forward. However, when myocardial 
thickness is borderline or more widespread, it can be challenging to exclude a 
diagnosis of HCM in athletes (Basavarajaiah et al., 2008; Rawlins et al., 2010). 
Establishing the correct diagnosis may then require the athlete to undergo a period 
of detraining, which is challenging in elite athletes (Pelliccia et al., 2002).  
Some endurance athletes display a cardiac phenotype of dilated left ventricle and 
low normal ejection fraction which can be difficult to differentiate clinically from 
early dilated cardiomyopathy (Abergel et al., 2004). This is usually less challenging 
than excluding HCM however in certain circumstances detraining can be 
necessitated too.  
In certain situations it can be difficult to differentiate physiological athletic RV 
dilatation from pathological arrhythmogenic right ventricular cardiomyopathy. It 
has been postulated that imaging during exercise may be able to differentiate the 
two pathologies better than other methods; RV function improves if there is 
physiological RV dilatation whereas it does not in patients with pathological 
dilatation associated with cardiomyopathy (La Gerche et al., 2015).  
1.3.2 Change in strain in trained athletes 
Although less well established than changes in volumetric parameters, there is also 
evidence for changes in functional parameters in the hearts of trained athletes. 
Endurance athletes have reduced ejection fraction, circumferential and 
longitudinal strain of both the left and right ventricles compared to healthy 
controls (Caselli et al., 2015; Nottin et al., 2008). It has also been reported that 
athletes have decreased LV twist and torsion when compared to sedentary 
controls (Nottin et al., 2008).  Several echocardiography studies using techniques 
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including tissue Doppler imaging and speckle tracking have been used to 
investigate left ventricular torsion in athletes. Contrasting findings have been 
reported including decreased apical rotation and LV torsion in athletes with high 
levels of aerobic fitness (Stohr et al., 2012) no effect of high intensity exercise on 
LV torsion (Stewart et al., 2015), or even an increase in LV torsion (Weiner et al., 
2010). The inconsistent results that have been reported may in part reflect 
different sport and training techniques, research methodology used and also the 
difficulty in positioning the apical and basal slices in echocardiography studies, 
which is based upon anatomical landmarks with a degree of subjectivity. 
Conflicting findings have been reported when echocardiographic assessment of 
diastolic function has been used with some studies reporting augmented relaxation 
of both ventricles in endurance athletes (Caselli et al., 2015; Baggish et al., 2008) 
and others reporting no difference from controls (Pluim et al., 2000).      
1.3.3 Tissue characterisation in trained athletes 
In addition to the physiological subclinical changes that can be detected by CMR in 
athletes it is also possible to detect subclinical pathological change. One study 
reported the presence of LGE in 6 lifelong athletes over the age of 50 (N=12). 4/6 
had non-specific LGE, 1/6 had a previous myocarditis pattern and 1/6 had a 
subendocardial pattern suggestive of previous MI (Wilson et al., 2011). Another 
study reported a prevalence of non-ischaemic pattern LGE in 2/95 asymptomatic 
athletes (Mangold et al., 2013). One recent case series has attempted to establish 
the prognostic significance of non-ischaemic LGE detected on routine screening in 
asymptomatic athletes (Schnell et al., 2015). On following up 7 athletes with sub-
epicardial lateral LGE suggestive of previous myocarditis over three years 5/7 had 
symptomatic ventricular arrhythmias and 1/7 had progressive LV dysfunction. This 
study was small and the nature of the ventricular arrhythmia variable, ranging from 
exercise induced couplets to ventricular tachycardia requiring ICD implantation, 
however it does suggest that non-ischaemic LGE in athletes may be a 
prognostically significant pathological finding. 
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1.4 Detection of subclinical heart failure in diabetes 
The mechanisms that lead from chronic hyperglycaemia to heart failure are 
complex and are thought to involve altered substrate metabolism, impaired 
calcium handling, increased reactive oxygen species and microvascular advanced 
glycation end product deposition (Boudina and Abel, 2007; Seferovic and Paulus, 
2015). It is possible to detect the consequences of many of these pathways using 
cardiac imaging in the subclinical phase of disease. Changes in cardiac morphology, 
function and microscopic structure can all be detected in type 2 diabetes before 
the onset of heart failure symptoms. Many of these features have been associated 
with adverse outcomes.  
1.4.1 Changes in cardiac morphology 
Several studies have demonstrated that type 2 diabetes is associated with 
increased LV mass and concentric remodelling of the left ventricle independently 
of blood pressure. Original studies were carried out using echocardiography and 
demonstrated that diabetes was associated with increased LV wall thickness and 
LV mass (Galderisi et al., 1991; Devereux et al., 2000). Echocardiographic 
assessment of LV mass is dependent on image quality and echocardiographic 
windows. CMR assessment of LV dimensions is not hampered by these issues and 
consequently the assessment of LV mass by this technique is significantly more 
reproducible (Grothues et al., 2002).  
CMR data of 4869 patients from the large observational MESA (Multiethnic study 
of atherosclerosis) study (Heckbert et al., 2006) demonstrated that diabetes is 
associated with an increase in LV mass. After regression analysis for multiple risk 
factors including BMI and systolic blood pressure diabetes was associated with a 
3.5g greater LV mass (95% confidence interval 1.2-5.8g).  
In large population studies not specifically restricted to patients with type 2 
diabetes increased LV mass predicted the onset of heart failure after correction for 
other risk factors such as blood pressure and coronary disease (de Simone et al., 
2008; Bluemke et al., 2008). However no studies to date have been carried out 
investigating the association between LV mass and heart failure in low risk patients 
with diabetes.  
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1.4.2 Changes in cardiac function 
As many as 75% of asymptomatic patients with type 2 diabetes have abnormal 
parameters of diastolic function measured by conventional Doppler and tissue 
Doppler (TDI) echocardiography (Poirier et al., 2001; Boyer et al., 2004). In addition 
impaired peak longitudinal systolic velocity measured by TDI (Kosmala et al., 2004) 
and by speckle tracking (Ng et al., 2009) has also been reported in patients with 
type 2 diabetes. It is possible to measure strain in three dimensions using CMR 
tissue tagging. Using this technique both circumferential strain and longitudinal 
strain are reported to be impaired in type 2 diabetes (Fonseca et al., 2004).  
TDI echocardiography provides prognostic information in patients with type 2 
diabetes. E/E’ ratio measured by TDI is a relatively simple measurement and is a 
well validated non-invasive measure of left ventricular filling pressure (Ommen et 
al., 2000). A retrospective study of 1760 patient with diabetes by From et al 
identified 23% of patients with elevated E/E’ and therefore diastolic dysfunction 
(From et al., 2010).  Over 5 years follow up the cumulative proportion of those who 
developed heart failure was 36.9% in those with elevated E/E’ compared to 16.8% 
in those with normal E/E’. Age, hypertension, coronary artery disease and ejection 
fraction were stronger predictors of heart failure development than diastolic 
dysfunction but even after adjusting for these factors E/E’ was a strong predictor of 
the development of heart failure.  These findings were not replicated in a recent 
prospectively recruited study of 305 patients with type 2 diabetes without history 
of coronary artery disease (Poulsen et al., 2013) who all underwent single-photon 
emission computed tomography (SPECT) and TDI echocardiography. They found 
that age, hypertension, E/E’ and left atrial volume but not ischaemia on SPECT 
were predictors of a composite of cardiovascular events or mortality. However on 
multivariable regression analysis left atrial volume and ejection fraction were the 
only independent predictors of cardiovascular events or mortality. Measuring E’ by 
TDI during exercise can provide incremental evidence about diastolic function 
which appears to have prognostic information. E’, representing passive filling of the 
left ventricle, normally increases during exercise. It is reported that that this 
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response can be impaired in diabetes and has been associated with increased 
mortality and heart failure admissions on follow up (Kim et al., 2011). 
The prognostic significance of systolic strain parameters in type 2 diabetes has also 
been studied. Impaired global longitudinal strain measured by speckle tracking 
echocardiography was associated with increased mortality and hospitalisation 
(Holland et al., 2015). Although not specifically studied in diabetes impaired global 
circumferential strain measured by CMR tagging has been shown to be associated 
with subsequent development of heart failure (Choi et al., 2013).  
Measurement of diastolic dysfunction by echocardiography is a comparatively 
cheap screening tool that does not involve exposure to ionising radiation. There is 
some conflicting data that suggests diastolic dysfunction may predict the onset of 
heart failure in type 2 diabetes. However diastolic dysfunction is a prevalent finding 
and has significant interactions with other risk factors such as age, blood pressure 
and presence of coronary disease. Furthermore randomised studies of 
interventions have failed to demonstrate an improvement in E/E’ with intervention 
(van der Meer et al., 2009; Ofstad et al., 2014).  
Left ventricular torsion is a measure of the wringing motion of the heart calculated 
from the basal clockwise rotation and apical anticlockwise rotation. It can be 
measured by speckle tracking echocardiography or tagged CMR images. A 
paradoxical increase in left ventricular torsion has been reported in diabetes 
(Chung et al., 2006) and is thought to be due to small vessel ischaemia, 
subendocardial myofibre dysfunction and compensatory increased subepicardial 
myofibre contraction (Larghat et al., 2014). It was demonstrated in a randomised 
study of sildenafil, a phosphodiesterase type 5 inhibitor, in patients with diabetes 
that these changes could be overcome and torsion normalised (Giannetta et al., 
2012). However it remains to be established whether torsion is associated with 
increased heart failure or mortality on long term follow up.  
1.4.3 Changes in myocardial tissue characteristics  
ECV fraction has been demonstrated to be increased in asymptomatic patients 
with type 2 diabetes and also associated with impaired diastolic strain detected by 
TDI echocardiography (Jellis et al., 2011; Ng et al., 2012).  A recent study by Wong 
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et al followed up 231 patients with type 2 diabetes who had clinically indicated 
CMR for a median duration of 1.3 years (Wong et al., 2013). They found those with 
a higher ECV were at higher risk of heart failure admission or death (hazard ratio 
1.52 per 3% increase in ECV). However it should be noted that in the study of Wong 
et al the patients were recruited from clinical scans they were not asymptomatic 
and in fact had a high rate of prior coronary revascularisation (33%) and prior 
myocardial infarction (11%).   
ECV holds real promise as a potential screening tool for identifying those at highest 
risk of heart failure. However the prognostic value of ECV in asymptomatic patients 
and whether ECV can be altered by any intervention remains to be established.  
Magnetic resonance spectroscopy is able to measure the concentration of 
metabolites within the heart non-invasively without the use of ionising radiation. 
Studies have shown that patients with type 2 diabetes have increased cardiac 
triglyceride content, termed steatosis (McGavock et al., 2007). Furthermore cardiac 
steatosis in type 2 diabetes is associated with impaired function measured by both 
systolic and diastolic strain measured by TDI and speckle tracking 
echocardiography (Rijzewijk et al., 2008; Ng et al., 2010). However it remains to be 
established whether this process can be reversed and whether it is independently 
associated with adverse prognosis.  
1.4.4 Changes in microvascular function 
Silent ischaemia due to epicardial coronary artery stenosis can be detected by 
several techniques including nuclear imaging, stress echocardiography and first 
pass perfusion CMR (see 1.5.4). SPECT measures relative blood flow and is 
therefore not able to detect abnormalities in the microvasculature. Conversely, 
positron emission tomography (PET) allows the non-invasive quantification of 
absolute myocardial blood flow at rest and during pharmacological vasodilator 
stress. Comparing the blood flow at rest and stress allows the calculation of 
coronary flow reserve (CFR). In the absence of coronary disease impairment of CFR 
reflects microvascular dysfunction.  
Impaired CFR detected by PET is has been reported in asymptomatic patients with 
type 2 diabetes without known coronary disease (Nahser et al., 1995) and is shown 
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to correspond with degree of hyperglycaemia measured by Hba1c rather than 
insulin resistance (Yokoyama et al., 1998). Patients with impaired CFR measured by 
PET are reported to also have increased ECV measured by CMR (Rao et al., 2013). 
Studies have shown that abnormalities in myocardial blood flow detected by PET 
can also be reversed by interventions including pioglitazone (Naoumova et al., 
2007) and spironolactone (Garg et al., 2015). There is also evidence that CFR 
impairment in type 2 diabetes is associated with excess cardiovascular risk. Murthy 
et followed up 1172 patients with diabetes after a clinically indicated PET scan for a 
median duration of 1.4 years (Murthy et al., 2012). Those with CFR below the 
median had an adjusted hazard ratio of 3.2 for cardiac death compared to those 
with CFR above the median. Diabetic patients without coronary artery disease but 
impaired CFR had a comparable event rate to diabetic patients with coronary 
artery disease. However these patients were not asymptomatic with 47.2% having 
the test because of chest pain and had a high rate of prior revascularisation (45.6%) 
and prior myocardial infarction (36.1%).   
Coronary blood flow during stress is impaired in patients with type 2 diabetes 
independent of epicardial coronary artery disease. These changes can be reversed 
by medical therapy and appear to be associated with adverse outcomes (Murthy et 
al., 2012; Garg et al., 2015). Cardiac PET however is not widely available and 
involves exposure to ionising radiation. It is possible to measure CFR with other 
techniques including stress first pass perfusion CMR (Ibrahim et al., 2002) and 
stress echocardiography (Cortigiani et al., 2007). However these techniques can be 
challenging and do not have as broad an evidence base as CFR measured by PET.  
 
1.5 Asymptomatic ischaemic heart disease in diabetes 
1.5.1 Myocardial infarction 
MI is the single largest cause of mortality in type 2 diabetes. Electrocardiogram 
(ECG) remains the most important diagnostic test in acute MI and is used to 
prioritise which patients should receive urgent reperfusion therapy. In patients 
with chest pain but ECG changes non-diagnostic of acute MI imaging modalities can 
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be used to detect acute changes in structure and function that may help confirm or 
rule out a diagnosis of MI. The presence of acute myocardial infarction can be 
confirmed by urgent echocardiography demonstrating wall motion abnormality. 
The diagnostic and prognostic accuracy can be improved further by the addition of 
strain imaging, intravenous contrast, physiological or pharmacological stress (Shah 
et al., 2013). The presence of a perfusion defect on resting SPECT is an alternative 
method to confirm the diagnosis (Udelson et al., 2002). CMR can detect the 
presence of acute MI by wall motion abnormality or perfusion defect and is also 
able to detect the presence of oedema using T2 weighted imaging or scar imaging 
by LGE (Cury et al., 2008). Finally using CT coronary imaging it is possible to exclude 
acute coronary stenosis with high negative predictive value (Hulten et al., 2013).  
After the acute phase of MI chronic changes such as scarring, fibrosis, associated 
wall motion abnormalities and perfusion defects can be detected. Therefore the 
techniques most commonly used to detect chronic MI include ECG, 
echocardiography, nuclear techniques and CMR.  
 
Chronic MI can be diagnosed by 12 lead ECG according to the presence of Q waves. 
Although a good screening test, the sensitivity to detect chronic MI is reported to 
be only 33% (Jaarsma et al., 2013). The prevalence of silent MI by the presence of 
Q waves in patients with newly diagnosed type 2 diabetes in UKPDS was reported 
to be 17% (Davis et al., 2013).   The adjusted hazard ratio for all cause mortality of 
diabetic patients with silent MI by Q waves compared to those without over 17 
years follow up was 1.31. The mortality of diabetic patients with silent MI detected 
by Q waves is reported to be similar to patients with recognised MI (Davis et al., 
2004).  
Silent MI can also be assessed by SPECT by intravenous injection of a gamma 
emitting radioisotope during rest and stress (either exercise induced or 
pharmacological). An area of myocardium that has decreased tracer uptake at both 
rest and stress is deemed non-reversible and has been shown to correspond to 
areas of prior myocardial infarction (Zellweger et al., 2002). The prevalence of 
silent MI assessed using this technique was reported to be 28.5% in patients with 
type 2 diabetes undergoing SPECT for clinical purposes (Arenja et al., 2013).  
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Currently the best validated method for the presence and extent of silent MI is the 
LGE technique measured by CMR. Kwong et al first reported a prevalence of 28% of 
silent MI using LGE imaging in symptomatic patients without prior MI type 2 
diabetes undergoing CMR (Kwong et al., 2006). Schelbert et al reported a 
prevalence of 21% of silent MI of diabetic patients enrolled in the ICELAND MI 
study who underwent CMR between 2004 and 2007 (Schelbert et al., 2012). 
However patients in both studies were not necessarily asymptomatic and in 
ICELAND MI 28% of those with silent MI had prior coronary revascularisation. In 
both of these studies the presence of silent MI in diabetes was associated with 
significant morbidity and mortality. Kwong et al reported that over 17 months 
follow up the presence of silent MI in patients with diabetes was associated with 
increased mortality (hazard ratio 3.72, P<0.001) and major adverse cardiovascular 
events (MACE) (HR3.61, P=0.007)(Kwong et al., 2006). Schelbert et al reported that 
that over 6.4 years follow up the mortality of all patients with silent MI was similar 
to those with recognised MI (28% vs 33%, P=0.40) (Schelbert et al., 2012).   
Asymptomatic patients with type 2 diabetes have increased risk of silent 
myocardial infarction compared to normoglycaemic patients. The exact prevalence 
of silent MI In type 2 diabetes varies according to imaging modality and the extent 
of symptoms patients had within the study. However whichever imaging modality 
is used it is clear that those with silent MI are at increased risk or mortality and 
morbidity. At present the LGE technique is favoured for the detection of silent MI 
given its improved sensitivity compared to ECG, echocardiography and SPECT 
(Ibrahim et al., 2007) without the need for ionising radiation. 
1.5.2 Plaque Imaging  
Most imaging methods can only detect MI, silent or recognised, after the event. 
Although the risk of future MI is highest in those with previous MI, it may also be 
possible to predict the likelihood of future MI directly with imaging. Molecular 
imaging techniques with radiolabelled molecules have been used to detect the 
pathological components of unstable coronary plaques. 18F-fluorodeoxyglucose 
(18F-FDG) PET can to identify high risk plaques in large arteries (Langer et al., 
2008). However this technique is unable to identify unstable plaque in the 
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coronary vessels as it is hampered by myocardial activity (Dweck et al., 2012).  18F-
sodium fluoride (18F-NaF) is able to overcome this issue and identify localised 
ruptured and unstable plaque particularly when combined with anatomical CT 
imaging (Joshi et al., 2014).  
Cross sectional imaging techniques are also reported to be able to identify high risk 
plaque according to its anatomical features. Plaques with positive remodelling and 
low attenuation identified by CT coronary angiography are at significantly higher 
risk of myocardial infarction over 3.9 years follow up (Motoyama et al., 2015). Non 
contrast CMR coronary imaging is able to identify plaques with increased T1 
weighted signal, a marker of increased tissue water content and potentially plaque 
instability (Hoshi et al., 2015). After a year treatment with high dose statin therapy 
there was a significant decrease in the intensity of the coronary signal suggesting 
plaque stabilisation (Noguchi et al., 2015).  
The prognostic utility of imaging techniques to identify unstable coronary plaque in 
low risk and asymptomatic patients (particularly those with diabetes) has not yet 
been established and requires significant expertise for acquisition and post 
processing. It is likely however that in the near future these techniques will be 
important to identify patients with diabetes at the highest risk of acute coronary 
events for inclusion in clinical trials.  
  
1.5.4 Stable Coronary Artery Disease 
It is possible to detect stable coronary artery disease either by detecting the 
stenosis itself by anatomical imaging of the coronary tree (usually by CT, CMR or 
invasive angiography) or by detecting the inducible ischaemia that occurs as a 
consequence of the stenosis. Testing for ischaemia typically involves the 
administration of pharmacological or physiological stress and then imaging to 
detect either decreased uptake of contrast (SPECT, PET or CMR first pass perfusion) 
or wall motion abnormality as a consequence of ischaemia (stress 
echocardiography).  
Patients with diabetes and significant inducible ischaemia have increased 
mortality. It is reported that in patients with diabetes undergoing SPECT for clinical 
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purposes that mortality and non-fatal MI increase from 1-2% for those with normal 
MPS to 7% for those with moderate to severe inducible ischaemia (Kang et al., 
1999). Furthermore the high event rate associated with significant inducible 
cardiac ischaemia appears to be independent of the presence or absence of 
symptoms (Zellweger et al., 2004).  
However randomising asymptomatic diabetic patients to screening with SPECT in 
Detection of Silent Myocardial Ischemia in Asymptomatic Diabetics (DIAD) study 
did not alter their mortality (Young et al., 2009). 1123 patients with type 2 diabetes 
were randomised to investigation by SPECT screening or not. 113/522 patients 
(22%) in the SPECT arm had silent ischemia (Wackers et al., 2004). Although the 
prevalence of ischaemia was high the reported cardiovascular event rate was very 
low (0.6% per year) leading the authors to suggest that routine SPECT could not be 
recommended in patients with type 2 diabetes (Young et al., 2009). These 
recommendations have been repeated in European guidelines (Perrone-Filardi et 
al., 2011).  
Similarly to DIAD the utility of screening asymptomatic diabetic patients for 
coronary artery disease using CT coronary angiography has been tested in the 
FACTOR 64 trial (Muhlestein et al., 2014). 900 patients were randomised to either 
CT or standard care. 76/336 patients who underwent CT coronary angiography had 
moderate or severe coronary stenosis which resulted in 25 coronary 
revascularisation procedures. However despite the intervention there was no 
difference in the primary outcome a composite of all-cause mortality, nonfatal MI, 
or unstable angina requiring hospitalization over 3 to 5 years follow up between CT 
guided or standard care (6.2% vs 7.6%, P=0.38).  
Despite the high prevalence of stable coronary artery disease detected in 
asymptomatic patients with type 2 diabetes by SPECT or CT the associated 
mortality appears to be low. Two high quality landmark trials (DIAD and FACTOR 
64) using different imaging modalities have both shown that intervening upon 
silent stable coronary artery disease in this population does not appear to alter 
long term outcomes. Although it is possible to detect silent stable coronary artery 
disease in asymptomatic patients with type 2 diabetes, it is associated with only 
modest increase in mortality which does not appear to be altered by intervention.  
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Therefore screening for subclinical stable coronary artery disease cannot be 
recommended.  
 
1.6 Aims of thesis  
Using CMR imaging it is possible to detect subclinical cardiac change in both 
disease and health. This has several potential applications in both clinical 
cardiology and research. Detection of subclinical change in asymptomatic subjects 
allows for the identification of disease prior to the onset of symptoms. For patients 
this facilitates early diagnosis and treatment, which has the potential to improve 
outcomes.  Certain imaging parameters that can be detected in asymptomatic 
patients have been independently associated with increased mortality. By 
specifically recruiting patients to studies who display subclinical pathology on 
imaging it may be possible to increase the event rate and even decrease the 
required sample size. Depending upon the parameter chosen it may also be 
possible to monitor the progression of subclinical disease. This could potentially be 
used clinically or as a surrogate end point in research.  
 
The subsequent chapters each have a specific aim with individual introduction, 
methods, results and discussion: 
Study 1: To establish whether T1 and ECV mapping can distinguish athletic cardiac 
remodelling from HCM 
Study 2: To investigate whether regional strain impairment in HCM is an early or 
late feature of HCM 
Study 3: To study the three dimensional changes in strain parameters in highly 
trained endurance athletes and their relationship with aerobic capacity 
Study 4: To identify whether increased risk of heart failure in patients with type 2 
diabetes is mediated by focal or diffuse cardiac fibrosis 
Study 5: To establish which parameters might be useful in screening for silent 
myocardial infarction in patients with type 2 diabetes  
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2  . Study 1- CMR to differentiate hypertrophic 
cardiomyopathy from athlete’s heart  
2.1 Abstract 
Background 
Athletes who train regularly can develop left ventricular (LV) hypertrophy, which 
can be difficult to differentiate from hypertrophic cardiomyopathy (HCM), the 
leading cause of sudden cardiac death in young athletes. Cardiovascular magnetic 
resonance (CMR) T1 and extracellular volume (ECV) mapping provide quantitative 
assessment of myocardial composition. We hypothesised that ECV could 
differentiate athletic from pathological hypertrophy, in particular in subjects with 
indeterminate segment thickness. 
Methods  
50 HCM patients, 40 athletes and 35 volunteers underwent 3.0T CMR including 
5b(3s)3b Modified Look-Locker Inversion (MOLLI) T1 maps before and 15 minutes 
after administration of 0.15mmol/kg intravenous gadobutrol. Native T1 and ECV 
were measured for each segment of each subject.  
Results  
Native T1 and ECV of the thickest segment were significantly lower in athletes than 
HCM (1175.5±37.3ms vs 1261.1±52.3ms and 22.2±3.5% vs 32.8 ±9.0%, P<0.001 for 
both). On receiver operator curve analysis the area under the curve (AUC) to 
differentiate HCM from athlete for native T1 was 0.91 and ECV 0.95 (P<0.001). The 
maximal segment thickness overlapped between HCM and athletes in 26 
individuals (13 athletes and 13 HCM).  The AUC of ECV, native T1 and EDV/LV mass 
to differentiate between athletes and HCM in these indeterminate subjects were 
0.99, 0.95, and 0.82 respectively, P<0.001 for all. The optimal cut-off to diagnose 
HCM was ECV>22.5% (sensitivity 100%, specificity 92%), native T1>1190.4 
(sensitivity 100%, specificity 77%). In these subjects diagnostic accuracy of ECV was 
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significantly better than EDV/LV mass or the presence of LGE, P=0.03 and P<0.001, 
respectively. 
Conclusions 
T1 mapping and ECV measurement by CMR can be used to distinguish HCM and 
athletic remodelling with high diagnostic accuracy and has a potential role in the 
exclusion of HCM in athletes presenting with intermediate left ventricular wall 
thickness. 
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2.2 Introduction  
Athletes who train and compete regularly develop changes in cardiac morphology 
and function, most notably an increase in LV mass (Maron and Pelliccia, 2006). This 
increase in LV mass occurs as early as 6 months after commencement of 
endurance training (Arbab-Zadeh et al., 2014) and may be accompanied by an 
increase in LV end-diastolic volume (LVEDV) resulting in a typical phenotype of 
eccentric remodelling referred to as “athlete’s heart” (Maron, 2003; Utomi et al., 
2013). An important differential diagnosis of athlete’s heart is HCM. Although rare 
(Basavarajaiah et al., 2008), HCM is the leading cause of sudden cardiac death in 
young athletes (Maron et al., 2009a). Current guidelines advise that patients with 
HCM should avoid competitive sport and it is therefore imperative that HCM and 
physiological remodelling are correctly distinguished in an athlete with LV 
hypertrophy (Gersh et al., 2011; Elliott et al., 2014). Several imaging parameters 
have been reported to differentiate athletic from pathological hypertrophic 
remodelling (Pelliccia et al., 1991; Pelliccia et al., 2012; Luijkx et al., 2013). In 
subjects with very localised and asymmetric hypertrophy, the differentiation 
between the two entities can be straight-forward. However, when myocardial 
thickness is borderline or more widespread, it can be challenging to exclude a 
diagnosis of HCM in athletes (Basavarajaiah et al., 2008; Rawlins et al., 2010). 
Establishing the correct diagnosis may then require the athlete to undergo a period 
of detraining, which is challenging in elite athletes (Pelliccia et al., 2002).  
CMR is increasingly used to aid in the differential diagnosis of LV hypertrophy 
because it provides more accurate measurements of LV thickness than 
echocardiography (Valente et al., 2013) and permits detection of focal scar 
according to the presence of LGE (Maron et al., 2009b). While LGE imaging appears 
to have merits in risk stratification, it is a qualitative technique, and detection of 
pathology requires a contrast between normal and abnormal tissue, limiting 
application in diffuse myocardial change. In contrast, T1 mapping provides 
quantitative assessment of myocardial composition and diffuse fibrotic change, by 
measuring either the native T1 alone or myocardial ECV from both native and post 
contrast T1 mapping (Flett et al., 2010). ECV in HCM has been shown to be 
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increased even in segments that do not have scar on LGE (Kellman et al., 2012). 
This elevation in ECV is thought to be related to myocardial disarray, the 
pathological hallmark of HCM (Sheppard, 2012). We hypothesised that athlete’s 
heart, conversely, is characterised by myocyte hypertrophy without ECV expansion 
and therefore, that T1and ECV mapping can differentiate between HCM and 
athlete’s heart. We specifically investigated the ability of the CMR methods to 
differentiate between the entities in those subjects with borderline myocardial 
thickness. 
 
2.3 Methods 
2.3.1 Enrolment Criteria 
40 athletes, 50 patients with HCM and 35 volunteers were enrolled in the study. 
Patients under the age of 65 with HCM were recruited from the Inherited 
Cardiovascular Conditions Service at Leeds General Infirmary, Leeds, UK. The 
diagnosis of HCM was made independently by clinicians in keeping with current 
guidelines and based upon imaging, ECG, exercise testing, family history and 
genetic testing if possible (Elliott et al., 2014; Gersh et al., 2011). We specifically 
identified patients with definite HCM but maximum segment thickness <15mm. 
Exclusion criteria were previous surgical myomectomy, previous septal ablation, 
atrial fibrillation, previous myocardial infarction, uncontrolled hypertension, 
permanent pacemaker, defibrillator or other contraindication to CMR. Of the 40 
athletes, 11 were runners, 13 were triathletes and 16 were cyclists. These sports 
were chosen as they are reported to lead to cardiac remodelling to differing 
extents (Maron and Pelliccia, 2006; Utomi et al., 2013). All athletes trained more 
than 6 hours a week, competed at local or national level and were under the age of 
45. Athletes underwent cardio-pulmonary exercise testing to ensure high fitness 
levels. They had a mean VO2max of 58.3 ± 9.0 ml/min/kg, a similar level to that 
associated with athletic cardiac remodelling previously (Arbab-Zadeh et al., 2014; 
Sharma et al., 2000). The 35 healthy volunteers exercised less than three hours per 
week. No athletes or controls had any other medical conditions or took any regular 
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medication. The study was conducted in accordance with the declaration of 
Helsinki and was approved by the local ethics committee (14/YH/0126). All subjects 
gave informed written consent.  
2.3.2 CMR protocol 
All subjects underwent identical CMR protocol performed on a 3.0 Tesla Philips 
Achieva TX system (Philips, Best, The Netherlands) equipped with a 32 channel 
cardiac phased array receiver coil. A full blood count, including haematocrit was 
measured at the time of intravenous cannulation. The cardiac long and short axes 
were determined using standard scout views. Basal, mid and apical pre-contrast 
(native) T1 maps were generated using a validated MOLLI protocol (Kellman et al., 
2013) (ECG triggered 5b(3s)3b MOLLI scheme with voxel size of 1.98 x 1.98 mm2, 
slice thickness 10mm) and were planned using the 3 of 5 method (Messroghli et al., 
2005). Left ventricular volumes were obtained from cine imaging covering the 
entire LV in the short axis: balanced SSFP, voxel size 1.2 x 1.2mm2, slice thickness 
10mm with no gap, 50 cardiac phases. Left atrial (LA) volumes were obtained from 
cine imaging covering the entire heart in the transverse axis: balanced SSFP, voxel 
size 1.2 x 1.2mm2, slice thickness 6mm with no gap, 50 cardiac phases. 
0.15mmol/Kg Gadovist (Bayer Schering) was delivered by power injector (Medrad 
Inc, Warrendale, Pennsylvania, USA) as a single bolus via a cannula placed in the 
ante-cubital fossa followed by 20ml saline flush. Two-dimensional LGE imaging 
with whole heart coverage was performed seven to ten minutes following contrast 
administration and a Look Locker TI scout. Post contrast T1 maps were performed 
using the same MOLLI scheme fifteen minutes after contrast administration. 
2.3.3 CMR interpretation 
Analysis was carried out using standard software (cvi42, Circle CVI, Canada) by two 
physicians blinded to clinical and exercise data (BE & AKM). LV mass, end diastolic 
volumes (EDV), end systolic volume (ESV) and LV ejection fraction (EF) were 
measured from short axis cine images. LA volume was measured from the 
transverse image in atrial end diastole.  Native and post contrast T1 relaxation time 
of myocardium and blood pool were measured from the scanner generated T1 
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maps by contouring a region of interest in each segment of the American Heart 
Association (AHA) model (Cerqueira et al., 2002). ECV was calculated from native 
and post contrast T1 times of myocardium and blood pool and haematocrit as 
previously reported (Flett et al., 2010). Segment thickness was measured from 
diastolic SSFP cine images with corresponding slice location to the T1 maps. The 
thickest maximal thickness athlete segment was 13.8mm the thinnest maximal 
thickness HCM segment was 10.6mm.  Segments that fell in this overlapping range 
were therefore defined as indeterminate in this cohort (Valente et al., 2013). The 
presence of LGE in each AHA segment was reported by 2 physicians experienced in 
CMR interpretation.  
2.3.4 Statistical analysis 
Continuous variables were expressed as means ± SD. Categorical variables were 
expressed as N (%). Shapiro-Wilk test was used to test normality and depending on 
the result analysis of variance (ANOVA) and Kruskal Wallis test were used to 
compare means of athletes, HCMs and controls.  Mann Whitney U test was used to 
compare athletes and HCMs. Pearson’s correlation coefficient and Spearman’s rank 
correlation were used for linear correlations as appropriate. 
Receiver operating characteristic (ROC) analysis was used to determine the 
diagnostic accuracy of native T1, ECV, LV mass and EDV/LV mass on a per subject 
and per segment analysis. The diagnostic accuracy is expressed as area under the 
ROC curves (AUC) and 95% confidence interval. Nested models were used to assess 
the additive value when combining native T1, ECV and EDV/LV mass. AUCs were 
compared by using validated methods described by DeLong et al (DeLong et al., 
1988). Optimal sensitivity and specificity were calculated using Youden index. 
Reclassification tables were constructed using decile cut-offs  from which net 
reclassification index (NRI) was calculated to assess the incremental value of native 
T1 and ECV over EDV/LV mass (Pencina et al., 2008). ROC and NRI analysis was 
repeated in subjects who were defined as indeterminate. P<0.05 was considered 
statistically significant.  
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Figure 2.1 CMR images comparing a healthy athlete (left) and patient with HCM 
(right). On SSFP cine imaging both the athlete (A) and HCM patient (B) had a 
maximal end diastolic septal thickness of 13mm and EDV/LV mass of 1.6. On LGE 
imaging neither the athlete (C) or HCM (D) had any focal scarring or fibrosis. On 
ECV mapping the septal ECV of the athlete (E) was 22% and HCM (F) was 30%. 
Using the cut-off of 22.5% only ECV identified both subjects correctly.  
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2.4 Results 
Baseline characteristics are shown in Table 2.1. Weight and BMI were lower in 
athletes than controls and HCMs (P=0.02 and P<0.01 respectively). CMR findings of 
LV EDV, ESV, EF, LV mass, EDV/LV mass, maximal segment thickness, LVOT 
obstruction, native T1 and ECV in the three groups are shown in Figures 2.1 & 2.2 
and Table 2.2. The range of maximum segment thicknesses was 6.4-10.8mm, 7.0-
13.8mm and 10.6-28.0mm in control, athlete and HCM respectively.     
 
 
Table 2.1 Subject characteristics. FH, family history; HCM, hypertrophic 
cardiomyopathy 
 Athlete Control HCM P value 
N 40 35 50 NA 
Male gender, n (%) 32 (80) 27 (77) 37 (74) 0.80 
Age, years 31.3 ± 6.9 36.2 ± 11.7 46.9 ± 11.7 <0.001 
Height, cm 178.5±8.2 174.6±13.0 171.2 ± 9.0 <0.01 
Weight, kg 72.3±9.8 80.2±12.6 81.7±14.6 <0.001 
Body mass index, kg/m2 22.6±2.2 26.6±5.6 27.7±3.7 <0.001 
Systolic blood pressure, 
mmHg 
119.3±8.2 117.8±12.5 125.5±17.6 0.05 
Diastolic blood pressure, 
mmHg 
69.0±9.3 65.4±11.9 74.5±12.5 <0.01 
Heart rate 54.9±6.8 61.9±8.0 60.6±10.2 <0.001 
FH of HCM, n (%) 0 0 19 (38) <0.001 
Hours training per week 11.7±4.7   NA 
Number of years training at 
>6 hours per week 
8.7±5.9   NA 
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45/50 HCM patients had maximal segment thickness measured by 
echocardiography prior to CMR (5 had apical HCM where segment thickness could 
not be assessed accurately by echocardiography). Maximum segment thickness by 
echocardiography was on average 2.2mm thicker than by CMR (19.8±4.9mm vs 
17.6±3.9mm, P=0.001).  
 
Figure 2.2 Box and whisker plots showing maximum segment thickness, native T1, 
ECV and EDV/LVM for athletes, controls and HCMs showing median (line), mean 
(small square), interquartile range (box) and outliers (whiskers).  
 
Native T1 and ECV of the thickest segment were both significantly lower in athletes 
than HCMs (1175.5.8 ±37.3ms vs 1261.1±52.3ms and 22.2±3.5% vs 32.8 ±9.0%, 
P<0.001 for both). LV mass and LVMI were not significantly different between 
athlete and HCM (P=0.46 and P=0.97 respectively). LV EDV and LV EDVI were 
higher in athletes (219.4±34.3ml vs 155.0±32.2ml and 115.1±14.3ml/m2 vs 
78.7±13.13ml/m2, P<0.001 for both) and EF lower (56.0 ± 4.5% vs 62.3 ± 5.9%, 
P<0.001). EDV/LV mass was higher in athletes than HCMs (1.7±0.2ml/g vs 
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1.2±0.3ml/g, P<0.001). Two (5.8%) athletes had subepicardial lateral LGE in a 
myocarditis pattern, no controls had LGE and 35 (70%) HCMs had LGE.  
Native T1 and ECV of the thickest segment were both significantly lower in athletes 
than controls (1175.5±37.3 vs 1195.9±42.7ms, P=0.049 and 22.2±3.5% vs 
24.4±2.8%, P=0.004). 
 
Figure 2.3 Scatter plot showing maximal segmental thickness and corresponding 
ECV of the same segment. HCMs are hollow diamonds with solid trend line and 
athletes are filled circles with a dashed line. They grey area highlights the 
indeterminate zone between the thinnest maximal thickness HCM segment 
(10.6mm) and thickest maximal thickness athlete segment (13.8mm). 
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 Athlete  Control  HCM  P value 
LV EDV, ml 219.4±34.3 183.5±32.3 155.0±32.2 <0.001 
LV EDV indexed to BSA, 
ml/m2 
115.1±14.3 92.6±14.3 78.7±13.1 <0.001 
LV ESV, ml 96.6±19.0 79.2±18.3 59.1±17.7 <0.001 
LV Ejection Fraction, % 56.0±4.5 57.1±4.4 62.3±5.9 <0.001 
LV Mass, g 130.7±25.3 99.1±22.0 143.2 ± 50.1 <0.001 
LV Mass indexed to BSA, 
g/m2 
68.7±10.6 50.0±9.6 72.8 ± 26.3 <0.001 
LV EDV/ LV mass, ml/g 1.7±0.2 1.9±0.3 1.2±0.3 <0.001 
Left atrial volume, ml 100.0±17.2 88.1±19.2 116.6±28.9 <0.001 
LAV indexed to BSA, 
ml/m2 
53.1±8.1 44.4±7.8 59.3±13.5 <0.001 
Maximal segment 
thickness, mm 
9.9±1.5 8.9±1.2 17.1±4.0 <0.001 
LGE, n (%) 1 (2.9) 0 (0) 35 (70) <0.001 
LVOT obstruction, n (%) 0 0 11 (22) <0.001 
LVOT gradient, mmHg 0 0 68.5 ± 40.0 NA 
Thickest segment native 
T1, ms 
1175.5±37.3 1195.9±2.7 1261.1±2.3 <0.001 
Thickest segment ECV, % 22.2±3.5 24.4±2.8 32.8±9.0 <0.001 
 
Table 2.2 CMR findings. BSA, body surface area; ECV, extracellular volume; EDV, 
end diastolic volume; ESV, end systolic volume; LAV, left atrial volume; LGE, late 
gadolinium enhancement; LV, left ventricle; LVOT, left ventricular outflow tract 
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In athletes there were significant negative correlations between ECV and maximum 
segment thickness(r=-0.54, P<0.001), LV mass (r=-0.48, P<0.01) and LVMI (-0.42, 
P<0.01), see Figure 2.3. In controls there were significant negative correlations 
between ECV and maximum segment thickness(r=-0.45, P<0.01), LV mass (r=-0.42, 
P=0.01) and LVMI (-0.34, P=0.046). In HCMs there was a significant positive 
correlations between ECV and maximum segment thickness (rs=0.51, P<0.001) but 
no correlation with LV mass (P=0.42) or LVMI (P=0.34). For athletes, controls and 
HCM there were no significant correlations between native T1 and maximum 
segment thickness, LV mass or LVMI.  
2.4.1 Diagnostic performance 
To detect the 50 HCMs from the 40 athletes the diagnostic accuracy (AUC) of 
maximal segment thickness, native T1, ECV and EDV/LV mass were 0.962 [0.899-
0.991], 0.914 [0.836-0.963], 0.945 [0.876-0.982] and 0.944 [0.875-0.982] 
respectively, P<0.001 for all. There was no significant difference between AUCs, 
Figure 2.4.  In this cohort the optimal cut-offs to diagnose HCM were maximal 
segment thickness>12.4mm (sensitivity 84%, specificity 98%), ECV >24.1% 
(sensitivity 98%, specificity 78%), native T1 >1207.8ms (sensitivity 90%, specificity 
83%) and EDV/LV mass ≤1.36ml/g (sensitivity 78%, specificity 100%).  
We identified 26 indeterminate subjects (13 athlete and 13 HCMs) whose 
maximum segment thickness fell in the overlapping range of 10.6-13.8mm, Table 
2.3.  AUCs for native T1, ECV, and EDV/LV mass were 0.953 [0.790-1.000], 0.994 
[0.857-1.000], and 0.793 [0.590-0.925] respectively P<0.001 for all, Figure 2.5. AUC 
for maximal segment thickness was not significant 0.553 (0.124-0.747) P=0.46. The 
diagnostic accuracy of ECV was significantly better than EDV/LV mass (P=0.03). 
Native T1 was not significantly better than EDV/LV mass (P=0.08). The difference 
between ECV and native T1 was not significant (P=0.29). Native T1 and ECV were 
better than segment thickness (P<0.001 for both). EDV/LV mass was not 
significantly better than segment thickness (P=0.1). In patients with indeterminate 
maximal segment thickness the optimal cut-offs to diagnose HCM were ECV>22.5% 
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(sensitivity 100%, specificity 92%), native T1>1190.4 (sensitivity 100%, specificity 
77%). 
We also identified 15 subjects with maximum segment thickness of 12-15mm 
(Elliott et al., 2014; Gersh et al., 2011) (4 athletes and 11 HCMs). AUCs were; native 
T1 0.977[0.909-1.000] P=0.006 and ECV 1.000[1.000-1.000] P=0.006. AUCs for 
EDV/LV mass 0.818 [0.599-1.000] P=0.07 and segment thickness 0.761 [0.488-1.00] 
P=0.13 were not significant. Differences between AUCs were not significant.   
 
 
Table 2.3 Characteristics of 26 subjects in the indeterminate range of maximal 
segment thickness 10.6-13.8mm. BSA, body surface area; ECV, extracellular 
volume; EDV, end diastolic volume; ESV, end systolic volume; LAV, left atrial 
volume; LGE, late gadolinium enhancement; LV, left ventricle; LVOT, left ventricular 
outflow tract 
 
 Athlete HCM P value 
N 13 13 NA 
Male gender; n (%) 13 (100) 8 (74) 0.80 
Age, years 35.3±5.7 44.0±12.2 0.03 
LV EDV indexed to BSA, ml/m2 117.7±17.3  81.4±12.9 <0.001 
LV Mass indexed to BSA, g/m2 73.6±11.7 62.2±24.1 0.03 
LV EDV/ LV mass, ml/g 1.6±0.2 1.4±0.3 0.01 
LAV indexed to BSA, ml/m2 55.9±8.7 48.5±7.8 0.03 
LGE (%) 1 (8) 6 (46) 0.03 
LVOT obstruction (%) 0 0 NA 
Thickest segment native T1, ms 1166.1±35.7 1249.8±42.6 <0.001 
Thickest segment ECV, % 20.3±2.1 28.4  ±4.6 <0.001 
FH of HCM; N (%) 0 5 (38) 0.04 
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2.4.2 Combinations of Native T1, ECV and EDV/LV mass 
When the results of native T1 and ECV were combined with EDV/LV mass there 
were further improvements in the diagnostic accuracy. AUCs for the nested models 
were EDV/LV mass + native T1 0.979 [0.954-1.000] and EDV/LV mass + ECV 0.996 
[0.989-1.000] (P<0.001 vs EDV/LV mass for both). In indeterminate subjects AUCs 
for nested models were EDV/LV mass + native T1 0.911 [0.798-1.000] and EDV/LV 
mass + ECV 0.994 [0.975-1000] (P<0.001 vs EDV/LV mass for both).  
2.4.3 Net Reclassification Index 
When native T1 was added to EDV/LV mass 14 HCMs (28%) were re-classified 
correctly and 2 (4%) re-classified incorrectly. 19 (47.5%) athletes were reclassified 
correctly and 5 (12.5%) incorrectly (NRI=0.59, P<0.001). When ECV was added to 
EDV/LV mass 16 HCMs (32%) were re-classified correctly and 2 (4%) re-classified 
incorrectly. 21 (52.5%) athletes were reclassified correctly and 3 (7.5%) incorrectly 
(NRI=0.73, P<0.001). 
In indeterminate subjects when native T1 was added to EDV/LV mass 6 HCMs 
(46%) were re-classified correctly and 1 (7.7%) re-classified incorrectly. 7 (54%) 
athletes were reclassified correctly and 1 (8%) incorrectly (NRI=0.85, P=0.005). 
When ECV was added to EDV/LV mass 7 HCMs (54%) were re-classified correctly 
and 2 (15%) re-classified incorrectly. 9 (69.2%) athletes were reclassified correctly 
and 0 (0%) incorrectly (NRI=1.08, P=0.001). 
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Figure 2.4 Receiver operator characteristic curves for maximal segment thickness, 
native T1, ECV and EDV/LV mass for the detection of HCM against athletes. AUCs 
were 0.96, 0.91, 0.95 and 0.94 respectively P<0.001 for all. There was no significant 
difference between each of the measures. 
2.4.4 Segmental Analysis 
For segmental analysis, 640 athlete segments and 800 HCM segments were 
available. Of these, there were 23 athlete segments and 128 HCM segments in the 
indeterminate wall thickness range of 10.6-13.8mm. There were 123 HCM 
segments and no athlete segments >13.8mm. Native T1 and ECV were analysable 
for 149/151 of all indeterminate segments. The AUCs for ECV, native T1 and 
segment thickness to detect HCM segments against athlete segments in the 
indeterminate wall thickness diagnostic range were 0.90, 0.86, and 0.74 
respectively (P<0.001 for all, Figure 3.5). The diagnostic accuracy of ECV was 
superior to segment thickness (P= 0.03). The differences between native T1 and 
segment thickness, and native T1 and ECV were non-significant (P=0.06 and P=0.32 
respectively). 
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2.4.5 Late Gadolinium Enhancement 
2/40 athletes and 35/50 HCMs had LGE. Therefore the sensitivity and specificity of 
LGE on a per patient basis to diagnose HCM were 70% and 95% respectively. The 
AUC of LGE to diagnose HCM correctly was 0.825[0.731-0.897] P<0.001. The AUC 
of segment ECV was significantly better than LGE (P=0.002) although the difference 
between native T1 and LGE was non-significant (P=0.08). Of the 26 subjects with 
indeterminate maximal segment thickness 1/13 (8%) athletes and 6/13 (46%) 
HCMs had LGE. The AUC of LGE to diagnose HCM in these subjects was 
0.692[0.482-0.857] P=0.02 and was significantly worse than the AUC of native T1 
and ECV (P<0.001 for both).     
24/151 indeterminate HCM segments had LGE and 1/23 indeterminate athlete 
segments had LGE.  T1 maps were degraded by artefact in 2 HCM segments from 
the same patient and could not be analysed. When ROC analysis was performed on 
the 147 remaining LGE -ve segments of indeterminate wall thickness AUCs of ECV, 
native T1 and segment thickness remained significant  (0.89, 0.86, 0.74 
respectively, P<0.001 for all).  
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Figure 2.5 Receiver operator characteristic curves for native T1, ECV and EDV/LV 
mass for the detection of HCM against athletes of the 26 subject (13 HCM and 13 
HCM) in with indeterminate maximal segment thickness. AUCs were 0.95, 0.99 and 
0.82 respectively P<0.0001 for all. AUC for maximal segment thickness was 0.553 
P=0.46. The diagnostic accuracy of ECV was significantly better than EDV/LV mass 
(P=0.03). EDV/LV mass was not significantly better than segment thickness (P=0.1). 
2.5 Discussion 
In this study we have demonstrated that ECV measured by CMR T1 mapping is 
lower in athletes than in patients with HCM and this difference can be utilised to 
distinguish athlete’s heart from HCM, in particular in subjects with indeterminate 
maximal wall thickness, where the differential diagnosis between the two entities 
is most challenging. In these intermediate subjects, ECV was 20.3±2.1% in athletes 
and 28.4±4.6% in HCMs, permitting accurate distinction. Furthermore we have 
demonstrated that ECV is lower in athletes than healthy controls and that in both 
athletes and controls there is a strong negative correlation between ECV and LV 
mass suggesting that the increase in LV mass in healthy myocardium is mediated 
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by cellular hypertrophy rather than extracellular expansion. ECV was a better 
discriminator between athlete’s heart and HCM than EDV/LV mass or the presence 
of LGE.  
HCM is characterised by macroscopic and microscopic cardiac changes. 
Macroscopic changes are typified by differing patterns of LV hypertrophy, including 
asymmetric septal, concentric or apical hypertrophy and mitral valve 
abnormalities. Microscopic change is characterised by expansion of the 
extracellular space secondary to fibrosis and myocyte disarray (Varnava et al., 
2001), with the development of replacement fibrosis as the disease progresses. 
Current non-invasive imaging techniques rely upon the identification of gross 
cardiac abnormalities to confirm the diagnosis of HCM but do not interrogate 
microscopic change and change in tissue composition.  
A CMR protocol including assessment of cardiac morphology, scar with LGE 
imaging and myocardial tissue composition using T1 mapping and ECV calculation 
can provide a comprehensive assessment of both macroscopic and microscopic 
change associated with HCM. Several imaging parameters have been previously 
proposed to distinguish between physiological LVH and HCM including: left atrial 
remodelling (Pelliccia et al., 2005), changes in strain pattern (Vinereanu et al., 
2001), maximal oxygen consumption during cardiopulmonary exercise testing 
(Sharma et al., 2000) or composite assessments of multiple imaging findings 
(Caselli et al., 2014). Of these EDV/LV mass has been reported to be one of the best 
CMR discriminatory methods (Luijkx et al., 2013). In this study, to differentiate 
HCM from athletic remodelling native T1 and ECV performed as well as EDV/LV 
mass and maximum segment thickness in all patients and significantly better when 
segment thickness fell in the indeterminate zone. Therefore both native T1 and 
ECV have incremental value over established parameters. Furthermore we have 
demonstrated that in patients with indeterminate maximal segment thickness, a 
cut-off of 1190ms for native T1 or 22.5% for ECV was able to identify all patients 
with HCM correctly.    
We have also demonstrated that segmental wall thickness correlates with ECV in 
HCM with an inverse correlation seen in athletic adaptation. It is widely recognised 
that in HCM that ECV correlates with histological (Flett et al., 2010; Iles et al., 2015) 
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and cellular markers of fibrosis (Fang et al., 2013). The divergent finding that with 
increasing hypertrophy ECV decreases in athletes but increases in HCM provides a 
mechanistic explanation as to why ECV has high diagnostic accuracy and performs 
better than maximum segment thickness or EDV/LV mass in subjects with 
indeterminate hypertrophy.  
Myocyte disarray and fibrosis are the earliest pathological changes seen in HCM. 
Therefore changes in ECV can be detected before the development of hypertrophy. 
Left atrial dilatation, LVOT obstruction and replacement fibrosis (detectable as LGE) 
occur much later in the disease process and these parameters are therefore less 
useful in subjects with indeterminate maximal segment thickness.  
On analysis of indeterminate subjects and segments ECV performed better than 
native T1 for the diagnosis of HCM.  However measurement of native T1 still has 
merits that would support its use in this clinical application. Its measurement does 
not require intravenous cannulation, administration of contrast, or a blood sample 
to measure haematocrit. The major shortcoming of native T1 is that it varies 
significantly between field strengths, scanner vendor and technique used to 
measure it (Raman et al., 2013). Use of native T1 maps in clinical practice requires 
validation for the specific pulse sequence and field strength used (Moon et al., 
2013) . ECV on the other hand is less dependent on imaging platforms and field 
strengths (Raman et al., 2013) but does require the administration of a gadolinium 
based contrast agent. 
In our study 70% of HCM patients had abnormal LGE consistent with the reported 
prevalence of 40 to 80% (Chan et al., 2014; Rudolph et al., 2009). The high 
specificity (97.5%) of LGE in diagnosing HCM indicates that it is useful for 
confirming the diagnosis. In our study ECV still had a high diagnostic accuracy even 
in segments without focal scar on LGE. Therefore ECV is useful in differentiating 
athlete’s heart from the significant proportion of HCM that does not have LGE. 
2.6 Limitations 
All athletes were white and it remains to be established if our findings are 
applicable to other racial groups. The athletes in this study trained predominantly 
in endurance sports and had a high aerobic capacity (mean VO2max 58.3 ± 9.0 
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ml/kg/min) and whether our findings are applicable to non-endurance athletes is 
not known. However there is conflicting evidence about whether non-endurance 
training leads to cardiac remodelling (Utomi et al., 2013; Maron and Pelliccia, 
2006). 
The indeterminate zone from our population was 10.6-13.8mm which is less than 
the 12-15mm termed indeterminate in current guidelines (Gersh et al., 2011; Elliott 
et al., 2014). However we have measured segment thickness only from the same 
slice as the T1 maps to ensure they are from identical tissue. In our cohort 
maximum thickness measured by echocardiography was 2.2mm greater and it is 
likely that our indeterminate zone corresponds to 12-15mm measured from 
anywhere in the LV.  
There are still controversies about which is the most robust pulse sequence for 
measurement of myocardial T1 relaxation time. The dose of contrast, the number 
and timings of acquisitions also need to be considered. ECV was marginally lower in 
our healthy controls than in other published work which may reflect differences in 
vendor, field strength, pulse sequence, contrast regime and number of T1 
measurements after contrast administration (Kellman et al., 2012; Dabir et al., 
2014). At present it is therefore recommended that each site establish normal 
values considering these variables (Moon et al., 2013) prior to the clinical use of 
ECV in the athlete with unexplained LV hypertrophy.    
2.7 Conclusions 
 As LV hypertrophy increases ECV decreases in athletes but increases in HCM.  
Based on this divergent finding ECV can be used distinguish HCM and athletic 
remodelling with high diagnostic accuracy, in particular in subjects with 
indeterminate maximal segmental wall thickness. CMR using T1 mapping thus has 
a potential role in the exclusion of HCM in athletes presenting with left ventricular 
hypertrophy, but requires further validation in larger and more varied patient 
populations.  
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3. Study 2- Regional contractile dysfunction in 
hypertrophic cardiomyopathy is associated with 
extent of hypertrophy rather than diffuse fibrosis 
3.1 Abstract 
Introduction 
At present the diagnosis of hypertrophic cardiomyopathy (HCM) is made when one 
or more segment measure ≥15mm using cardiac imaging. International guidelines 
recommend the use of strain imaging in borderline cases. Using cardiovascular 
magnetic resonance (CMR) extracellular volume (ECV) mapping techniques it is 
possible to detect early phenotypic manifestation of HCM, such as extracellular 
matrix expansion, which can occur before overt hypertrophy. It is unknown 
whether strain impairment occurs early in the disease process when there is ECV 
expansion with overt hypertrophy.   
Methods  
50 patients with HCM underwent CMR studies at 3.0T including cine imaging in 
multiple planes, T1 mapping for calculation of ECV and late gadolinium 
enhancement (LGE) imaging. For each segment of the American Heart Association 
(AHA) model of each subject segment thickness, the presence of LGE and strain by 
feature tracking were measured.  
Results  
Circumferential strain by feature tracking (Ecc-FT) was lower in segments with ECV 
expansion (-17.0±10.3 vs -19.9±8.4%, N=783 P<0.001).  However in segments 
<15mm Ecc-FT was not significantly different between those with and without ECV 
expansion (19.7±9.2 vs -20.6±7.9%, N=684, P=0.43). In segments <15mm Ecc-FT 
was significantly lower in those with LGE (-12.9±8.2 vs -20.9±8.1%, N=684, P<0.001) 
There were significant correlations between Ecc-FT and both segment thickness 
and ECV (Rs=0.616 and 0.176 P<0.001 for both). However on multivariable linear 
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regression only segment thickness had a significant association with Ecc-FT (beta=-
0.54, p<0.001).  
Conclusion 
Regional strain impairment is predominantly associated with the degree of 
hypertrophy and replacement fibrosis assessed by the presence of LGE. In non-
hypertrophied segments strain is not significantly impaired by the presence of 
interstitial fibrosis detected by ECV expansion on T1 mapping. Therefore the 
presence of interstitial fibrosis may be a more useful method than impairment of 
strain of identifying HCM in subjects with borderline LV hypertrophy.  
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3.1 Introduction  
HCM is commonly defined as a disease of hypertrophy of the LV in the absence of 
another cardiac or systemic cause (Gersh et al., 2011).  It is typically caused by 
autosomal dominant mutations of genes encoding sarcomeric proteins and 
myofilament elements (Bos et al., 2009). These mutations lead to micro- and 
macroscopic changes within the heart including cellular disarray, hypertrophy and 
interstitial fibrosis. When myocyte disarray is widespread it is a sensitive and 
specific marker for HCM (Hughes, 2004). These changes lead to hypertrophy that 
can affect the heart in a variety of patterns, and may affect any segment  of the LV 
(Klues et al., 1995). Although hypertrophy can be widespread, phenotypic 
expression within the same heart can be variable and less than half of the ventricle 
may be hypertrophied in as many as 50% of patients (Maron et al., 2009b).  
At present the diagnosis of HCM is primarily made by the identification of one or 
more hypertrophied segments by a cardiac imaging modality (Gersh et al., 2011; 
Elliott et al., 2014).  In the majority of cases this involves identification of a 
segment ≥15mm by echocardiography. Increasingly CMR is used to confirm or 
make diagnosis of HCM when echocardiography is restricted by limited acoustic 
windows or the inability to assess all segments of the left ventricle.  
In addition to accurate volumetric measurement, CMR may also make an 
assessment of microscopic expression of the HCM phenotype. Cellular disarray and 
extracellular matrix expansion occur early in the disease process and can be 
detected by using quantitative T1 and ECV mapping; techniques which 
demonstrate good correlation with histology specifically in HCM (Flett et al., 2010; 
White et al., 2013). ECV expansion can be detected in genotype positive patients 
prior to the onset of overt hypertrophy (Ho et al., 2013). Replacement fibrosis 
occurs later in the disease process and is detected as the presence of LGE. 
Replacement fibrosis is progressive over the course of the disease (Todiere et al., 
2012) and its presence is associated with an adverse prognosis (Chan et al., 2014).  
 
Studies, predominantly using echocardiography speckle tracking to measure 
regional and global strain have demonstrated that impaired contractility is related 
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to the extent of hypertrophy and the presence of replacement fibrosis detected by 
LGE (Urbano-Moral et al., 2014; Popovic et al., 2008). Current guidelines therefore 
recommend that strain imaging could be used to investigate unexplained left 
ventricular hypertrophy that is not diagnostic of HCM (Gersh et al., 2011; Elliott et 
al., 2014). An alternative method to echocardiography for the assessment of 
regional strain is CMR tagging which is highly reproducible in this setting (Shehata 
et al., 2009; Swoboda et al., 2013). More recently, post processing feature tracking 
of cine CMR images allows quantification of strain without the need for acquisition 
of tagged images. Strain measured by feature tracking and tissue tagging are 
reported to show good agreement (Moody et al., 2015).   
Current evidence suggests that regional function assessed by strain imaging may be 
impaired later in the disease process of HCM when there is overt hypertrophy and 
replacement fibrosis. It is unknown whether impairment of contractile function 
occurs earlier in the disease process when there is myocyte disarray and 
extracellular matrix expansion in the absence of overt hypertrophy.  
We hypothesised that ECV expansion occurs prior to impairment of contractile 
function in the pathogenic process. We therefore assessed contractile function in 
segments with early (non-hypertrophied with ECV expansion) and late 
(hypertrophied with replacement fibrosis) phenotypic expression to  establish 
whether impairment of systolic function is an early or late feature of HCM.  
 
3.2 Methods 
3.2.1 Enrolment Criteria 
 50 patients with HCM under the age of 65 with HCM were prospectively recruited 
from the Inherited Cardiovascular Conditions Service at Leeds General Infirmary, 
Leeds, UK. The diagnosis of HCM was made independently by clinicians in keeping 
with current guidelines and based upon imaging including CMR, ECG, exercise 
testing, family history and genetic testing if possible (Elliott et al., 2014; Gersh et 
al., 2011). Exclusion criteria were previous surgical myomectomy, previous septal 
ablation, atrial fibrillation, previous myocardial infarction, uncontrolled 
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hypertension, permanent pacemaker, defibrillator or other contraindication to 
CMR. 35 healthy controls who had no existing medical conditions were also 
recruited to establish the normal range of ECV using the CMR protocol. The study 
was conducted in accordance with the declaration of Helsinki and was approved by 
the local ethics committee (14/YH/0126). All subjects gave informed written 
consent.  
3.2.2 CMR protocol 
All subjects underwent an identical CMR protocol performed on a 3.0 Tesla Philips 
Achieva TX system (Philips, Best, The Netherlands) equipped with a 32 channel 
cardiac phased array receiver coil. A full blood count, including haematocrit was 
measured at the time of intravenous cannulation. The cardiac long and short axes 
were determined using standard scout views. Basal, mid and apical pre-contrast 
(native) short axis T1 maps were generated using a validated MOLLI protocol 
(Kellman et al., 2013) (ECG triggered 5b(3s)3b MOLLI scheme with voxel size of 
1.98 x 1.98 mm2, slice thickness 10mm) and were planned using the 3 of 5 method 
(Messroghli et al., 2005). Tissue tagging using a spatial modulation of 
magnetization (SPAMM) pulse sequence (spatial resolution 1.51x1.57x10mm3, tag 
separation 7 mm, ≥18 phases, typical TR/TE 5.8/3.5 ms, flip angle 10o, typical 
temporal resolution 55ms) was acquired in the same three short axis slices in 
34/50 patients.  Left ventricular volumes were obtained from cine imaging covering 
the entire LV in the short axis: balanced SSFP, voxel size 1.2 x 1.2mm2, slice 
thickness 10mm with no gap, 50 cardiac phases. Left atrial (LA) volumes were 
obtained from cine imaging covering the entire heart in the transverse axis: 
balanced SSFP, voxel size 1.2 x 1.2mm2, slice thickness 6mm with no gap, 50 
cardiac phases. 0.15mmol/Kg Gadovist (Bayer Schering) was delivered by power 
injector (Medrad Inc, Warrendale, Pennsylvania, USA) as a single bolus via a 
cannula placed in the ante-cubital fossa followed by 20ml saline flush. Typical 
parameters were TR/TE 3.5/2.0 ms, flip angle 25o, acquired spatial resolution 
1.54x1.76x10mm3 and performed in 10-12 short axis slices with ≥3 long axis 
orientations and phase-swapped acquisitions if indicated. Post contrast T1 
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mapping was carried out in the same three slices exactly 15 minutes following last 
contrast injection (as above). 
3.2.3 CMR interpretation 
Analysis was carried out using CVI42 (Circle Cardiovascular Imaging Inc. Calgary, 
Canada) and inTag (v1.0, CREATIS lab, Lyon, France) by two physicians blinded to 
clinical data. LV mass, EDV, ESV and LV EF were measured from short axis cine 
images. Native and post contrast T1 relaxation time of myocardium and blood pool 
were measured from the scanner generated T1 maps by contouring a region of 
interest in each segment of the American Heart Association (AHA) model 
(Cerqueira et al., 2002). ECV was calculated from native and post contrast T1 times 
of myocardium and blood pool and haematocrit as previously reported (Flett et al., 
2010). Segment thickness was measured for each AHA segment from end-diastolic 
SSFP cine images corresponding to the T1 maps. Feature tracking analysis was 
carried out on the same images by drawing endocardial and epicardial contours 
and circumferential (Ecc-FT) and radial (Err-FT) strain calculated for each AHA 
segment.  
For tagging analysis endocardial and epicardial contours were drawn on the short 
axis SPAMM sequences. Peak circumferential strain was measured for each 
segment of the AHA model. Strain was measured in the mid-myocardial layer 
which has previously been reported to be the most reproducible (Swoboda et al., 
2013).  
Segments were defined as hypertrophied if the maximal thickness was ≥15mm in 
keeping with current guidelines (Gersh et al., 2011; Elliott et al., 2014). The normal 
range for ECV derived from healthy volunteers was 24.4±2.8%. Therefore segments 
that were >30% (+2SD from the normal range) were defined as having extracellular 
expansion. Replacement fibrosis was defined as the presence of LGE reported by 2 
physicians experienced in CMR interpretation for each segment for a 
corresponding slice to T1 maps. All analyses were carried out blinded to the results 
of strain analysis.  
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3.2.3 Statistical analysis 
Continuous variables were expressed as means ± SD. Categorical variables were 
expressed as N (%). Shapiro-Wilk test was used to test normality then unpaired T 
test or Mann Whitney U test used as appropriate.  Spearman’s rank correlation was 
used for linear correlations. Univariable analyses were performed to identify 
predictors of strain. Variables with a probability value <0.1 in the univariable 
analysis were included in a multivariable linear regression analysis. P<0.05 was 
considered statistically significant. 
 
Figure 3.1 CMR images from a patient with asymmetric septal HCM.  A- SSFP 
imaging of the basal septum showing gross hypertrophy (>15mm) in anteroseptum 
and inferoseptum. All other segments are less than 15mm. B- Radial strain map 
derived from feature tracking of the same slice, shown in systole. Colour scale 
ranges from akinetic (red) to >20% strain (blue). C- Late gadolinium enhancement 
imaging showing a discrete area of replacement fibrosis in inferoseptum (white 
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arrow). D- ECV map ranging from 0 (blue) to 100% (red). The transition point of 
30% above which is defined as extracellular expansion is cyan. Note the 
replacement fibrosis seen on LGE imaging (black arrow) and the non-hypertrophied 
anterior and anterolateral walls have marked ECV expansion (35-45%) yet have 
normal radial strain on FT imaging. 
3.3 Results 
Patient characteristics are shown in Table 3.1. The distribution of hypertrophy was 
asymmetrical septal 36 (72%), concentric 5 (10%), mid cavity 4 (8%), apical 3 (6%) 
and isolated lateral 2 (4%). An example of cine imaging, strain, LGE and ECV 
mapping from an identical slice of one patient is shown in Figure 3.1. Maximum 
segment thickness, ECV, the presence of LGE and circumferential and radial strain 
findings are shown in Table 3.2. Segment thickness, LGE and tissue tagging could 
be analysed in all available segments. ECV could not be analysed in 43/800 
segments because of artefact. Ecc-FT could not be analysed in 17/800 and Err-FT in 
12/800 because of either artefact or poor tracking of myocardial features.  
There were 99 hypertrophied segments (>15mm) and 701 non-hypertrophied 
segments. Ecc-FT (-8.5±8.6 vs -20.3±8.3%, N=783, P<0.001), Err-FT (15.2±12.8 vs 
45.0±27.2%, N=788, P<0.001) and Ecc-SPAMM (-11.1±4.8 vs -20.4±8.1%, N=544, 
P<0.001) were all lower in hypertrophied segments than non-hypertrophied 
segments. 
There were 296 segments with extracellular expansion (ECV>30%) and 504 without 
extracellular expansion. Ecc-FT (-17.0±10.3 vs -19.9±8.4%, N=783, P<0.001), Err-FT 
(38.0±29.4 vs 43.2±26.4%, N=788, P=0.001) and Ecc-SPAMM (-17.3±8.7 vs -
20.7±7.9%, N=544, P<0.001) were all lower in those with extracellular expansion 
than those without.  
There were 107 segments with replacement fibrosis (LGE +ve) and 693 without 
replacement fibrosis. Ecc-FT (-10.6±8.5 vs -20.1±8.7%, N=783, P<0.001), Err-FT 
(18.7±15.5 vs 44.8±27.5%, N=788, P<0.001) and Ecc-SPAMM (-11.1±4.7 vs -
20.5±8.1%, N=544, P<0.001) were all lower in those with replacement fibrosis than 
in those without.  
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N 50 FH of HCM, n (%)  19 (38) 
Male gender, n (%) 37 (74) CMR findings  
Age, years 46.9±11.7 LV EDV, ml/m2 78.7 ± 13.1 
Height, cm 171.2±9.0 LV EF, % 62.3 ± 5.9 
Weight, kg 81.7±14.6 LV Mass, g/m2 72.8 ± 26.3 
Body mass index, kg/m2 27.7±3.7 LAV, ml/m2 59.3 ± 13.5 
Systolic blood pressure, 
mmHg 
125.5±17.6 LGE, n (%) 35 (70) 
Diastolic blood pressure, 
mmHg 
74.5±12.5 Medications  
Heart rate 60.6±10.2 Beta blocker, n (%) 24 (48) 
Echocardiography  CC blocker, n (%) 8 (16) 
LVOT obstruction, n (%) 11 (22) Disopyramide, n (%) 4 (8) 
LVOT gradient, mmHg 68.5 ± 40.0 Diuretic, n (%) 2 (4) 
 
Table 3.1 Patient characteristics and CMR findings. CC, calcium channel; EDV, end 
diastolic volume indexed to body surface area; EF, ejection fraction; FH, family 
history; LAV, left atrial volume indexed to body surface area; LGE, late gadolinium 
enhancement; LV, left ventricle; LVOT, left ventricular outflow tract 
3.3.1 Linear correlation and regression 
There were significant correlations between segment thickness and Ecc-FT, Err-FT 
and Ecc-SPAMM (Rs=0.616, -0.617 and 0.458 respectively, P<0.001 for all). There 
were significant but weaker correlations between ECV and Ecc-FT, Err-FT and Ecc-
SPAMM (Rs=0.176, -0.165 and 0.195 respectively P<0.001 for all). There was also a 
significant correlation between segment thickness and ECV (Rs= 0.244, P<0.001) 
which is shown with radial strain in Figure 3.2.  
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On univariable linear regression analysis segment thickness, ECV and the presence 
of LGE all had significant associations with Ecc-FT, Err-FT and Ecc-SPAMM and were 
all included in multivariable analysis (Table 3.3). Only segment thickness had a 
significant multi-variate association with Ecc-FT and Err-FT (beta=-0.540 and 0.584 
respectively, P<0.001 for both). Both segment thickness (beta=0.437, P<0.001) and 
LGE (beta=0.136, P=0.002) had significant associations with Ecc-SPAMM.  
Figure 3.2 Scatter plot showing segment thickness (mm) and extracellular volume 
fraction (%) and radial strain (%) of each segment. Radial strain is represented as a 
colour scale ranging from akinetic (red) to hyperdynamic (blue). The upper left 
quadrant shows patients with phenotypic expression of HCM manifested as ECV 
expansion without hypertrophy. A significant proportion of segments in this 
quadrant have normal strain. 
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3.3.2 Analysis according to cellular composition of each segment 
We examined strain in segments without overt hypertrophy according to the 
presence of early disease extracellular matrix expansion (ECV>30%) or later disease 
demonstrated by replacement fibrosis (LGE +ve). 
Of the 701 segments of <15mm thickness, 474 had ECV<30% and 227 had ECV 
>30%. Ecc-FT (-19.7±9.2 vs -20.6±7.9%, N=684, P=0.43) and Err-FT (45.0±29.2 vs 
44.9±26.1%, N=689, P=0.81) in non-hypertrophied segments were not significantly 
different in segments with ECV >30% compared to those with ECV<30% (Figure 
3.3). Ecc-SPAMM however was significantly lower in non-hypertrophied segments 
with ECV>30% (-18.8±8.7 vs -21.1±7.8%, N=496, P=0.003).  
Of the 701 segments of <15mm thickness 651 were LGE-ve and 50 LGE +ve. Ecc-FT 
(-12.9±8.2 vs-20.9±8.1%, N=684, P<0.001), Err-FT (23.3±16.0 vs 46.7±27.2, N=689, 
P<0.001) and Ecc-SPAMM (-11.9±4.9 vs -20.9±8.0, N=496, P<0.001) were all lower 
in non-hypertrophied segments with LGE compared to those without (Figure 3.3). 
Of the 681 segments without replacement fibrosis (LGE -ve) 42 segments were 
>15mm, 192 were <15mm with ECV>30% and 459 were <15mm with ECV<30%. 
Comparing the non-hypertrophied segments (<15mm) there was no significant 
difference according to whether ECV was more or less than 30% Ecc-FT (-21.2±8.5 
vs -20.8±7.9%, N=634, P=0.43), Err-FT (49.3±29.0 vs 45.5±26.3%, N=639, P=0.81) 
and Ecc-SPAMM (-19.7±8.8 vs -21.4 ±7.6, N=467, P=0.053). 
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Figure 3.3 Circumferential and radial strain in hypertrophied segments and non-
hypertrophied segments split into those with extracellular expansion (ECV>30%) 
and replacement fibrosis (LGE +ve) displayed as mean ± 95% confidence intervals. 
In non-hypertrophied segments strain was impaired in those with replacement 
fibrosis but not those with ECV expansion. 
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   Thickness (mm) ECV (%) LGE (N) Ecc-FT (%) Err-FT (%) Ecc-SPAMM (%) 
Base Anterior 8.9±3.3, 50 29.1±7.6, 49 4, 50 -21.7±7.4, 50 48.6±28.3, 50 -21.1±7.4, 34 
 Anteroseptum 14.9±3.8, 50 32.9±9.9, 50 20, 50 -10.7±7.9, 50 18.3±12.5, 50 -13.3±4.3, 34 
 Inferoseptum 14.6±4.8, 50 30.3±5.3, 50 16, 50 -6.8±8.9, 48 11.3±12.2,48 -14.3±4.7, 34 
 Inferior 8.1±2.7, 50 26.5±3.7, 48 1, 50 -16.0±10.1, 49 34.4±22.4, 50 -19.8±6.1, 34  
 Inferolateral 7.0±2.2, 50 27.0±4.6, 46 1, 50 -25.0±6.1, 48 58.5±25.9, 48 -27.1±7.8, 34 
 Anterolateral 7.4±2.6, 50 25.5±3.5, 45 1, 50 -26.2±6.7, 48 69.2±35.0, 49 -27.6±6.8, 34 
Mid LV Anterior 8.4±3.2, 50 32.1±9.4, 43 5, 50 -20.1±10.5, 50 46.3±27.4, 50 -21.9±8.9, 34 
 Anteroseptum 11.9±3.9, 50 33.0±9.1, 50 11, 50 -18.0±5.4, 50 33.5±15.7, 50 -14.1±5.5, 34 
 Inferoseptum 12.9±4.2, 50 31.1±6.2, 49 16, 50 -13.0±8.6, 49 23.3±18.3, 49 -14.1±5.5, 34 
 Inferior 8.3±2.9, 50 26.5±5.1, 48 3, 50 -17.4±6.2, 49 32.9±19.2, 49 -17.4±4.9, 34 
 Inferolateral 7.1±2.7, 50 26.4±4.9, 48 1, 50 -23.5±5.6, 48 50.8±20.4, 50 -26.9±7.4,34 
 Anterolateral 8.1±2.6, 50 27.0±4.9, 45 1, 50 -22.3±8.7, 47 52.7±27.2, 50 -22.0±5.5, 34 
Apex Anterior 8.6±4.5, 50 34.0±10.2, 46 7, 50 -20.1±7.7, 49 44.9±27.9, 49 -19.7±9.6, 34 
 Septum 9.2±4.0, 50 31.4±7.0, 47 9, 50 -20.7±6.4, 48 44.2±22.3, 48 -15.2±7.5, 34 
 Inferior 7.3±3.3, 50 28.7±7.2, 47 7, 50 -19.8±8.9, 50 44.4±27.1, 50 -16.9±8.8, 34 
 Lateral 8.3±3.5, 50 28.6±5.8, 47 4, 50 -20.3±8.5, 50 45.8±26.5, 50 -21.7±8.0, 34 
 
Table 3.2 Mean ± SD followed by number of segments analysed segment thickness, extracellular volume (ECV), circumferential strain 
measured by feature tracking (Ecc-FT), radial strain measured by feature tracking (Err-FT) and circumferential strain measured by tissue 
tagging (Ecc-SPAMM) for each segment of the American Heart Association model. The number of segments that display replacement 
fibrosis on late gadolinium enhancement (LGE) is reported followed by the number of segments analysed. 
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Table 3.3 Univariable and multivariable linear regression to evaluate which out of 
segment thickness, ECV and LGE have a significant association with impairment of 
segmental strain 
3.4 Discussion 
We have demonstrated that the main predictors of impairment of regional strain in 
HCM are degree of LV hypertrophy and presence of replacement fibrosis, which 
are both later features of HCM. Myocyte disarray and extracellular matrix 
expansion which can be detected by CMR as increased ECV earlier in the disease 
process do not appear to cause significant impairment of regional strain.  
Myocyte disarray and collagen deposition are early features in the phenotypic 
expression of HCM and can be detected histologically or biochemically in subjects 
without overt hypertrophy (Varnava et al., 2001; Ho et al., 2010). Using CMR ECV 
mapping we have identified 296/800 segments with clear extracellular matrix 
expansion in the absence of overt hypertrophy. This is in keeping with pathological 
studies that have demonstrated that the extent of myocyte disarray has no 
correlation with segment thickness (Maron et al., 1992) and CMR studies that have 
shown ECV expansion in genotype positive patients without overt expression of a 
hypertrophied phenotype (Ho et al., 2013).    
   Segment 
thickness 
Extracellular 
volume 
LGE 
Ecc-FT Univariable Beta 0.608 0.205 0.352 
P value <0.001 <0.001 .001 
Multivariable Beta 0.584 -0.008 0.58 
P value <0.001 0.80 0.10 
Err-FT Univariable Beta -0.554 -0.165 -0.323 
P value <0.001 <0.001 <0.001 
Multivariable Beta -0.540 0.038 -0.065 
P value <0.001 0.27 0.08 
Ecc-
SPAMM 
Univariable Beta 0.471 0.163 0.335 
P value <0.001 <0.001 <0.001 
Multivariable Beta 0.437 0.014 0.136 
P value <0.001 0.72 0.002 
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Our novel finding that contraction in non-hypertrophied segments is not 
significantly influenced by the presence of extracellular matrix expansion suggests 
that contractile dysfunction is a later process in the phenotypic expression of HCM. 
We have also reported that segmental strain is predominantly associated with 
segment thickness and the presence of replacement fibrosis assessed by the 
presence of LGE. These findings corroborate previous studies that have shown a 
relationship between degree of hypertrophy and presence of LGE and strain 
measured by speckle tracking echocardiography (Urbano-Moral et al., 2014; 
Popovic et al., 2008) and feature tracking by CMR (Smith et al., 2014). Dhillon et al 
measured longitudinal strain by feature tracking echocardiography in subjects with 
HCM undergoing surgical myomectomy, also reporting histological findings and in 
vitro contractility of the surgically excised myocardium. They found that the degree 
of histological fibrosis correlated with both strain measured by echocardiography 
and in vitro (Dhillon et al., 2014). However strain was measured in segments with 
severe hypertrophy causing LVOT obstruction and more than half of the specimens 
studied displayed small intramural coronary arteriole dysplasia which is known to 
correspond strongly with focal LGE detected by CMR (Kwon et al., 2009). Therefore 
the subjects studied were at the severe end of the hypertrophic spectrum and not 
directly comparable with our subjects and segments with a wide range of 
phenotypic presentations.  
Current international guidelines advocate the use of strain imaging to investigate 
patients with unexplained LV hypertrophy but without a clear diagnosis of HCM 
(Gersh et al., 2011; Elliott et al., 2014). Our novel finding that CMR strain 
measurements are not able to identify those non-hypertrophied segments with 
interstitial fibrosis suggests that it is of limited use early in the disease process 
before the onset of overt hypertrophy and replacement fibrosis. Given that it is 
able to identify disease before impairment of strain we would advocate that it 
should be used more widely and preferentially over measurement of strain in the 
investigation of possible HCM.  
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3.5 Limitations 
Our definition of 30% for ECV expansion was derived from 2SD above an age and 
sex matched normal range. ECV does not appear to be influenced by aging in 
healthy controls (Dabir et al., 2014) but may increase in patients with cardiac 
disease as they age (Ugander et al., 2012). ECV is influenced by pulse sequence, 
dose of contrast, number and timings of acquisitions. At present if ECV expansion is 
to be used to detect early HCM it is recommended that each centre derive their 
own normal range considering these variables and potentially a range of healthy 
controls of different ages (Moon et al., 2013).  
We have only measured strain from short axis measurements specifically because 
the strength of the segmental analysis that we have carried out is based on the fact 
that T1 maps, SSFP cines and LGE acquisitions can all be carried out in the identical 
short axis plane. Comparing strain from long axis cines to ECV from short axis maps 
would add an unacceptable degree of error.   
3.6 Conclusions 
Regional strain impairment measured by feature tracking and SPAMM is 
predominantly associated with the degree of hypertrophy and replacement fibrosis 
assessed by the presence of LGE. In non-hypertrophied segments strain is not 
significantly impaired by the presence of interstitial fibrosis. Therefore the 
presence of interstitial fibrosis (defined as ECV>30% in this cohort) may be a more 
useful method than impairment of strain for identification of HCM in subjects with 
borderline LV hypertrophy.  
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4. Study 3- Changes in cardiac strain parameters in 
highly trained athletes 
4.1 Abstract 
Background 
Athletic training leads to remodelling of both left and right ventricles with 
increased myocardial mass and cavity dilatation. Changes in cardiac strain 
parameters are less well established. In this study we investigated the relationship 
in trained athletes between cardiovascular magnetic resonance (CMR) derived 
strain parameters of cardiac function and aerobic capacity that has not previously 
been investigated.   
Methods  
35 endurance athletes and 35 age and sex matched sedentary controls underwent 
CMR at 3.0T including cine imaging in multiple planes and tissue tagging by spatial 
modulation of magnetization (SPAMM). CMR data were analysed quantitatively 
reporting circumferential strain and torsion from tagged images and left and right 
ventricular longitudinal strain from feature tracking of cine images. Athletes 
underwent a standard ramp-incremental step-exercise protocol to estimate lactate 
threshold (LT) aerobic capacity (VO2max).    
Results  
LV circumferential strain at all levels, LV twist and torsion, LV late diastolic 
longitudinal strain rate, RV peak longitudinal strain and RV early and late diastolic 
longitudinal strain rate were all lower in athletes than controls. On multivariable 
linear regression only LV torsion (beta=-0.37, P=0.03) had a significant association 
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with LT. Only age (beta=-0.36, P=0.01), sex (beta=0.38, P=0.04) and RV longitudinal 
late diastolic strain rate (beta=-0.39, P=0.02) had a significant association with 
VO2max. 
Conclusions  
The cohort of endurance athletes in this study had lower LV circumferential strain, 
LV torsion and biventricular diastolic strain rates than sedentary controls. The 
linear association between LT and LV torsion has potential applications in clinical 
cardiology and sports science including differentiation of athletic remodelling from 
early dilated cardiomyopathy. 
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4.2 Introduction 
It is well recognised that athletic training leads to ventricular remodelling, 
specifically increases in left and right ventricular end diastolic volume (LVEDV & 
RVEDV) and left ventricular mass (LVM) (Maron and Pelliccia, 2006; Arbab-Zadeh et 
al., 2014). These structural changes are most frequently seen in athletes who 
undergo prolonged periods of endurance training (Utomi et al., 2013).   
Although less well established, there is also evidence for changes in functional 
parameters in the hearts of trained athletes. Endurance athletes have reduced 
ejection fraction, circumferential and longitudinal strain of both the left and right 
ventricles compared to healthy controls (Caselli et al., 2015; Nottin et al., 2008). 
The heart has a complex twisting motion where the base rotates clockwise in early 
systole and the apex rotates anticlockwise in later systole. These opposing 
directions of rotation at the apex and base generate maximal torsional force at end 
systole (Burns et al., 2008). It has been reported that athletes have decreased LV 
twist and torsion when compared to sedentary controls (Nottin et al., 2008).     
Both strain and torsion parameters can be measured using CMR tagging techniques 
(Ibrahim el, 2011). CMR tagging is considered to be the gold standard for 
measurement of myocardial strain and torsion (Shehata et al., 2009; Young and 
Cowan, 2012). More recently, post processing feature tracking to track the features 
of cine sequences through the cardiac cycle has been proposed for quantification 
of strain without the need for acquisition of tagged cines (Moody et al., 2015). 
Previous studies have shown good agreement between strain parameters derived 
from feature tracking and tissue tagging (Moody et al., 2015).  
Cardiopulmonary exercise testing (CPX) allows analysis of gas exchange responses 
at rest and during exercise and provides a non-invasive estimate of lactate 
threshold (LT) and measure of maximal aerobic capacity (VO2max) (Balady et al., 
2010). This information gives an accurate and reproducible measure of integrated 
cardiac, respiratory and skeletal muscle function and is frequently used to 
quantitatively measure performance of endurance athletes (Bentley et al., 2007). 
Previous studies have demonstrated a clear correlation between LV remodelling 
and VO2max in endurance athletes (Milliken et al., 1988; Scharhag et al., 2002). In 
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this study we have investigated the relationship between strain-derived 
parameters of cardiac function and CPX-derived performance parameters that has 
not previously been investigated.  We hypothesised that strain parameters 
measured at rest would be lower in athletes than in sedentary controls and lowest 
in athletes with the best aerobic fitness.  
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4.3 Methods 
4.3.1 Enrolment Recruitment 
35 endurance athletes were recruited from local sporting clubs. They all trained 
more than 6 hours a week and competed regularly at local, national or 
international level. Exclusion criteria were any medical illness or contraindication 
to CMR. 35 sedentary controls who exercised less than 3 hours a week were also 
recruited and prospectively matched to the athletes for age and gender. No 
athletes or controls had any medical condition or took any regular medication. The 
study was conducted in accordance with the Declaration of Helsinki and was 
approved by the local ethics committee (14/YH/0126). All subjects gave informed 
written consent. 
4.3.2 Cardiac Magnetic Resonance Protocol 
CMR was performed on a dedicated cardiovascular 3 Tesla Philips Achieva system 
equipped with a 32 channel coil and MultiTransmit® technology. Data was acquired 
during breath-holding at end expiration. From scout CMR images, the left 
ventricular long and short axes were determined. 
Cine images covering the entire heart in the LV short axis plane and orthogonal 
long-axis planes were acquired (balanced SSFP, spatial resolution 1.2x1.2x10mm³, 
30 cardiac phases TR/TE 2.6/1.3ms, flip angle 40o, field of view 300-420mm, typical 
temporal resolution 39ms).  Then axial cine images planned to cover the right 
ventricle were acquired (balanced SSFP, spatial resolution 1.2x1.2x6mm³, 30 
cardiac phases TR/TE 2.6/1.3ms, flip angle 40o, field of view 300-420mm).   
Tissue tagging by SPAMM (spatial resolution 1.51x1.57x10mm3, tag separation 7 
mm, ≥18 phases, typical TR/TE 5.8/3.5 ms, flip angle 10o, typical temporal 
resolution 55ms) was acquired in the three short axis slices acquired at the apex, 
mid-ventricle, and base. Slices were positioned using the highly reproducible “3 of 
5 technique” (Messroghli et al., 2005).  
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Myocardial perfusion CMR was planned in the same three short axis slices using a 
spoiled fast gradient-echo sequence (TR/TE 1.28/ 2.8 ms, flip angle 15°, acquired 
spatial resolution 2.42x2.42×10 mm, field of view 300–420mm, sensitivity encoding 
factor 2.4, 0.65 partial Fourier acquisition and a saturation pre-pulse delay of 
80ms). During the breath held acquisition 0.075 mmol/kg of gadobutrol (Gadovist®, 
Bayer Schering Pharma, Berlin, Germany) was administered at a rate of 4.0ml/s 
followed by a 20ml saline flush (Medrad Spectris Solaris power injector, Pittsburgh, 
Pennsylvania). 
4.3.3 Image Analysis 
CMR data were analysed quantitatively using commercially available software 
(CVI42, Circle Cardiovascular Imaging Inc. Calgary, Canada and inTag v1.0, CREATIS 
lab, Lyon, France). Epicardial and endocardial borders were traced on the LV and 
RV cine stack at end-diastole and end-systole to calculate end diastolic volume 
(LVEDV), end systolic volume (ESV), stroke volume (SV), ejection fraction (EF) and 
LV mass. Volumes were indexed to body surface area (BSA) calculated using the 
Mosteller equation. 
For tagging analysis endocardial and epicardial contours were drawn on the short 
axis SPAMM sequences using a semi-automated process. Peak circumferential LV 
strain was measured for the three slices at apex, mid-ventricle, and base. Peak 
systolic and both early and late diastolic LV strain rates were measured from the 
mid-ventricular slice. Strain was measured in the mid-myocardial layer which has 
previously been reported to be the most reproducible (Swoboda et al., 2013). LV 
twist was calculated by subtracting the basal from apical rotation.  Basal and apical 
radius was calculated from cine images in diastole at the same slice location as the 
tagged images. The equation used to determine torsion was (Young and Cowan, 
2012):  
𝑇𝑜𝑟𝑠𝑖𝑜𝑛 =  
𝑃𝑒𝑎𝑘 𝑇𝑤𝑖𝑠𝑡 × (𝐴𝑝𝑖𝑐𝑎𝑙 𝑅𝑎𝑑𝑖𝑢𝑠 + 𝐵𝑎𝑠𝑎𝑙 𝑅𝑎𝑑𝑖𝑢𝑠)
2 × 𝐴𝑝𝑒𝑥 𝑡𝑜 𝐵𝑎𝑠𝑒 𝑙𝑒𝑛𝑔𝑡ℎ
 
For feature tracking analysis endocardial and epicardial contours were drawn on a 
long axis 4 chamber cine using a semi-automated process. Peak longitudinal strain, 
systolic strain rate, early and late diastolic strain rates were measured for both the 
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LV & RV. Late diastolic strain rates were defined as peak rate during active atrial 
contraction.  
Contours were traced on mid-slice perfusion CMR images to define the endo- and 
epicardial surfaces of the left-ventricular myocardium and a region within the left-
ventricular blood pool. The myocardium was segmented into four regions 
circumferentially (anterior, lateral, posterior and septal), each of which were split 
into endo- and epicardial layers of equal thickness. Rigid motion correction was 
applied manually for respiratory motion where required. Signal intensity-time 
courses were extracted from the intra-ventricular blood pool (to provide an arterial 
input function, AIF) and the eight myocardial regions and further analysis on these 
data was completed using in-house software developed in MATLAB (Mathworks, 
Mattick, MA, USA). 
The timing of the arrival of contrast agent in the blood pool and the end of the 
first-pass were identified visually from the AIF for each subject. Mean pre-contrast 
signal intensity was subtracted from each dataset and estimates of myocardial 
blood flow (MBF) were derived by performing Fermi constrained deconvolution on 
the resulting signal enhancement-time courses (Jerosch-Herold M et al., 1998). 
Endo-to-epicardial perfusion ratio (EER) was calculated for each circumferential 
segment by dividing the MBF estimate from the endocardial layer by that from the 
corresponding epicardial layer. 
4.3.4 Exercise Protocol 
Participants were instructed to abstain from alcohol and strenuous exercise in the 
preceding 24 hours and caffeine for the preceding 3 hours. To non-invasively 
estimate the lactate threshold (LT) and determine the maximal oxygen uptake 
(VO2max) participants undertook a ramp-incremental (RI) step-exercise (SE)(Rossiter 
et al., 2006) test on an electronically-braked cycle ergometer (Excalibur Sport, Lode 
BV, Groningen, the Netherlands). RISE test allows for determination of VO2max 
(rather than peak VO2) in a single test(Rossiter et al., 2006). Participants wore a 
nose-clip and breathed through a low-dead space, low-resistance mouthpiece 
which was connected to a bi-directional pitot tube flow sensor and gas sample line 
assembly, allowing for breath-by-breath measurement of gas volumes and 
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concentrations (O2, Galvanic; CO2 infrared), and subsequent calculation of 
ventilatory and pulmonary gas exchange variables (Cardio2, Medical Graphics 
Corporation, St Paul, MN, USA). Prior to each test the pitot tube flow sensor was 
calibrated over a range of flow rates using a 3 l syringe, while the gas analysers 
were calibrated using precision gases that spanned the inspired and expired 
physiological range. The RISE test was preceded by rest period (~ 2 minutes) and 
unloaded cycling (20W) (~ 4 minutes), with these phases continued until a steady 
state was attained, after which work rate increased as a linear function of time at a 
rate of 20-30W/min (depending upon reported training history), with the intention 
of bringing participants to the limit of tolerance in ~10-12 min (Buchfuhrer et al., 
1983). The RI was then followed by 5 min of active recovery (20W) after which a SE 
was performed at 95% of the RI work rate peak, with this SE also continued to the 
limit of tolerance. In both RI and SE parts of the test the limit of tolerance was 
defined as the point at which cycling cadence fell below 50 rpm despite strong 
verbal encouragement.  
Breath-by-breath data were edited using the VO2 response to eliminate erroneous 
breaths (occurring outside the local mean 99% prediction limits), that were 
considered unphysiological (Lamarra et al., 1987). LT was then estimated using the 
V-slope method(Beaver et al., 1986), and supporting ventilatory and pulmonary gas 
exchange criteria (i.e. the fractional end-tidal concentrations of O2 and CO2, and 
the ventilatory equivalents for O2 and CO2 (Whipp et al., 1986)). VO2peak was 
identified in both RI and SE phases as the highest 12-breath rolling average (highest 
mean VO2 over ~15-20 s), with this representing an appropriate sampling duration 
to balance identifying VO2peak in the presence of breath-by-breath noise, and 
including data from the transient phase of the response leading to VO2peak(Rossiter 
et al., 2006).  Within participants, the highest 12-breath rolling average from RI and 
SE phases were then compared using unpaired t-tests, with no difference (p> 0.05) 
between RI and SE VO2peak, and thus the attainment of  VO2max confirmed in each 
test (Bowen et al., 2012). 
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4.3.5 Statistical Analysis 
Statistical analysis was performed using IBM SPSS® Statistics 20.0 (IBM Corp., 
Armonk, NY). Continuous variables were expressed as means ± SD. Categorical 
variables were expressed as N (%). Shapiro-Wilk test was used to test normality 
and unpaired t tests and Mann Whitney U test used to compare athletes and 
controls. Pearson’s coefficient was used to measure correlation between exercise 
and CMR parameters. Univariable analyses were performed to identify predictors 
of LT and VO2max. Variables with a probability value <0.1 in the univariable analysis 
were included in a multivariable linear regression analysis. P<0.05 was considered 
statistically significant. 
4.4 Results 
4.4.1 Study Participant Demographics and Characteristics  
Of 35 athletes 7 were runners, 15 cyclists and 13 triathletes. The athletes trained 
11.5 ± 3.7 hours per week and had all trained >6 hours per week for 8.4 ± 6.0 years. 
All athletes completed both the RI and SE phases of the RISE protocol to the limit of 
tolerance. Mean ramp duration was 772 ± 93s reaching a peak work rate of 370 ± 
64W. HR rose from 55 ± 7 at rest to 182 ± 10 at peak exercise. Mean LT was 2.60 ± 
0.57 l/min, 36.5 ± 6.7ml/min/kg (normalised to body weight) or 62.1 ± 8.0% of 
VO2max. Mean VO2max was 4.2 ± 0.80l/min or 58.9 ± 8.2 ml/min/kg.  
Athletes and controls were prospectively matched for age and gender (Table 4.1). 
BMI and resting heart rate were lower in athletes than controls (P=0.001 and 
P<0.001 respectively).  
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Table 4.1  Subject characteristics BMI, body mass index; SBP, systolic blood 
pressure; DBP, diastolic blood pressure 
 
 
Figure 4.1 Apical rotation (red), basal (blue) rotation and twist (green) of the left 
ventricle of 35 endurance athletes (A). Each point represents mean rotation/twist 
and time in the cardiac cycle corrected to end-systole, error bars represent standard 
error of mean rotation/twist. Tagged images of anticlockwise apical (A) systolic 
rotation (yellow and red) and clockwise basal (C) rotation (green and blue). 
 Athlete Control P value 
Age 31.3±7.6 30.6 8.5 0.72 
Male, % 27 (77) 27 (77) 1.0 
Height, cm 178.7±8.7 176.5±8.2 0.29 
Weight, kg 71.4±9.9 77.0±14.8 0.07 
BMI, kg/m2 22.3±1.9 24.5±3.3 0.001 
HR 55.0±6.5 65.1±8.7 <0.001 
SBP, mmHg 118.8±8.7 114.7±10.6 0.16 
DBP, mmHg 71.0±9.2 59.2±10.6 <0.001 
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4.4.2 CMR Findings 
LV volumes for athletes and controls are shown in Table 4.2.  LVEDV, LV mass and 
RVEDV indexed to BSA were greater in athletes than controls. LVEF was lower in 
athletes than controls (P=0.04) but there was no difference in RVEF (P=0.27). Strain 
parameters are shown in Table 4.3. LV circumferential strain at all levels, LV twist 
and torsion (Figure 1), LV late diastolic longitudinal strain rate (Figure 2), RV peak 
longitudinal strain and RV early and late diastolic longitudinal strain rate were all 
lower in athletes than controls.  
 Athlete Control P value 
Left ventricle    
 EDV, ml 217.1±34.8 176.5±34.8 <0.001 
 EDV indexed to BSA, ml/m2 115.4±14.2 90.8±12.9 <0.001 
 ESV, ml 96.1±18.7 74.7±18.7 <0.001 
 EF, % 55.7±4.5 57.9±4.1 0.04 
 LV mass, g 127.9±24.6 100.5±23.4 <0.001 
 LV mass indexed to BSA, g/m2 67.8±9.9 51.5±9.1 <0.001 
Right ventricle    
 EDV, ml 219.7±37.2 204.8±50.1 0.16 
 EDV indexed to BSA, ml/m2 116.8±15.8 105.1±19.7 0.01 
 ESV, ml 104.2±22.7 99.5±27.5 0.44 
 EF, % 52.8±4.7 51.6±3.7 0.27 
 
Table 4.2 CMR measured volumetric parameters.  EDV, end diastolic volume; EF, 
ejection fraction; ESV, end systolic volume; LV, left ventricle 
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 Athlete Control P value 
LV Circumferential Strain    
 Apex, % 18.4±5.2 23.4±4.9 <0.001 
 Mid LV, % 19.6±3.9 21.5±2.5 0.02 
 Base, % 17.0±4.0 20.5±2.5 <0.001 
 Systolic SR, %/s 115.3±12.8 116.6±10.0 0.66 
 Early diastolic SR,%/s 50.8±16.4 51.0±16.0 0.95 
 Late diastolic SR, %/s 140.1±40.7 151.4±40.3 0.27 
Torsion    
 LV twist, o 9.7±3.6 13.3±3.8 <0.001 
 LV torsion, o 8.8±3.0 11.9±3.1 <0.001 
 LV twist rate, o/s 63.2±18.9 72.4±27.8 0.048 
 LV untwist rate, o/s 88.1±25.5 101.8±34.5 0.07 
LV Longitudinal Strain    
 Peak, %  17.1±2.8 17.7±2.3 0.30 
 Systolic SR, %/s 101.6±29.6 103.2±19.8 0.29 
 Early diastolic SR, %/s 90.6±32.4 102.4±31.7 0.13 
 Late diastolic SR, %/s 41.7±15.6 57.3±19.6 <0.001 
RV Longitudinal Strain    
 Peak, %  19.8±3.7 22.6±3.4 0.002 
 Systolic SR, %/s 137.7±49.9 138.4±37.0 0.50 
 Early diastolic SR, %/s 108.6±32.1 124.6±32.9 0.03 
 Late diastolic SR, %/s 69.2±40.2 89.5±42.4 0.02 
 
Table 4.3 CMR measured strain parameters LV, left ventricle; SR, strain rate 
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Figure 4.2 LV longitudinal strain rate of 35 endurance athletes(A).  Each point 
represents mean longitudinal strain rate at each point in the cardiac cycle corrected 
to end-systole, error bars represent 95% confidence interval of mean strain. Peak 
systolic strain rate (SSR), early diastolic strain rate (EDSR) and late diastolic strain 
rate (LDSR). SSFP cine image at end diastole showing manually drawn endocardial 
and epicardial contours (B). Feature tracked end systolic image (C).    
4.4.3 Relationship between CPX and Functional CMR Parameters 
The only significant correlations with LT (as percent of VO2max) were with torsion 
parameters. Peak twist (r=-0.45, P=0.01), peak torsion (r=-0.36, P=0.04) and twist 
rate (r=-0.38, P=0.03) all had a significant correlation with LT. There was no 
significant correlation between LT and any demographic, ventricular volume or 
other strain parameter.  
There was a correlation between VO2max and both LVMI (r=0.59, P<0.001) and 
LVEDVI (r=0.47, P=0.01) consistent with previously reported findings (Osborne et 
al., 1992; Milliken et al., 1988). There was also a trend to correlation between 
RVEDVI and VO2max (r=0.33, P=0.05). Both age (r=-0.35 P=0.04) and sex (r=0.40, 
P=0.02) correlated with VO2max. No LV strain parameters had a significant 
correlation with VO2max. RV longitudinal systolic strain rate (r=-0.33, P=0.05) and RV 
late diastolic strain rate (r=-0.38, P=0.02) both correlated with VO2max. 
- 97 - 
 
 
 
We identified 8 athletes in the highest quartile of LT (72.7±2.0%) and 8 in the 
lowest quartile of LT (51.7±2.9%). Peak twist and torsion were lower in the athletes 
in the highest quartile than those in the lowest quartile (8.5 ± 2.9 vs 12.9 ± 2.6o 
P=0.008 and 8.0 ± 3.4 vs 11.2 ± 1.8o P=0.048, respectively). There were no other 
significant differences between demographics, ventricular volumes or strain 
parameters between the groups. The difference in LV twist and torsion was 
secondary to decreased apical rotation in the athletes with VAT in the highest 
quartile (Figure 4.3) 1.0 ± 3.3 vs 6.0 ± 3.1o P<0.001. Basal rotation was not different 
between the groups 6.5 ± 1.4 vs 6.1 ± 2.6o P=0.75.  
MBF and EER values are shown in Table 4.4. The only significant correlation was 
between EER in the anterior segment and absolute LT (r=0.34, P=0.047) and LT 
corrected for weight (r=0.39, P=0.02).   
 
Figure 4.3 Plots showing the mean ± standard error of rotation/twist of the athletes 
in the lowest quartile of LT (left) and highest quartile of LT (right). Peak twist was 
lower in athletes in the highest quartile of LT (8.5 ± 2.9 vs 12.9 ± 2.6o P=0.008) 
which was secondary to a loss of apical rotation (1.0 ± 3.3 vs 6.0 ± 3.1o P<0.001). 
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Table 4.4 Endocardial and epicardial myocardial blood flow (MBF) and endo-to-
epicardial perfusion Ratio (EER) for athletes in 4 mid ventricular sectors 
4.4.4 Regression Analysis 
On univariable linear regression of the parameters shown in Table 4.5 only LV 
torsion and sex were associated with LT. On multivariable linear regression only LV 
torsion (beta=-0.37, P=0.03) had a significant association with LT. 
On univariable linear regression of the parameters shown in Table 4.6 age, sex, RV 
longitudinal strain, RV systolic strain rate and RV diastolic strain rate were 
associated with VO2max. On multivariable linear regression only age (beta=-0.36, 
P=0.01), sex (beta=0.38, P=0.04) and RV longitudinal late diastolic strain rate 
(beta=-0.39, P=0.02) had a significant association with VO2max.  
 
 
  
 Anterior Lateral Inferior Septum 
Endocardial MBF (ml/g/min) 1.95±1.19 1.78±1.17 1.57±1.43 1.74±1.22 
Epicardial MBF (ml/g/min) 1.74±1.40 1.59±1.52 1.31±1.00 1.54±0.98 
EER 1.18±0.23 1.21±0.31 1.25±0.38 1.12±0.22 
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 Univariable Multivariable 
 Beta P value Beta P value 
Age -0.07 0.70   
Sex 0.29 0.09 0.29 0.08 
LVEF, % -0.43 0.81   
RVEF, % 0.10 0.56   
Apex circumferential strain, % 0.15 0.38   
Mid LV circumferential strain, % -0.11 0.55   
Base circumferential strain, % -0.05 0.77   
LV torsion, o -0.36 0.04 -0.37 0.03 
LV longitudinal strain, % 0.09 0.61   
LV longitudinal systolic SR, %/s 0.15 0.40   
LV longitudinal early diastolic SR, %/s -0.23 0.19   
LV longitudinal late diastolic SR, %/s -0.01 0.95   
RV longitudinal strain, % -0.01 0.97   
RV longitudinal systolic SR, %/s 0.04 0.84   
RV longitudinal early diastolic SR, %/s -0.01 0.97   
RV longitudinal late diastolic SR, %/s -0.22 0.20   
 
Table 4.5 Univariable and multivariable linear regression analysis of factors with a 
significant association with lactate threshold. EF ejection fraction; LV, left ventricle; 
RV, right ventricle; SR, strain rate  
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 Univariable Multivariable 
 Beta P value Beta P value 
Age -0.37 0.04 -0.36 0.01 
Sex 0.40 0.02 0.38 0.04 
LVEF, % -0.12 0.50   
RVEF, % -0.52 0.77   
Apex circumferential strain, % 0.27 0.11   
Mid LV circumferential strain, % 0.18 0.92   
Base circumferential strain, % -0.17 0.33   
LV torsion, o -0.21 0.24   
LV longitudinal strain, % 0.17 0.32   
LV longitudinal systolic SR, %/s 0.04 0.80   
LV longitudinal early diastolic SR, %/s -0.04 0.81   
LV longitudinal late diastolic SR, %/s -0.14 0.41   
RV longitudinal strain, % 0.30 0.08 -0.05 0.78 
RV longitudinal systolic SR, %/s -0.33 0.05 -0.25 0.09 
RV longitudinal early diastolic SR, %/s -0.01 0.96   
RV longitudinal late diastolic SR, %/s -0.38 0.02 -0.39 0.02 
 
Table 4.6 Univariable and multivariable linear regression analysis of factors with a 
significant association with VO2max. EF ejection fraction; LV, left ventricle; RV, 
right ventricle; SR, strain rate  
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4.5 Discussion 
We have carried out comprehensive cardiac functional assessment of 35 
endurance athletes from a broad spectrum of sport, age and athletic ability. This 
diverse, but well characterised group has allowed us to investigate specifically the 
ventricular strain parameters that have a relationship with quantitative measures 
of athletic performance, namely LT and VO2max (Bassett and Howley, 2000).  
The most striking finding was the inverse linear correlation between both LV twist 
and torsion, and LT. On multivariable linear regression no other factors significantly 
influenced LT. To our knowledge this is the first time a significant association 
between a cardiac structural or functional parameter and LT has been reported. 
Furthermore we have found that in athletes with the highest LT the decrease in 
torsion is secondary to decreased apical rotation.   
We have reported with high statistical significance that LV torsion was lower in 
endurance athletes than sedentary controls. Previous CMR tagging studies have 
been small and insufficiently powered and therefore unable to report a difference 
in baseline torsion parameters between endurance athletes and sedentary controls 
(Scott et al., 2010; Esch et al., 2010). Scott et al. reported in 9 highly trained 
endurance athletes that LV ejection fraction, untwist rate, apical rotation rate and 
circumferential strain were all depressed 30 minutes after high intensity interval 
training (Scott et al., 2010). Athletes with the highest LT undertake high intensity 
training (Bentley et al., 2007) and it is therefore likely that our finding of decreased 
torsion in these athletes is due to the cumulative effect of many years of high 
intensity interval training.  
Several echocardiography studies using techniques including tissue Doppler 
imaging and speckle tracking have been used to investigate left ventricular torsion 
in athletes. Previous echocardiographic studies have reported similar findings to 
ours of decreased apical rotation and LV torsion in athletes with high levels of 
aerobic fitness (Stohr et al., 2012) whereas others have reported that high intensity 
exercise either had no effect (Stewart et al., 2015), or even caused an increase 
(Weiner et al., 2010) in LV torsion. The inconsistent results that have been 
reported may in part reflect different sport and training techniques, research 
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methodology used and also the difficulty in positioning the apical and basal slices in 
echocardiography studies, which is based upon anatomical landmarks with a 
degree of subjectivity. In CMR on the other hand, positioning of the slices is carried 
out objectively based upon the length of the ventricle (Messroghli et al., 2005).  
There are several possible mechanisms that explain the association between LT 
and LV torsion. In diffuse myocardial diseases such as aortic stenosis (Stuber et al., 
1999) and type 1 diabetes mellitus (Chung et al., 2006) increased LV torsion is 
attributed to subendocardial microvascular hypoperfusion and contractile 
dysfunction. It is hypothesized that there is a compensatory increase in 
subepicardial fibre contraction giving rise to increased LV torsion yet unchanged 
overall circumferential strain. It is possible that the converse could be true in 
athletes with high LT. It is recognised that interval training leads to increased 
vascularity (Pereira et al., 2013) and improved substrate utilisation (Hafstad et al., 
2011) within the myocardium. It is possible that these changes may improve 
myocyte contractile function in the subendocardium to such an extent that 
subepicardial contraction is not needed at rest and there is a subsequent reduction 
in LV torsion.  
We have demonstrated a correlation between LT and EER in the anterior segment, 
which is in keeping with this hypothesis. Although the correlation is relatively weak 
and only seen in one segment, it does suggest that athletes with the highest LT 
who undergo regular high intensity training may have increased subendocardial 
blood flow and myocardial capillary vascularity which may in part explain the 
decrease in torsion parameters that we have reported. Measuring EER is 
technically challenging because the segments assessed are relatively small and 
therefore vulnerable to dark rim and respiratory artefact. This may explain why the 
relationship was not seen in all segments.  
It has been reported that spherical remodelling of the LV, particularly in disease 
states, leads to impairment of LV twist (van Dalen et al., 2010). Although we did 
not find a significant association between LT and LV remodelling an alternative 
hypothesis is that many years of high intensity training leads to changes in fibre 
orientation and therefore decreased apical rotation and LV torsion.  
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We have also reported lower global LV late diastolic strain rate, RV early and late 
diastolic longitudinal strain rates in athletes versus controls. On multivariable linear 
regression only increasing RV late diastolic strain rate, female gender and older age 
were significantly associated with lower VO2max. To our knowledge this is the first 
time that CMR strain techniques have been used to compare longitudinal 
functional changes in athletes and controls. Conflicting findings have been 
reported when echocardiographic assessment of diastolic function has been used 
with some studies reporting augmented relaxation of both ventricles in endurance 
athletes (Caselli et al., 2015; Baggish et al., 2008) and others reporting no 
difference from controls (Pluim et al., 2000).  Our finding of reduced longitudinal 
late diastolic strain rates of both ventricles of athletes and a negative correlation 
between longitudinal late diastolic strain rate and VO2max can be attributed to 
reduced active atrial contraction late in diastole. In athletes the atrial contribution 
to ventricular filling is not required at rest but of course can be utilised when 
required during exercise.  
The observations from this study, particularly of the relationship between LT and 
LV torsion, have potential uses both in sports science and in clinical medicine. 
Some endurance athletes display a cardiac phenotype of dilated left ventricle, low 
normal ejection fraction and decreased LV torsion. This can be difficult to 
differentiate clinically from early dilated cardiomyopathy (Abergel et al., 2004). We 
have demonstrated that only athletes with high LT had depressed LV torsion. 
Therefore it may be possible to differentiate athletic remodelling from early 
cardiomyopathy by carrying out CPX. If the subject has a normal LT then it should 
not be assumed that their cardiac changes are due to athletic remodelling. LV 
torsion also has the potential to be used as a quick and non-invasive assessment of 
cardiac function in endurance athletes as a quantitative measure of the effect of 
training.   
4.6 Limitations 
Our study was carried out on a cross sectional cohort and it is important in the 
future to demonstrate that these findings can be replicated in a longitudinal study. 
The cohort in the study also has a wide range of age and athletic ability although 
- 104 - 
 
 
 
this was deliberate to allow study of athletes with a range of CPX results. All of the 
cardiac changes reported are during rest. We have used feature tracking rather 
than SPAMM for the analysis of longitudinal strain. However, tissue tagging is 
hampered by a lower temporal resolution than cine imaging and tag fading during 
diastole. As we specifically wanted to examine longitudinal strain rates in diastole 
we therefore chose to use feature tracking for this while using SPAMM tagging for 
assessment of circumferential strain parameters.  
4.7 Conclusions 
This cohort of endurance athletes had lower LV circumferential strain, LV torsion 
and biventricular diastolic strain rates than sedentary controls. There was a linear 
association between LT and LV torsion, which is secondary to decreased apical 
rotation in athletes with high LT. This association could be utilised to differentiate 
athletic remodelling from early dilated cardiomyopathy.  
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5. Study 4- Quantification of extracellular fibrosis in 
patients with type 2 diabetes at high risk of 
developing heart failure 
5.1 Abstract  
Background 
Type 2 diabetes is an independent risk factor for the development of heart failure. 
Patients with elevated urinary albumin creatinine ratio (ACR), high sensitivity 
cardiac troponin T (hs-cTnT) and amino-terminal pro-brain natriuretic peptide (NT-
proBNP) appear to be at the highest risk of heart failure although mechanisms by 
which this occurs are not clear. We hypothesised that increased risk of heart failure 
would be mediated by both diffuse fibrosis and silent MI.   
Methods 
We carried out comprehensive cardivascular magnetic resonance (CMR), 
assessment in 100 asymptomatic patients with type 2 diabetes and 30 controls. 50 
patients had persistent microalbuminuria but were yet to start an ACE inhibitor 
and 50 had never had microalbuminuira. The CMR protocol included T1 mapping 
using  Modified Look-Locker Inversion (MOLLI) to assess for diffuse fibrosis and late 
gadolinium enhancement imaging (LGE) to assess for focal fibrosis or prior 
myocardial infarction (MI).  
Results 
Extracellular volume (ECV), a CMR marker of diffuse fibrosis, was higher in ACR +ve 
than ACR -ve patients 27.2±4.1 vs 25.1±2.9% P=0.004. ECV was also higher in hs-
cTnT +ve than hs-cTnT -ve patients 30.3±4.8 vs 25.6±3.2%, P<0.0001 and NT-
proBNP +ve than NT-proBNP -ve patients 29.3±4.5 vs 25.7±3.4%, P=0.002. The rate 
of silent MI was higher than expected in this low risk asymptomatic cohort (17%) 
but there were no differences in the rate according to biomarker (ACR, hs-cTnT or 
NT-proBNP) status. Patients with 2 or 3 +ve biomarkers had the highest ECV which 
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was significantly higher than those with 1 or 0 +ve risk factors 30.7±4.2 vs 
25.5±3.1%, P<0.0001. 
Conclusions 
The increased risk of heart failure in patients with persistent microalbuminuria, +ve 
hs-cTnT and NT-proBNP appears to be mediated by increased cardiac ECV and 
diffuse fibrosis. The rate of silent MI was high but not related to biomarker status. 
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5.2 Introduction  
Type 2 diabetes mellitus is well established as an independent risk factor for the 
development of heart failure (Kannel and McGee, 1979). The risk of heart failure is 
approximately doubled by the presence of diabetes and appears to be 
independent of conventional risk factors including age, gender, existing coronary 
disease and hypertension (Gottdiener et al., 2000). Once patients with diabetes 
establish heart failure they have higher mortality than normoglycaemic heart 
failure patients (MacDonald et al., 2008; Cubbon et al., 2013). Epidemiological 
evidence suggests that poor control of blood glucose in type 2 diabetes is 
associated with increased rates of heart failure (Iribarren et al., 2001). However 
data from randomised controlled trials demonstrate that intensive control of 
glucose does not reduce the risk of hospitalisation for heart failure (Castagno et al., 
2011). To complicate matters, several pieces of evidence suggest that type of 
hypoglycaemic agents used can modulate the risk of heart failure in patients with 
diabetes (Dormandy et al., 2005; Zinman et al., 2015). 
Patients with type 2 diabetes and nephropathy appear to be at the highest risk of 
heart failure and treatment directed at modulating the renin-angiotensin-
aldosterone system decreases rate of hospitalisation with cardiac decompensation. 
In both the LIFE and RENAAL studies, patients with type 2 diabetes and 
nephropathy were randomised to treatment with losartan versus atenolol (LIFE) or 
Losartan versus placebo (RENAAL) (de Zeeuw et al., 2004). In both studies, the 
albumin creatinine ratio (ACR) at baseline was found to be associated with an 
increased risk of first heart failure admission (hazard ratio 1.3 in LIFE and 1.4 in 
RENAAL over 4-5 years follow up) (Carr et al., 2005). In both studies treatment with 
losartan was associated with decreased rates of hospitalisation for heart failure 
(Carr et al., 2005). Given the poor clinical outcome of patients with diabetes and 
heart failure, studies attempted to identify a reliable biomarker for heart failure 
risk in this population. Elevated high sensitivity cardiac troponin T (hs-cTnT) in 
patients without overt cardiovascular disease has shown an association with 
increased risk of heart failure (hazard ratio 6.37 [confidence interval, 4.27-9.51]) 
over 14 years follow up) (Selvin et al., 2014). Elevated B-type natriuretic peptide 
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(BNP) has been associated with increased risk of both myocardial ischaemia 
detected by exercise tolerance test (Rana et al., 2006) and cardiovascular events 
(Huelsmann et al., 2008).  However, these tests fail to reliably detect all patients 
with early stages heart failure and more robust techniques are needed for the 
timely identification of those at risk.  
CMR allows for further investigation of the relationship between diabetes and 
heart failure in vivo. CMR studies have demonstrated that diabetes is associated 
with increased LV mass (Heckbert et al., 2006) and concentric LV remodelling 
(Velagaleti et al., 2010) independently of other factors such as age, blood pressure, 
tobacco use and alcohol use.  
Furthermore, CMR is able to measure and quantify the presence of focal and 
diffuse fibrosis in patients with diabetes. With LGE CMR focally scarred 
myocardium can be detected and the location and transmural distribution of scar 
provide an indication of the aetiology of heart failure. The scar most commonly 
detected in diabetes is due to previous myocardial infarction (MI), either 
recognised or silent (Schelbert et al., 2012), and is associated with increased 
mortality (Kwong et al., 2006).  CMR is also able to measure diffuse fibrosis using 
T1 and ECV mapping based techniques. Type 2 diabetes is associated with 
increased ECV  when measured by these techniques (Jellis et al., 2011) and those 
with the highest ECV have highest cardiovascular mortality and increased heart 
failure admissions (Wong et al., 2013). 
We hypothesised that CMR offers an accurate tool to characterise cardiac change 
in asymptomatic patients with type 2 diabetes with the ability to stratify those at 
high and low risk of heart failure. We aimed to establish whether the high risk of 
heart failure in certain patients was mediated by diffuse fibrosis or silent MI.  
5.3 Methods 
5.3.1 Enrolment Criteria 
The study was approved by the local ethical committee (13/YH/0098) and 
individuals were enrolled onto the study after informed consent. A total of 100 
patients with type 2 diabetes were recruited from 30 primary care health centres 
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in the local area. 50 consecutive ACR +ve patients were recruited after their annual 
diabetes check before commencement on an angiotensin converting enzyme (ACE) 
inhibitor in line with national guidelines (Sibal and Home, 2009). All ACR +ve 
patients had laboratory albumin: creatinine ratio repeated within 4 months to 
confirm persistent microalbuminuria. Thresholds to diagnose microalbuminuria 
were two or more measurements >2.5mg/mol in males and >3.5mg/mol in females 
(Sibal and Home, 2009). In addition, 50 patients with type 2 diabetes were 
recruited who had never had ACR above the thresholds (ACR -ve). This group was 
prospectively matched for age, gender and clinic blood pressure to ACR +ve 
patients.   Exclusion criteria for ACR +ve and ACR -ve were known cardiac disease, 
kidney disease (eGFR <30), uncontrolled hypertension, treatment with insulin or 
ACE inhibitor/angiotensin receptor blocker (ARB). Patients taking an ACEi or ARB 
were excluded because observational data has suggested that it may influence ECV 
in patients with diabetes (Wong et al., 2013). Finally, 30 age and gender matched 
controls were recruited.  
5.3.3 CMR protocol 
All patients and controls underwent CMR using an identical protocol on a 
dedicated cardiovascular 3 Tesla Philips Achieva TX system equipped with a 32 
channel coil and MultiTransmit® technology (Philips, Best, The Netherlands). Data 
were acquired during breath-holding at end expiration. From scout CMR images, 
the left ventricular long and short axes are determined. Then, precontrast T1 maps 
were acquired at the apex, mid-ventricle, and base positioned with the highly 
reproducible “3 of 5 technique” (Messroghli et al., 2005). T1 mapping used a 
breath-held Modified Look-Locker Inversion recovery (MOLLI) acquisition (ECG 
triggered 5(3s)3 balanced turbo gradient recalled echo (GRE) acquisition, spatial 
resolution 1.98x1.98x10mm³ (reconstructed to 1.25*1.25mm), single-shot, SENSE 
factor 2, prepulse delay 350ms, trigger delay set for end-diastole (adaptive), flip 
angle 35°, acquisition duration per image 170-185ms (dependent on field of view  
(FOV)). 
Tissue tagging by spatial modulation of magnetization (SPAMM) imaging (spatial 
resolution 1.51×1.57×10mm3, tag separation 7 mm, ≥18 phases, typical TR/TE 
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5.8/3.5 ms, flip angle 10°) was then performed in the same three short axis slices as 
T1 maps. 
Next, myocardial perfusion CMR was planned in the same three short axis slices 
using a spoiled turbo gradient-echo sequence (TR/TE 1.28/ 2.8 ms, flip angle 15°, 
acquired spatial resolution 2.42x2.42×10 mm, FOV 300–420, variable matrix 
between 124x124 – 172x172 (dependent on FOV), sensitivity encoding factor 2.4, 
0.65 partial Fourier acquisition and a saturation pre-pulse delay of 80ms). 
Intravenous adenosine was administered at 140mcg/kg/min for 3 minutes under 
continuous ECG monitoring. Adequate haemodynamic response was assessed by 
either a heart rate increase by ≥10% or symptoms attributed to adenosine 
administration. Imaging was undertaken during the last minute of adenosine 
infusion with a weak intravenous bolus of 0.0075mmol/kg followed by a strong 
bolus of 0.075 mmol/kg of gadobutrol (Gadovist®, Bayer Schering Pharma, Berlin, 
Germany). Both were administered at a rate of 4.0ml/s followed by a 20ml saline 
flush (Medrad Spectris Solaris power injector, Pittsburgh, Pennsylvania). 
Cine images covering the entire heart in the LV short axis plane were acquired 
(balanced SSFP, spatial resolution 1.2x1.2x10mm³, 50 cardiac phases TR/TE 
2.6/1.3ms, flip angle 40o, field of view 300-420mm) and in orthogonal long-axis 
planes.  Cine images planned to cover the entire left atrial short axis plane in end 
systole were acquired (balanced SSFP, spatial resolution 1.2x1.2x5mm³, 50 cardiac 
phases TR/TE 2.6/1.3ms, flip angle 40o, field of view 300-420mm) and in orthogonal 
long-axis planes.   
Rest perfusion imaging was acquired a minimum of 15 minutes after stress 
perfusion with a further injections of 0.0075mmol/kg and 0.075mmol/kg of 
gadobutrol in an identical geometry to the stress images. Rest images were 
acquired with the same FOV and acquisition duration as the stress scan. 
LGE was then carried out more than 6 minutes after rest perfusion imaging using 
inversion recovery-prepared T1-weighted echo. The optimal inversion time to null 
signal from normal myocardium was determined using a Look-Locker approach. 
Typical parameters were TR/TE 3.5/2.0 ms, flip angle 25o, acquired spatial 
resolution 1.54x1.76x10mm3 and performed in 10-12 short axis slices with further 
slices acquired in the vertical and horizontal long axis orientations, or phase-
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swapped, if indicated based on LGE imaging obtained, wall-motion or perfusion 
defects. Post contrast T1 mapping was carried out exactly 15 minutes following last 
contrast injection (as above).  
 
 
Figure 5.1 Recruitment flowchart. 
5.3.4 CMR interpretation 
CMR data was assessed quantitatively using commercially available software 
(CVI42, Circle Cardiovascular Imaging Inc. Calgary, Canada). Epicardial and 
endocardial borders were traced offline on the LV cine stack at end-diastole and 
end-systole to calculate end-diastolic (ED), end- systolic (ES) LV volumes, stroke 
volume (SV), ejection fraction (EF) and LV mass. Left atrial (LA) volume was 
calculated by tracing the LA endocardial border at end-systole when the left atrium 
was largest.    
 
Pre and post contrast myocardial T1 values with a 3-parameter exponential fit with 
Look-Locker correction were measured from the mid ventricular short axis slice in 
the septum. ECV was calculated from native and post contrast T1 times of 
258 ACR+ve DM 
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75 ACR+ve 
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30 healthy 
controls 
25 not scanned: 
19 repeat ACR -ve 
2 claustrophobic 
2 MRI CI 
2 dropped out 
206 ACR-ve DM 
invited 
50 ACR-ve 
patients 
50 ACR+ve 
patients 
3 not scanned: 
1 claustrophobic 
2 MRI CI 
Prospective matching 
53 ACR-ve agreed 
Prospective matching 
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myocardium and blood pool and haematocrit as previously reported (Flett et al., 
2010). Mass of LGE was quantified using the Otsu automated threshold method 
and divided by LV mass calculated from short axis cines to give a percentage of LV 
with LGE.  
5.3.5 Echocardiogram protocol and analysis 
All patients underwent echocardiography (vivid e9, GE Medical Systems, 
Milwaukee, WI) focused on Doppler measurements of mitral inflow and tissue 
Doppler imaging (TDI) of the mitral annulus. E/A ratio, E', A' and S' are measured on 
the machine using inbuilt software. Diastolic dysfunction was graded 0-3 by a 
according to the international guidelines (Nagueh et al., 2009) by an accredited 
echocardiographer blinded to clinical details.  
5.3.6 Ambulatory blood pressure 
All patients underwent 24 hour blood pressure monitoring using a Welch-Allyn 
6100 ambulatory blood pressure monitor (Welch-Allyn, NY, USA) that has been 
validated for clinical use by the British Hypertension Society. The cuff was set to 
inflate every 30 minutes during the day and every 60 minutes during the night. 
Mean 24 hour systolic and diastolic BP were recorded.  
5.3.7 Biomarker assessment 
20mL of blood was drawn from each subject at the time of CMR. Full blood count, 
urea & electrolytes and HbA1c are measured at that time. Serum was stored at -
70C and tested in one batch for hs-cTnT typical CV 4.4% at 13.7ng/L and 3.6% at 
95.3 ng/L, amino-terminal pro-brain natriuretic peptide (NT-proBNP) typical CV 
2.9% at 91 ng/L and 2.1% at 415 ng/L (Cobas 8000, Roche Diagnostics,  Burgess Hill, 
West Sussex) and aldosterone ('in-house' radioimmunoassay) typical between 
batch CV <10% at 282, 402 and 1833 pmol/L 
5.3.8 Statistical analysis 
Statistical analysis was performed using IBM SPSS® Statistics 20.0 (IBM Corp., 
Armonk, NY). Continuous variables were expressed as means ± SD. Categorical 
variables were expressed as N (%) and compared using Fisher exact test. Shapiro-
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Wilk test was used to test normality and depending on the result analysis of 
variance (ANOVA) & and Kruskal Wallis test were used to compare means of ACR 
+ve, ACR -ve and controls.  Unpaired t test and Mann Whitney U test were used to 
calculate significance when there were 2 variables. Correlations were calculated 
using Spearmans correlation coefficient. P<0.05 was considered statistically 
significant.  
A power calculation based on previous studies of ECV in diabetes estimated that 50 
subjects would be needed in the ACR +ve and ACR -ve groups (power 0.9 and type 
1 error 0.05) (Jellis et al., 2011). We estimated that the difference in ECV in those 
with and without microalbuminuria would be similar to those with and without 
diastolic impairment in the previous study. 
5.4 Results 
A total of 464 patients with diabetes were approached of whom 128 patients 
agreed to participate. 50 ACR +ve and 50 ACR -ve completed the full protocol 
(Figure 5.1). 30 age and sex matched controls (N=30) were also recruited. 6/30 
controls chose not to receive adenosine stress after learning of possible symptoms. 
Patient and control characteristics and regular medications are shown in Table 5.1. 
There was no difference between ACR +ve and ACR -ve patients in age, gender, 
BMI, diabetes duration, HbA1c or 24 hour blood pressure. 
Native T1 and ECV were higher in patients with diabetes than in controls 
1242.2±53.9 vs 1209.7±47.4ms, P=0.004 and 26.1±3.4 vs 23.3±3.0% P=0.0002. 
Native T1 and ECV were also higher in ACR +ve than ACR -ve patients 1252.6±66.0 
vs 1231.72±35.8ms, P=0.05 and 27.2±4.1 vs 25.1±2.9%, P=0.004 (Figure 5.2).  
A total of 17/100 patients with diabetes had silent MI compared with 0/30 
controls, P=0.01. There was no difference in the rate of silent MI between ACR +ve 
and ACR-ve patients (9/50 vs 8/50, respectively P=0.79). 2/50 ACR +ve and 2/50 
ACR -ve patients had significant inducible ischaemia on adenosine stress perfusion 
imaging. The location and mass of infarction is shown in Table 5.2. Figure 5.3 shows 
an example of a patient with 2 distinct silent subendocardial myocardial 
infarctions.   
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There were no significant differences in LV EDV, LV mass, EF or left atrial volume 
between ACR +ve, ACR -ve or control (Table 5.2). LV mass/EDV was higher in 
patients with diabetes than in control 0.61±0.11 vs 0.66±0.13 g/ml P=0.008. 
Although a difference was detected in LV mass/EDV comparing ACR +ve with ACR -
ve, this failed to reach statistical significance (0.65±0.14 vs 0.68±0.12 g/ml, P=0.07 
(Figure 5.4). 
 
Figure 5.2 Late gadolinium enhancement (LGE) and extracellular volume (ECV) 
maps of an ACR -ve patient (left) and ACR +ve patient (right). LGE imaging showed 
no focal fibrosis in either patient but ECV mapping demonstrated the ECV to be 
significantly higher in the ACR +ve patient. 
 
Circumferential strain was lower in patients with diabetes compared to control at 
apex, mid LV and base (-0.22, -0.22 & -0.20 vs -0.19, -0.18 & -0.18; P=0.001, 
P<0.0001 & P=0.001 respectively). Circumferential strain was also lower at the mid 
LV level in ACR +ve than ACR-ve patients-0.17±0.03 vs -0.19±0.05, P=0.01.  There 
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was no difference in strain rates, LV twist or LV torsion between patients with 
diabetes or control (Table 5.1).  
There was no difference in any echocardiography measured Doppler parameter 
between ACR +ve and ACR -ve patients (Table 5.3). There were no significant 
differences in hs-cTnT, NT-proBNP and serum aldosterone between ACR +ve and 
ACR -ve. 
  
Control ACR -ve ACR +ve 
P value 
for trend 
P value 
for ACR -
ve vs +ve 
N 30 50 50 
 
 
Age 59.1±11.5 61.1±9.1 60.2±12.7 0.76 0.69 
Male gender, n (%) 21 (70) 42 (84) 40 (80) 0.32 0.60 
Body mass index , 
kg/m
2
 
26.6±3.2 28.6±4.0 29.1±4.6 0.04 0.61 
Duration of diabetes, 
years 
- 4.6 ± 4.4 5.3±4.4 - 0.40* 
HbA1c, mmol/mol 36.2±3.8 60.2±13.7 65.9±23.9 <0.0001 0.47 
Systolic BP, mmHg 130±13 130±13† 133±17† 0.66 0.46 
Diastolic BP, mmHg 70±11 71±8† 74±10† 0.20 0.12 
Total cholesterol - 4.4±1.2 4.4±1.1 - 0.94 
Smoking 0 6 9  0.40 
      
Metformin 0 49 38 <0.0001 0.002 
Sulphonylurea 0 12 21 <0.0001 0.09 
Other OH 0 3 1 0.28 0.62 
Insulin 0 0 0 1.0 1.0 
ACE inhibitor 0 0 0 1.0 1.0 
Beta blocker 0 1 3 0.28 0.62 
Calcium channel 
blocker 
1 6 4 0.40 0.74 
Diuretic 0 2 3 0.40 1.0 
Statin 2 36 33 <0.0001 0.67 
Aspirin 3 4 14 0.01 0.02 
 
Table 5.1 Subject characteristics. *ACR -ve vs ACR +ve only. †24 hour BP; OH, oral 
hypoglycaemic agent   
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  Control ACR -ve ACR +ve P value for trend P value for ACR -ve vs +ve 
LV EDV, ml 162.2±41.4 149.2±32.4 147.2±36.3 0.16 0.40 
LV EDV index, ml/m2 83.5±18.7 74.1±13.9 73.1±14.5 0.03 0.34 
Ejection fraction, % 60.5±6.6 61.2±5.1 60.6±6.9 0.59 0.93 
LV mass, g 95.5±22.6 93.9±17.6 98.5±23.3 0.65 0.35 
LV mass index, g/m2 49.1±9.3 46.8±7.7 48.9±9.4 0.48 0.30 
Mass/EDV, g/ml 0.61± 0.11 0.65±0.14 0.68±0.12 0.02 0.07 
LAV, ml 91.6±26.6 87.5±17.0 89.8±22.5 0.92 0.99 
LAV index, ml/m2 46.9±12.3 43.7±8.2 44.9±9 0.69 0.78 
Native T1, ms 1209.7±47.4 1231.72±35.8 1252.6±66.0 0.002 0.05 
Extracellular volume, % 23.3±3.0 25.1±2.9 27.2±4.1 <0.0001 0.004 
Myocardial Infarction, n (%) 0 (0) 8 (16) 9 (18) 0.01* 0.79 
Mass of Infarction, g - 3.1±2.1 8.7±11.7 - 0.50† 
Mass of infarction, % of LV - 2.9±1.8 8.5±11.2 - 0.50† 
Apex Ecc  -0.22±0.05 -0.19±0.05 -0.18±0.05 0.001α 0.12 
Mid LV Ecc  -0.22±0.02 -0.19±0.05 -0.17±0.03 <0.0001 0.01 
Base Ecc -0.20±0.03 -0.18±0.04 -0.17±0.03 0.001β 0.14 
Mid LV systolic SR -1.11±0.12 -1.06±0.16 -1.02±0.20 0.10 0.27 
Mid LV early diastolic SR 0.53±0.15 0.45±0.20 0.44±0.18 0.02γ 1.0 
Mid LV late diastolic SR 1.37±0.26 1.13±0.30 1.06±0.32 <0.0001δ 0.29 
Peak LV twist 14.6±4.2 15.0±3.0 15.4±4.3 0.67 0.57 
Peak LV torsion 13.4±3.1 14.5±3.6 14.4±3.7 0.45 0.92 
Table 5.2 CMR findings. BSA, body surface area; Ecc, circumferential strain EDV, end diastolic volume; ESV, end systolic volume; LAV, left 
atrium volume; LV, left ventricle; SR, strain rate *DM vs control. †One ACR +ve patient had discrete lateral and antero-apical infarction that 
corresponded to two coronary severe stenoses on subsequent coronary angiography. α DM vs control P=0.001. β DM vs control P=0.001. γ 
DM vs control P=0.01. δ DM vs control <0.0001. 
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Figure 5.3 Adenosine stress perfusion imaging showing severe anteroseptal 
inducible ischaemia (A). Late gadolinium enhancement images showing 2 distinct 
silent myocardial infarctions in one ACR +ve patient. Antero-apical (B) and lateral 
(C) subendocardial infarctions caused by a chronic total occlusion of the left 
anterior descending artery (D) and severe obtuse marginal disease (E)   
5.4.1 High Sensitivity cardiac Troponin T 
Eleven of all 100 patients with diabetes had hs-cTnT ≥14ng/L. CMR findings of 
these patients are shown in Table 5.4. Both native T1 and ECV were higher in 
patients with hs-cTnT ≥14ng/L than those with normal hs-cTnT levels (1293.3±80.2 
vs 1235.8±46.5ms, P=0.0001 and 30.3±4.8 vs 25.6±3.2%, P<0.0001 respectively).  
Hs-cTnT level had a modest correlation with CMR tagging derived late diastolic 
strain rate r=-0.25 P=0.02. Hs-cTnT also had a modest correlation with E wave by 
spectral mitral Doppler -0.211, P=0.04, medial and lateral E’ by TDI r=-0.32 P=0.001 
and r=-0.22, P=0.03 respectively. There was also a significant correlation between 
Hs-cTnT and NT-proBNP r=0.30, P=0.003.    
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5.4.2 NT-ProBNP 
There were 11 patients with NT-proBNP ≥125ng/L. CMR findings of these patients 
are shown in Table 5.4. Patients with NT-proBNP ≥125ng/L had increased LA 
volume indexed to BSA compared with patients with normal NT-proBNP (54.3±16.0 
vs 43.1±7.6 ml/m2, P=0.004), as well as higher native T1 1285.6±79.6 vs 
1236.8±47.8ms, P=0.07 and ECV 29.3±4.5 vs 25.7±3.4%, P=0.002. S’ average by TDI 
was lower in those with NT-proBNP ≥125ng/L -3.2 vs-4.3 cm/s, P=0.02.  
 
Figure 5.4 Box and whisker plots showing ejection fraction, LV mass/EDV, native T1 
and extracellular volume according to ACR status. Brackets above show the P value 
between groups. 
5.4.3 Correlates of ECV 
Of the patient characteristics listed in Table 5.4 only HbA1c (r=0.28, P=0.004) and 
female gender (r=0.38, P<0.0001) were associated with higher ECV. None of the 
medications listed in Table 5.1 were associated with increased ECV. LV mass, EDV 
and ESV all had a significant correlation with ECV (r=-0.24, P=0.02; r=-0.30, P=0.002 
and r=-0.36, P<0.001 respectively). There were no significant correlations between 
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any of the strain parameters measured by CMR shown in Table 5.2 or by 
echocardiography shown in Table 5.3 and ECV.  
5.4.4 Correlates of Native T1 
Of the patient characteristics listed in Table 5.4 only female gender (r=0.22, 
P=0.03) was associated with higher native T1 (r=0.38, P<0.0001). No medication 
was associated with increased native T1. EDV and ESV had a significant correlation 
with native T1 (r=-0.24, P=0.02 and r=-0.29, P=0.003). Of the strain parameters 
measured by CMR shown in Table 5.2 only peak systolic strain rate had a significant 
correlation with native T1 (r=0.25, P=0.01). None of the strain parameters 
measured by echocardiography shown in Table 5.3 had a correlation with native 
T1.  
 
Table 5.3 Echocardiography & biomarker results 
  ACR -ve ACR +ve P value 
E/A ratio 0.87±0.27 0.85±0.34 0.28 
E/E’ medial 8.6±2.6 8.6±2.2 0.89 
E/E’ lateral 6.1±2.4 6.4±2.2 0.32 
E/E’ average 7.0±2.3 7.2±2.0 0.40 
Diastolic dysfunction grade 0.84±0.58 0.98±0.47 0.12 
 0 12 5  
 1 35 42  
 2 2 2  
 3 1 1  
S’ medial, cm/s 9.1±2.4 9.3±2.3 0.87 
S’ lateral, cm/s 10.2±2.5 9.5±2.1 0.11 
S’ average, cm/s 9.7±2.0 9.4±1.8 0.42 
hs-cTnT, ng/L 6.4±4.3 8.4±5.8 0.09 
NT-proBNP, ng/L 54.0±81.9 67.0±129.7 0.34 
Serum Aldosterone, pmol/L 299.0±194.6 322.55±182.5 0.32 
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5.4.5 Combinations of ACR, hs-cTnT and NT proBNP 
Eleven patients had elevated levels of 2 or 3 of the bioamrkers for developing heart 
failure (ACR, hs-cTnT or NT-proBNP, Figure 5). In those with 2 or 3 positive 
biomarkers native T1 and ECV were higher than in those with only one positive 
biomarker (1293.4±76.7 vs 1240.7±54.6ms, P=0.005 and 30.7±4.2 vs 26.2±3.5%, 
P=0.0001 respectively) or none (1293.4±76.7  vs 1229.9±36.6ms, P=0.001 and 
30.7±4.2 vs 24.9±2.7%, P<0.0001). 
 
Figure 5.5 Venn diagram showing overlap between positive ACR, hs-cTnT≥14ng/ml 
and NT-proBNP≥125ng/ml and their relationship with ECV. 
  
 
N=4 
31±4% 
N=5 
31±6% 
N=2 
29±3% 
N=1 
31% 
N=45 
25±3% 
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 hs-cTnT≥14 hs-cTnT<14 P value NT-
proBNP≥125 
NT-
proBNP<125 
P value 
N 11 89  11 89  
ACR +ve, N (%) 9 (82) 41 (46) 0.05 7 (64) 41 (46) 0.53 
hs-cTnT, ng/L 19.5±4.0 5.9±2.7 - 12.7±6.8 6.7±4.5 0.01 
NT-proBNP, ng/L 201.8±227.1 43.0±67.0 0.01 279.5±218.1 33.4±31.8 - 
24 hour SBP, mmHg 125±10 132±15 0.18 125±11 132±15 0.14 
24 hour DBP, mmHg 64±10 74±9 0.001 63±9 74±8 <0.001 
LV EDV, ml 141.0±38.5 149.1±33.8 0.46 143.7±39.9 148.7±33.7 0.65 
LV EDV index, ml/m2 69.7±16.4 74.1±13.9 0.33 72.7±16.2 73.8±14.0 0.81 
Ejection fraction, % 60.6±10.7 61.0±5.3 0.84 60.5±10.6 61.0±5.3 0.80 
LV mass, g 97.2±13.8 96.0±21.4 0.86 90.7±14.9 96.8±21.2 0.36 
LV mass index, g/m2 48.7±9.2 47.8±8.6 0.74 46.0±5.3 48.1±9.0 0.46 
Mass/End diastolic volume, 
g/ml 
0.72±0.14 0.66±0.13 0.15 0.66±0.13 0.67±0.13 0.82 
Left atrial volume, ml 103.0±31.4 86.8±17.4 0.12 106.1±31.7 86.4±17.0 0.07 
Left atrial volume index, ml/m2 51.3±15.0 43.4±8.3 0.12 54.3±16.0 43.1±7.6 0.004 
Native T1, ms 1293.3±80.2 1235.8±46.5 0.0001 1285.6±79.6 1236.8±47.8 0.07 
Extracellular volume, % 30.3±4.8 25.6±3.2 <0.0001 29.3±4.5 25.7±3.4 0.002 
Myocardial Infarction , n (%) 2 (18) 15 (17) 1.0 3 (27) 14 (16) 0.39 
Mass of Infarction, g 19.8±23.8 4.3±4.3 0.53 13.3±20.2 4.6±4.3 0.53 
Mass of infarction, % of LV 19.9±22.0 4.0±4.0 0.49 13.4±19.2 4.2±4.0 0.49 
Table 5.4 CMR and biomarker findings of 100 patients with type 2 diabetes according to whether they had elevated hs-cTnT or NT-proBNP. 
ACR, albumin creatinine ratio; DBP, diastolic blood pressure; SBP, systolic blood pressure; EDV, end diastolic volume 
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5.5 Discussion 
Data from our prospectively recruited cohort of low risk asymptomatic patients 
with diabetes demonstrates that patients who are at a higher risk of heart failure 
have higher ECV and extracellular matrix (ECM) expansion. ACR, hs-cTnT and NT-
proBNP are all known surrogates of heart failure risk and all correlated with an 
increased ECV. There was also a high rate of silent MI in this low risk asymptomatic 
cohort however there was no correlation between silent MI and ACR, hs-cTnT or 
NT-proBNP status.  
There is now considerable data demonstrating that diabetes is associated with 
increased ECV and diffuse cardiac fibrosis (Jellis et al., 2011; Ng et al., 2012; van 
Heerebeek et al., 2008) and that elevated ECV is associated with increased heart 
failure and mortality (Wong et al., 2013). Several biomarkers including urine ACR 
(Carr et al., 2005), hs-cTnT (Selvin et al., 2014) and NT-proBNP (Rana et al., 2006) 
have also been linked with increased heart failure risk in diabetes although the 
mechanisms underlying this risk are not clear. We have shown that elevated levels 
in each of these biomarkers are associated with increased ECV suggesting ECM 
expansion as a mechanism for heart failure in this population.  
Microalbuminuria is typically the earliest clinical manifestations of diabetic kidney 
disease as well as a marker of vascular pathology. The mechanisms that lead from 
hyperglycaemia to renal dysfunction are complex and are thought to involve 
altered pathways of cellular glucose metabolism, increased fatty acid oxidation, 
increased reactive oxygen species secondary to mitochondrial dysfunction and 
ultimately production of advanced glycation end products within vulnerable cells of 
the kidney (Brownlee, 2005; Wendt et al., 2003). These pathways lead to the 
microscopic changes within the kidney including glomerular basement thickening, 
mesangial cell enlargement and increased extracellular matrix secretion which all 
may be detected in patients with microalbuminuria (Tervaert et al., 2010) . 
The cellular processes that lead from hyperglycaemia to cardiac fibrosis and 
dysfunction are similar to those in the kidney and involve altered substrate 
metabolism, impaired calcium handling, increased reactive oxygen species and 
microvascular advanced glycation end product deposition (Boudina and Abel, 2007; 
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Seferovic and Paulus, 2015). These pathways lead to increased cardiac interstitial 
fibrosis (van Heerebeek et al., 2008) that can ultimately be detected by CMR T1 
mapping. It is therefore likely that similar cellular mechanisms lead to both cardiac 
and renal fibrosis and dysfunction in type 2 diabetes. This may explain the 
relationship between microalbuminuria and cardiac extracellular matrix expansion 
that we have reported.  
It is also likely that renal dysfunction in patients with microalbuminuria leads to 
cardiac fibrosis. In diabetes there is increased expression of angiotensin II in the 
leading to volume expansion via salt and water reabsorption in the kidney (Price et 
al., 1999). This increases cardiac afterload and may explain the concentric 
remodelling with increased LV mass/EDV we have reported in patients with 
microalbuminuria. We had also anticipated that serum aldosterone level would be 
elevated in ACR +ve patients, which was not the case. Rao et al have previously 
reported a correlation between urinary aldosterone excretion and ECV which fits 
with the hypothesis that angiotensin II expression is important in cardiac fibrosis.  
Despite deliberate exclusion of ACE inhibitors and low use beta blockers that both 
influence aldosterone levels we did not find an association between ECV and 
serum aldosterone level in our cohort.  It is possible that factors such as fluid status 
and posture prior to blood testing have had a deleterious effect on the measured 
aldosterone levels. 
We have also reported the novel finding of an association between cardiac 
biomarkers and cardiac extracellular matrix expansion in diabetes. This finding is in 
keeping with other disease states that involve expansion of the extracellular matrix 
including cardiac amyloidosis (Barison et al., 2015) and HCM (Kawasaki et al., 2013) 
where diffuse cardiac fibrosis detected by CMR has been shown to correspond with 
both BNP and cardiac troponin.    
Our finding that rates of silent MI did not vary according to ACR status was 
surprising. ACR reflects a microvascular complication of diabetes which is 
recognised to be directly related to glycaemic control (Stratton et al., 2000). 
Elevated ACR however, is also a marker of vascular injury. The relationship 
between risk of MI and glycaemic control is complex. For example, only after 10 
years post study follow up of improved glycaemic control in UKPDS was a decrease 
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in rates of MI apparent (Holman et al., 2008). Our finding that ACR status did not 
influence the chance of silent MI likely reflects this complex relationship.  
Diastolic dysfunction detected by echocardiography was a very common finding in 
our study  in 83/100 patients which is in keeping with previously reported rates 
(Poirier et al., 2001). Previous studies have demonstrated that diastolic dysfunction 
in type 2 diabetes is strongly influenced by age, hypertension and coronary disease 
and have given conflicting results about whether it leads to heart failure and 
increased mortality (From et al., 2010; Poulsen et al., 2013) . We have reported no 
difference in any measure of diastolic dysfunction between ACR +ve and ACR -ve 
and furthermore that there was no correlation between any echocardiographic 
measure of diastolic dysfunction and ECV. Our finding add further weight to the 
argument that diastolic dysfunction is influenced by too many factors to be a useful 
screening tool for subclinical cardiac dysfunction secondary to diffuse fibrosis in 
type 2 diabetes.  
However mid LV circumferential strain measured by CMR tagging was lower in ACR 
+ve than ACR -ve patients, although there was no significant correlation with ECV. 
Previous studies have suggested that impairment of this parameter is associated 
with increased risk of heart failure on follow up (Choi et al., 2013).  This was the 
only functional parameter that was different between ACR +ve and ACR -ve and 
further studies are required to establish whether it may have prognostic value in 
type 2 diabetes.  
It has been postulated that future clinical trials should be directed at patients with 
diabetes and increased ECV to try and prevent the onset of heart failure. ACR, hs-
cTnT, NT-proBNP, or even a combination of all three, have the potential to be 
relatively simple and cost effective screening tools to detect patients with diabetes 
most likely to have elevated ECV. Recruiting those most likely to have elevated ECV 
to clinical trials could increase the event rate and decrease sample size.  
5.6 Limitations 
In this study we have explored the relationships between ECV and three 
biomarkers associated with increased risk of heart failure in diabetes. Our study 
was not powered to compare clinical outcomes or risk of heart failure. We have 
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not carried out invasive coronary angiography because it would not be ethically 
appropriate to put asymptomatic low risk patients through an invasive procedure. 
However we have carried out high resolution stress perfusion imaging to exclude 
significant silent ischaemia and the prevalence of which was the same between 
groups. For the same reasons we did not carry out myocardial biopsy to confirm 
increased ECM histologically. However ECV measured by CMR has been validated 
against histology in other disease processes (Iles et al., 2008) and there is now 
considerable evidence suggesting that the increased ECV in diabetes represents 
ECM expansion and diffuse cardiac fibrosis (Jellis et al., 2011; Ng et al., 2012; Rao 
et al., 2013). 
5.7 Conclusions 
Patients with type 2 diabetes and persistent microalbuminuria, positive hs-cTnT or 
NT-proBNP have cardiac extracellular matrix expansion detected by CMR, 
suggesting that the increased risk of heart failure in these patients is mediated by 
diffuse cardiac fibrosis. There was a high rate of silent MI in this low risk cohort 
that was not related to biomarker status.  
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6. Study 5– Identification of patients with type 2 
diabetes with evidence of silent myocardial 
infarction 
6.1 Abstract  
Aims 
Silent myocardial infarction (SMI) is a prevalent finding in patients with type 2 
diabetes and is associated with significant mortality and morbidity. Late gadolinium 
enhancement (LGE) by cardiovascular magnetic resonance (CMR) is the best 
validated technique for detection of SMI but is time consuming, costly and requires 
administration of intravenous contrast. We therefore planned to develop a 
population screening tool to identify those at highest risk of SMI.   
Methods 
100 asymptomatic patients with type 2 diabetes underwent ECG, 24 hour blood 
pressure, echocardiography, biomarker assessment and CMR at 3.0T including 
assessment of ejection fraction (EF) and LGE. Global longitudinal strain (GLS) 
measured from basic 2 and 4 chamber cines was measured using feature tracking. 
Risk factors, imaging and biomarker findings were compared in those with and 
without SMI.   
Results 
17/100 patients had SMI. Risk factors for SMI included older age but not fasting 
cholesterol, 24hrBP, smoking or hsCRP. Q waves on ECG, Doppler 
echocardiography EA ratio ≤ 0.79, GLS ≥ -18.4% and NT-proBNP > 29ng/L were all 
associated with SMI. We tested a simple risk score derived from these 4 factors 
and age. The combined score had an AUC of 0.836 (0.749-0.902), P<0.0001. A score 
of ≥3/5 had 88% sensitivity and 70% specificity for SMI.  
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Conclusions 
We have developed a simple screening test, using measures that can be derived in 
a cardiology outpatient clinic, for the detection of SMI in type 2 diabetes. 
Identifying those most likely to have SMI would allow appropriate investigation and 
initiation of treatment.  
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6.2 Introduction  
Cardiovascular disease, primarily stroke and myocardial infarction, account for the 
vast majority of mortality associated with type 2 diabetes (Morrish et al., 2001). 
Silent myocardial infarction (SMI) is a relatively common finding in patients with 
type 2 diabetes (Kwong et al., 2006; Schelbert et al., 2012) although the exact 
prevalence in contemporary asymptomatic populations is unknown (Davis et al., 
2013). 
Currently the most extensively validated method to assess for the presence and 
extent of silent MI is the LGE technique measured by CMR. Using this technique it 
is possible to establish the location and distribution of scar tissue. The prevalence 
of SMI according to the presence of LGE in symptomatic patients with type 2 
diabetes is reported to be between 21-28% (Kwong et al., 2006; Schelbert et al., 
2012). In these cohorts the presence of SMI was strongly associated with an 
increase in MACE and mortality.  
There has been a decrease in the rate of acute MI in type 2 diabetes in the past 
two decades (Gregg et al., 2014). This may reflect improvements in glycaemic 
control and modification of other concomitant risk factors such as smoking, 
dyslipidaemia and blood pressure. It is unknown whether these same risk factors 
influence the likelihood of SMI. Comparatively the detection of LGE by CMR is time 
consuming, costly and requires administration of intravenous contrast making it a 
less than ideal population screening tool. 
Several imaging and biomarker tests have been shown to be able to detect the 
presence and determine the extent of MI measured by LGE  including Q waves on 
12 lead electrocardiogram (ECG) (Moon et al., 2004a), ejection fraction 
(Ingkanisorn et al., 2004), strain parameters (Biere et al., 2014), hs-cTnT (Nguyen et 
al., 2015) and NT-proBNP (Garcia-Alvarez et al., 2009). However, the sensitivity and 
specificity of these tests to detect SMI in type 2 diabetes is at present unknown.  
We hypothesised that a risk score derived from routinely acquired clinical 
measurements could accurately predict the presence of SMI.  
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6.3 Methods 
6.3.1 Enrolment Criteria 
100 asymptomatic patients with type 2 diabetes were recruited from 30 primary 
care health centres in the local area. Exclusion criteria were known cardiac disease, 
kidney disease (eGFR <30), uncontrolled hypertension, treatment with insulin or 
ACE inhibitor/angiotensin receptor blocker.  
6.3.2 CMR protocol 
All patients underwent an identical CMR study on a dedicated cardiovascular 3 
Tesla Philips Achieva TX system (Philips, Best, The Netherlands) equipped with a 32 
channel coil and MultiTransmit® technology. Data were acquired during breath-
holding at end expiration.  
From scout CMR images, the left ventricular long and short axes were determined. 
Cine images covering the entire heart in the LV short axis plane and orthogonal 
long-axis planes were then acquired (balanced SSFP, spatial resolution 
1.2x1.2x10mm³, 50 cardiac phases TR/TE 2.6/1.3ms, flip angle 40o, field of view 
300-420mm). Cines planned to cover the entire left atrium (LA) short axis plane in 
end systole were also acquired (as LV stack but slice gap 5mm).  
LGE imaging was carried out more than 6 minutes after contrast injection using 
inversion recovery-prepared T1-weighted echo. The optimal inversion time to null 
signal from normal myocardium was determined using a Look-Locker approach. 
Typical parameters are TR/TE 3.5/2.0 ms, flip angle 25o, acquired spatial resolution 
1.54x1.76x10mm3 and performed in 10-12 short axis slices with further slices 
acquired in the vertical and horizontal long axis orientations, phase-swapped or 
imaged in systole, if indicated based on LGE imaging obtained or wall-motion 
abnormality.  
6.3.3 CMR interpretation 
CMR data were assessed quantitatively using commercially available software 
(CVI42, Circle Cardiovascular Imaging Inc. Calgary, Canada). LV mass, ejection 
fraction (EF) and LA volume were measured from short axis cine images.  
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For feature tracking analysis endocardial and epicardial LV contours were drawn on 
long axis 4 chamber and 2 chamber cines using a semi-automated process. Peak 
global longitudinal strain, systolic strain rate, early and late diastolic strain rates 
were measured. Late diastolic strain rates were defined as peak rate during active 
atrial contraction.  
The presence of SMI was identified by 2 physicians experienced in CMR 
interpretation based upon typical subendocardial distribution of LGE present. The 
mass of LGE was quantified by the Otsu method (Vermes et al., 2013).  
6.3.4 Echocardiography & Electrocardiography 
All patients underwent echocardiography (Vivid e9, GE Medical Systems, 
Milwaukee, WI, USA) focused on Doppler measurements of mitral inflow and tissue 
Doppler imaging (TDI) of the lateral and medial mitral annulus. E/A ratio, E', A' and 
S' are measured on the machine using inbuilt software. Diastolic dysfunction was 
graded 0-3 by an accredited echocardiographer blinded to clinical details according 
to international guidelines (Nagueh et al., 2009). 12 lead electrocardiography 
(MAC500, GE Medical Systems, Milwaukee, WI, USA) was analysed by 2 physicians 
blinded to clinical details for the presence of Q waves according to international 
guidelines (Thygesen et al., 2012).   
6.3.5 Ambulatory blood pressure 
All patients underwent 24 hour ambulatory blood monitor that has been validated 
for clinical use by the British Hypertension Society (6100, Welch-Allyn, NY, USA). 
The cuff was set to inflate every 30 minutes during the day and every 60 minutes 
during the night. Mean 24 hour systolic and diastolic BP were recorded.  
6.3.6 Blood tests 
Blood was drawn from each subject at the time of CMR and tested for HbA1c. 
Serum was stored at -70C and tested in one batch for hs-cTnT typical CV 4.4% at 
13.7ng/L and 3.6% at 95.3 ng/L, NT-proBNP typical CV 2.9% at 91 ng/L and 2.1% at 
415 ng/L (Cobas 8000, Roche Diagnostics,  Burgess Hill, West Sussex) and HS-CRP 
- 131 - 
 
 
 
(Advia, Siemens Healthcare Diagnostics, Marburg, Germany). Fasting cholesterol 
and previous HbA1c were recorded from review of electronic records.  
 
Figure 6.1 Examples of SMI detected by LGE. Horizontal panels are from the same 
patient and white arrows denote the area of MI. A and B show basal and mid 
inferolateral subendocardial MI. C and D show apical and mid septal near 
transmural infarction. E and F show basal inferior subendocardial infarction. 
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6.3.7 Statistical analysis 
Statistical analysis was performed using IBM SPSS® Statistics 20.0 (IBM Corp., 
Armonk, NY). Continuous variables were expressed as means ± SD and compared 
using Mann Whitney U test. Categorical variables were expressed as N (%) and 
compared using Fisher exact test. Spearman rank correlation was used to test for 
correlation.  
Receiver operating characteristic (ROC) analysis was used to determine the 
diagnostic accuracy of parameters that had been significantly different in those 
with SMI. The diagnostic accuracy is expressed as area under the curve (AUC) and 
95% confidence interval. Optimal sensitivity and specificity were calculated using 
Youden index. Nested models were used to assess the additive value variables 
associated with SMI. AUCs were compared by using validated methods described 
by DeLong et al (DeLong et al., 1988).   
Using the cut offs derived from the Youden analysis of the ROC curves each 
variable was given a binary classification. These five categorical variable were 
summed to calculate a SMI risk score (range 0-5). P<0.05 was considered 
statistically significant. 
 
Figure 6.2  American Heart Association bullseye model (right) demonstrating 6 
basal, 6 mid ventricular and 4 apical segments and their typical coronary arterial 
supply (LAD, left anterior descending; LCX, left circumflex; and RCA, right coronary 
artery). The right bullseye plot shows the location of infarcted segments from the 
17 patients with SMI.   
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Table 6.1 Patient characteristics according to the presence or absence of SMI ACE, 
angiotensin-converting enzyme; BP, blood pressure 
6.4 Results 
Seventeen of the 100 patients had evidence of SMI on LGE CMR. Figure 6.1 shows 
examples from 3 patients. Patient characteristics are shown in Table 6.1 according 
to SMI status. There was a significant range in the extent of SMI from 0.4g to 36.6g. 
Mean mass of infarction was 6.1±8.8g or as a percentage of the LV 5.8±8.5%. Mean 
 SMI No SMI P value  
N 17 83 
 
Age 65.4±9.2 59.8±11.0 0.05 
Male gender, n (%) 16 (94) 66 (80) 0.30 
Body mass index , kg/m
2
 27.8±3.1 28.9±4.6 0.32 
Duration of diabetes, years 4.1±4.1 5.2±4.4 0.24 
HbA1c, mmol/mol 57.1±12.5 64.3±20.6 0.23 
Median HbA1c, mmmol/mol 63.3±10.9 64.8±18.2 0.77 
24 hr systolic BP, mmHg 135.3±15.9 130.8±14.7 0.24 
24 hr diastolic BP, mmHg 72.5±10.1 72.7±8.9 0.89 
Total cholesterol 4.3±1.2 4.4±1.1 0.69 
Smoking, n (%) 4 (24) 11 (13) 0.28 
    
Metformin 13 74 0.227 
Sulphonylurea 5 28 1.0 
Other oral hypoglycaemic 0 4 1.0 
Insulin 0 0 - 
ACE inhibitor 0 0 - 
Beta blocker 2 2 0.133 
Calcium channel blocker 4 6 0.064 
Diuretic 1 4 1.0 
Statin 14 56 0.262 
Aspirin 2 16 0.73 
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transmurality of infarction was 60.3±28.0%. Figure 6.2 shows a bullseye plot of the 
areas affected by SMI demonstrating that SMI could occur in any segment.   
There was a trend to patients with SMI being older (65.4±9.2 vs 59.8±11.0, P=0.05) 
but there was no difference in any other patient characteristic or use of 
medication. There was no significant difference in any cardiac risk factors including 
24 hour BP, fasting cholesterol or smoking (P=0.24, 0.69 and 0.28 respectively).  
The mean number of previous HbA1c measurements included in the analysis was 
9.7±5.7 per patient over 4.3±2.7 years. There was no significant difference 
between mean, median or maximum HbA1c between those with and without SMI 
(P=0.69, 0.77 and 0.28 respectively).  
6.4.1 Electrocardiography 
Pathological Q waves on ECG were only present in 4/17 with SMI and 6/83 without 
SMI (sensitivity 24%, specificity 93%). Other ECG abnormalities were present in 
19/100 patients and included left axis deviation 5, right bundle branch block 5, left 
ventricular hypertrophy by voltage criteria 4, left anterior hemiblock 3, T wave 
abnormalities 3 and trifascicular block 1.  
6.4.2 Echocardiography 
Results of echocardiography are shown in Table 6.2. The only significant difference 
between those with and without SMI was a lower E/A ratio (0.75±0.30 vs 
0.89±0.30, P=0.03) in patients with SMI. Grade of diastolic dysfunction was not 
significantly different between those with and without SMI (grade 0, 6 vs 19%; 
grade 1, 88 vs 75%; grade 2, 0 vs 5%; and grade 3, 6 vs 1% P=0.24).  
6.4.3 Cardiovascular Magnetic Resonance 
CMR results are shown in Table 6.2. LV mass index to BSA was higher in those with 
SMI than those without (51.4±6.5 vs 47.2±8.7 g/m2, P=0.01). There was no other 
difference in volumetric parameters. Of the longitudinal strain parameters 
measured by feature tracking, global longitudinal strain (GLS-FT) -15.2±3.7 vs -
17.7±3.1%, P=0.004, peak systolic strain rate (SSR-FT) -93.8±31.8 vs -111.2±42%, 
P= 0.04 and early diastolic strain rate (EDSR-FT) 64.1±16.6 vs 84.0±33.1%, P=0.02 
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were all significantly lower in those with SMI. There was no difference in late 
diastolic strain rate (LDSR-FT) P=0.89.  
Of the patient characteristics shown in Table 6.1 none had a significant association 
with mass of SMI.  Of the investigation findings shown in Table 6.2 the mass of SMI 
only had significant correlations with EF (R=-0.81, P<0.0001), E/E’ (R=-0.58, P0.02) 
and hs-cTnT (R=0.58, P=0.02).  
 
Table 6.2 Investigations according to SMI status. EDSR, early diastolic strain rate; 
EDV, end diastolic volume; FT, feature tracking; GLS, global longitudinal strain; LA, 
left atrium; LDSR, late diastolic strain rate; LV, left ventricle; SSR, systolic strain rate 
  SMI No SMI P value  
CMR     
 LV EDV, ml 140.5±39.1 150.0±32.8 0.30 
 LV EDV index, ml/m2 70.4±17.1 74.5±13.4 0.27 
 Ejection fraction, % 58.0±9.7 61.7±4.9 0.30 
 LV mass, g 102.5±16.3 95.0±21.0 0.34 
 LV mass index, g/m2 51.4±6.5 47.2±8.7 0.01 
 LA volumes, ml 89.0±31.6 88.5±16.8 0.93 
 LA volume index, ml/m2 44.9±15.9 44.2±7.7 0.87 
Feature Tracking     
 GLS-FT -15.2±3.7 -17.7±3.1 0.004 
 SSR-FT -93.8±31.8 -111.2±42 0.04 
 EDSR-FT 64.1±16.6 84.0±33.1 0.02 
 LDSR-FT 87.4±39.9 91.4±41.2 0.89 
Echocardiography     
 E/A ratio 0.75±0.30 0.89±0.30 0.03 
 E/E’ average 7.4±2.4 7.1±2.1 0.96 
 S’ average, cm/s 9.8±2.2 9.5±1.8 0.72 
Electrocardiography     
 Q waves (%) 4 (20) 6(7) 0.06 
Biomarker findings     
 Hs-cTnT, ng/L 7.5±4.1 7.4±5.4 0.42 
 NT-proBNP, ng/L 105.8±132.2 51.9±100.8 0.003 
 HS-CRP, mg/L 3.5±3.5 3.7±5.9 0.57 
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 Figure 6.3 Receiver operator characteristic curves for age, E/A ratio, NT-proBNP 
global longitudinal strain (GLS) measured by feature tracking, the 5 variable nested 
model of age, Q waves, EA ratio , GLS and NT-proBNP (AUC= 0.85, P<0.0001) and 
the SMI risk score using the same 5 variables (AUC=0.84, P<0.0001). 
Age EA ratio 
SMI risk score 5 variable nested model 
NT-proBNP GLS 
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 AUC P value Optimum 
cut-off 
Sensitivity 
at cut-off 
Specificity 
at cut-off 
Age 0.668 
(0.522-0.803) 
0.02 >62 76% 63% 
E/A ratio 0.673  
(0.71-0.763) 
0.005 ≤0.72 71% 59% 
GLS-FT 0.684  
(0.540-0.828) 
0.01 ≥-18.4% 88% 41% 
NT-proBNP 0.730  
(0.604-0.855) 
<0.001 >29ng/L 88% 57% 
5 variable 
nested model 
0.851  
(0.766-0.914) 
<0.0001 - 94% 72% 
 
Table 6.3 Area under the curve (AUC) of continuous parameters for detecting silent 
MI for each of the 5 factors used in the SMI risk score and the 5 variable nested 
model. Optimum cut-off, sensitivity and specificity derived from Youden index are 
also shown.   
6.4.4 Biomarkers 
NT-proBNP was significantly higher in those with SMI (105.8±132.2 vs 
51.9±100.8ng/L, P=0.003). There was no difference in HS-CRP or hs-cTnT (P=0.57 
and 0.42 respectively).   
6.4.5 ROC analysis 
The area under the curve (AUC) for age, Q waves, E/A ratio, GLS-FT, and NT-proBNP 
are shown in Table 6.3 and Figure 6.3. The AUC for the nested model of all 5 
variables was 0.851 (0.766-0.914), P<0.0001 and the maximum possible sensitivity 
was 94% and specificity 72%. The nested model had higher diagnostic accuracy 
than Q waves, GLS, age and E/A ratio alone (P<0.0001, 0.02, 0.02 and 0.006 
respectively). The improvement over NT-proBNP did not reach statistical significant 
(P=0.06).  
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6.4.6 Development of a screening tool 
The number of patients with SMI according to their SMI risk score is shown in 
Figure 6.4. The combined score had an AUC of 0.836 (0.749-0.902), P<0.0001 and 
better diagnostic accuracy than Q waves, age and EA ratio (P<0.001, 0.01 and 0.02 
respectively). The improvement in diagnostic accuracy against GLS-FT and NT-
proBNP did not reach significance (P=0.05 and 0.09 respectively). The sensitives 
and specificities for each possible SMI risk score are shown in Table 6.4.  
 
SMI risk score Sensitivity 95% CI Specificity 95% CI 
0 100.0 - 0.0 - 
1 100.0 - 0.0 - 
2 100.0 80.5 - 100.0 42.17 31.4 - 53.5 
3 88.2 63.6 - 98.5 69.9 58.8 - 79.5 
4 52.9 27.8 - 77.0 88.0 79.0 - 94.1 
5 5.9 0.1 - 28.7 96.39 89.8 - 99.2 
 
Table 6.4 SMI risk score calculated from age  > 62, presence of Q waves on ECG, GLS 
≥ -18.4%, EA ratio ≤ 0.79 and NT-proBNP  >29ng/L. The sensitivity and specificity to 
detect SMI for each possible score is shown. 
6.5 Discussion 
The prevalence of SMI (17%) detected by LGE imaging in this low risk 
asymptomatic cohort was higher than expected. We have found increasing age to 
be the only conventional risk factor associated with SMI. We have identified 
several markers of SMI that can be detected by ECG, echocardiography or blood 
test and have shown that these markers can be added to develop a simple 
screening tool with good diagnostic accuracy.  
We have demonstrated that a simple risk score can predict the presence of SMI in 
patients with type 2 DM as shown by LGE on CMR. The risk score is composed of 
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age, Q waves on ECG, EA ratio ≤ 0.79, GLS ≥ -18.4% and NT-proBNP > 29ng/L. These 
are all parameters that are often measured in a cardiology clinic or could easily be 
measured in community based screening. In the model we derived GLS from 
feature tracking of CMR cines. However if such a model was to be validated and 
used in larger populations GLS could be measured from standard echocardiography 
which has been demonstrated to show good agreement with GLS measured from 
CMR (Obokata et al., 2015). 
 
 
Figure 6.4 Number of patients with SMI (red) and without SMI (blue) according to 
their SMI risk score. 
 
The decision about where to make the cut off to recommend further investigation 
depends on whether sensitivity or specificity is the main clinical priorities (Table 
6.4). If the cut off was set at a score ≥2 (100% sensitivity and 42% specificity) it 
would ensure that the vast majority of SMI was detected with only 2.5 patients 
needing CMR to identify one patient with SMI. Alternatively if the cut off was 
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higher with a score ≥3 (88% sensitivity and 70% specificity) roughly 1 in 9 patients 
with SMI would be missed but only 1.5 patients would need to be screened to 
detect one patient with SMI.  
All of the measured components within the score that is impaired GLS (Holland et 
al., 2015), elevated NT-proBNP (Huelsmann et al., 2008), EA ratio (From et al., 
2010) and Q waves on ECG (Davis et al., 2013) have been associated with adverse 
outcomes in patients with type 2 diabetes without prior history of MI. It is likely 
that a proportion of the mortality reported in these patients is due to SMI. It has 
also been shown that larger infarcts have greater impairment of GLS (Biere et al., 
2014), higher NT-proBNP (Garcia-Alvarez et al., 2009), altered mitral inflow (Nijland 
et al., 1997) and are more likely to develop Q waves (Moon et al., 2004a). 
Therefore all of the measured parameters have biological validity and prognostic 
significant that supports their inclusion in a risk score.  
The imaging parameters associated with mass of SMI were different from those 
included in the SMI risk score and included EF, E/E’ and hs-cTnT. These parameters 
are all recognised to correlate with extent of infarction and prognosis after 
symptomatic MI (Ingkanisorn et al., 2004; Nguyen et al., 2015; Naqvi et al., 2006). 
However, we have demonstrated that they were insensitive for the detection of 
SMI in type 2 diabetes and of limited value in this setting.  
It was an unexpected finding that conventional risk factors including fasting 
cholesterol, 24 hour BP, smoking and even previous glycaemic control had no 
influence on the likelihood of SMI in our cohort. It is unclear whether the 
pathological processes that lead to SMI are identical to acute MI. The lack of 
association with conventional risk factors suggests that further research is needed 
to identify alternative risk factors specifically for SMI.  
To our knowledge this is the first time that the rate of SMI assessed by LGE CMR 
has been assessed in a truly asymptomatic diabetic cohort. Previous studies have 
demonstrated that in patients with diabetes silent MI detected on CMR is 
associated with increased mortality and adverse cardiovascular events (Kwong et 
al., 2006; Schelbert et al., 2012). Kwong et al reported an incidence of silent MI of 
28% in symptomatic patients with diabetes undergoing clinical CMR (Kwong et al., 
2006). Schelbert et al reported a prevalence of 21% of silent MI of diabetic patients 
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enrolled in the ICELAND MI study who underwent CMR between 2004 and 2007 
(Schelbert et al., 2012). However patients in both studies were not necessarily 
asymptomatic and in ICELAND MI and in fact 28% of those with silent MI had prior 
coronary revascularisation. The rate of infarction was the same between our study 
and the work of Schelbert et al despite patients in our study being younger, lower 
risk and asymptomatic.  
SMI in type 2 diabetes is associated with significant mortality and morbidity 
(Kwong et al., 2006; Schelbert et al., 2012). However, it remains to be established if 
this prognosis can be altered by pharmacological or invasive intervention. Before 
recommending that a screening test can be used clinically it is of fundamental 
importance that an intervention exists that can alter the prognosis (Wilson and 
Jungner, 1968). This remains to be established in SMI in type 2 diabetes and should 
be the focus of future work. The SMI screening components that we have 
identified may help in future clinical studies by identifying those most likely to have 
SMI who could be targeted with a lifestyle, pharmacological or interventional 
procedure.  
6.6 Limitations 
The subjects we recruited were specifically low risk, for example those on insulin or 
ACE inhibitors were excluded. The SMI risk model would need to be validated in 
larger more varied populations to broaden its clinical use. We have not performed 
coronary angiography to confirm that SMI was caused by coronary disease. 
However in an asymptomatic cohort an invasive procedure would not be 
appropriate. The cut off points that we have used are based on Youden index 
which assigns equal importance to sensitivity and specificity. Depending on which 
of these is more important in clinical practice the thresholds would need to be 
altered accordingly. We have also assigned an equal score to each of the 
components which may oversimplify the complex nature of the disease process.  
6.7 Conclusions 
The rate of SMI in this low risk asymptomatic cohort of patients with type 2 
diabetes was higher than expected (17%). No conventional risk factors other than 
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age were associated with SMI. Several simple clinical parameters including Q 
waves, EA ratio, GLS and NT-proBNP were associated with SMI. By combining them 
we were able to define a simple screening tool with good diagnostic accuracy for 
the detection of SMI.  
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7. Final Conclusions 
There is increasing evidence that CMR can provide accurate quantification of 
subclinical cardiac change in both health and disease. Detection of subclinical 
change has both diagnostic and prognostic potential that until now primarily been 
used in research but in the coming years will likely be integrated into clinical 
practice.  
In this thesis we have used tissue characterisation by both ECV and LGE to detect 
subclinical change in asymptomatic cohorts. We have also reported changes in 
strain and volumetric parameters that can be detected by CMR.  We have applied 
these techniques to a wide range of subjects including patients with HCM, 
endurance athletes and asymptomatic patients with type 2 diabetes mellitus.  
 
The main findings were: 
7.1 Diagnosing HCM 
i. As LV hypertrophy increases ECV decreases in athletes but increases in 
HCM.   
ii. Based on this divergent finding ECV can be used distinguish HCM and 
athletic remodelling with high diagnostic accuracy, in particular in subjects 
with indeterminate maximal segmental wall thickness.  
iii. CMR using T1 mapping thus has a potential role in the exclusion of HCM in 
athletes presenting with left ventricular hypertrophy, but requires further 
validation in more varied patient populations.  
iv. Regional strain impairment measured by feature tracking and tissue tagging 
is predominantly associated with the degree of hypertrophy and 
replacement fibrosis assessed by the presence of LGE.  
v. In non-hypertrophied segments strain is not significantly impaired by the 
presence of interstitial fibrosis. Therefore the presence of interstitial 
fibrosis (defined as ECV>30% in this cohort) may be a more useful method 
than impairment of strain of identifying HCM in subjects with borderline LV 
hypertrophy.  
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7.2 Cardiac Change in athletes 
i. This cohort of endurance athletes had lower LV circumferential strain, LV 
torsion and biventricular diastolic strain rates than sedentary controls.  
ii. There was a linear association between lactate threshold and LV torsion, 
which is secondary to decreased apical rotation in athletes with high lactate 
threshold.  
iii. This association could be utilised to differentiate athletic remodelling from 
early dilated cardiomyopathy.  
 
7.3 Subclinical Cardiac Change in diabetes  
i. Patients with type 2 diabetes and persistent microalbuminuria, positive hs-
cTnT and NT-proBNP have cardiac extracellular matrix expansion detected 
by CMR 
ii.  Therefore the increased risk of heart failure in these patients may be 
mediated by diffuse cardiac fibrosis.  
iii. The rate of SMI in this low risk asymptomatic cohort of patients with type 2 
diabetes was higher than expected (17%).  
iv. No conventional risk factors other than age were associated with SMI. 
Several basic parameters including Q waves, EA ratio, GLS and NT-proBNP 
were associated with SMI.  
v. By combining them we were able to propose a simple screening tool with 
good diagnostic accuracy for the detection of SMI.  
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